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Abstract 
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) 
signalling pathway is aberrantly activated in most head and neck squamous cell carcinomas 
(HNSCCs). PI3K signalling drives cellular proliferation, protein synthesis and cell 
survival. Although numerous targeted agents are available to inhibit PI3K signalling, 
results have been variable and factors influencing response to PI3K inhibition (e.g. 
genomic aberrations, pathway interconnectivity, acquired drug resistance) are not well 
defined. In this thesis, we employ a multifaceted approach to elucidate the molecular 
underpinnings of biomarkers of response and mediators of resistance to PI3K inhibition in 
HNSCC. We began by combining a large panel of HNSCC cell lines with a clinical trial of 
patient-derived xenograft (PDX) models to characterize biomarkers of response. In doing 
so, we discovered hotspot mutations in the PI3K-encoding PIK3CA gene to only correlate 
with treatment efficacy in vitro. In vivo, PI3K inhibition was broadly-active, though not 
clinically-effective as a single agent, pointing to its potential in neoadjuvant settings. 
Activating HRAS mutations were identified in models non-responsive to PI3K inhibition, 
indicative of innate resistance due to constitutively-active RAS/MAPK signalling. We 
identified persistent mTOR complex 1 (mTORC1) signalling in mutant HRAS cells and 
uncovered ERK-TSC2 signalling contributing to growth and survival despite PI3K 
inhibition. We also characterized acquired resistance to PI3K inhibition following 
prolonged drug treatment and identified upregulation of the receptor tyrosine kinases AXL 
and TYRO3, as well as activation of MAPK signalling in drug-resistant models. Targeting 
either AXL, TYRO3, or P90RSK downstream re-sensitized cells to PI3K inhibition and 
underscored the involvement of these signalling effectors in drug resistance. Finally, upon 
observing a pattern of upregulation of Akt (Ser473) phosphorylation following PI3K 
inhibition throughout our studies, we focused on mTORC2 as a mediator of response to 
PI3K inhibition. We generated a genomic knockout model of mTORC2 by targeting its 
obligate co-factor RICTOR and found that loss of mTORC2 improved sensitivity of 
HNSCC tumour cells to PI3K inhibition and other therapies. Collectively, this work defines 
several key effectors and considerations for targeted PI3K inhibition and provides a 
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mechanistic basis to aid the design of combination therapies and the stratification of 
HNSCC patients for PI3K inhibitor therapy. 
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Chapter 1  
 
1 Introduction 
1.1 Overview of Chapter 1 
This thesis is focused on examining PI3-kinase signalling in head and neck 
squamous cell carcinoma, particularly from the perspective of targeting PI3K signalling 
for therapeutic benefit. In the introductory chapter (Section 1.2), head and neck cancer is 
introduced, with emphasis on the genomic landscape of the disease and current treatment 
strategies. Oncogenic PI3K/Akt/mTOR signalling is presented in Section 1.3, as the studies 
from all data chapters of this thesis examine the effects of inhibiting or genomically 
modulating this pathway. Specifically, Section 1.3 addresses PI3K pathway activation, 
pathway dysregulation and the interconnectivity of PI3K signalling with adjacent networks 
(e.g. MAPK signalling). In Section 1.4, innate and acquired resistance to anti-cancer agents 
is introduced. Despite demonstrated efficacy, inhibition of PI3K signalling has been limited 
to date due to the inability to achieve durable patient responses. The final introductory 
section (Section 1.5) summarizes the overarching scope of our studies.  
 
1.2 Head and Neck Carcinoma 
1.2.1 Classification of head and neck malignancies 
‘Head and neck cancer’ describes a category of diverse tumour types that arise from 
various anatomic locations within the head and neck. The salivary glands, craniofacial 
bones, soft tissues, skin and mucosal membranes of the head and neck can all give rise to 
cancerous lesions(1). However, the vast majority (>90%) of head and neck cancers are 
squamous cell carcinomas (SCCs), derived from mucosal epithelial cells. These tumours 
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are referred to as ‘head and neck squamous cell carcinomas’ (HNSCC). The remaining 
~10% of head and neck tumours include adenocarcinomas, sarcomas and melanomas(2). 
HNSCCs, which are the focus of this thesis, typically arise from the mucosa of the oral 
cavity, oropharynx, larynx and hypopharynx (Fig. 1.1)(3,4). All cell lines and tumour 
tissues used in this thesis are HNSCCs unless otherwise indicated (e.g. T24 or HEK239T).  
Previously, HNSCC has been regarded as a fairly uniform group of tumours, 
differing primarily by the anatomic site of origin(3). However, more recent works have 
found HNSCC to not be as homogeneous as once thought. One of the major features that 
now classifies HNSCC tumours is the presence or absence of human papillomavirus (HPV) 
(5). HNSCC tumours can be divided into those that are HPV-positive—due to infection 
with a high risk HPV strain (typically HPV 16, 18, 33 or 52)—and those that are HPV-
negative and are typically associated with alcohol and/or tobacco consumption(5-7). 
Approximately 75% of HNSCC cases are believed to be associated with traditional risk 
factors (e.g. smoking, alcohol usage), as compared to HPV infection. However, the  number 
of HPV-driven HNSCCs is rapidly on the rise(8-10)(Fig. 1.2). Oropharyngeal HNSCC 
cases in particular are frequently driven by HPV, with estimates suggesting that 4590% 
of oropharyngeal HNSCC cases are HPV-positive and approximately 90% of them are 
associated with HPV type 16 specifically(11-13). Although vaccines against HPV (e.g. 
Gardasil, Cervarix) will affect the prevalence of HPV-driven HNSCC cases in the decades 
to come, at present, the incidence of HPV-positive HNSCC continues to rise(5). 
 Individuals with HPV-negative HNSCC are typically older and often present with 
more co-morbidities(9). HPV-negative HNSCC tumours generally result from the 
accumulation of genomic aberrations and clonal progression of cells following recurring 
exposure to carcinogens(5). In contrast, HPV-positive tumours generally harbour fewer 
mutations (2.28 mutations/megabase (Mb) versus (vs.) 4.83 mutations/Mb in HPV-
negative tumours), with specific, consistent, carcinogenic features, including p16 
overexpression(14,15). Clinically, p16 expression is used as a surrogate to evaluate the 
HPV status of HNSCC tumours and direct treatment planning(16). The presence of HPV 
results in the expression of the viral oncoproteins E6 and E7 which inactivate cellular  
Pharynx
Nasopharynx
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Oropharynx
Nasal Cavity
Oral
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Larynx
Salivary
Glands
Paranasal
Sinuses
Fig. 1.1. Anatomy of the human head and neck. Anatomical structures
relevant to head and neck squamous cell carcinoma (HNSCC) are indicated
(Adapted from: abdominalkey.com).
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Fig. 1.2. Proportion of tonsillar carcinomas positive and negative for the
human papillomavirus (HPV), stratified by year of diagnosis. All cases
are from the London Health Sciences Centre between 1993 and 2011. A rise
in HPV-positive tonsillar HNSCC cases was observed beginning in 2000
(Nichols AC et al., Current Oncology, 2013).
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tumour suppressors (p53 and retinoblastoma (Rb), respectively), resulting in perturbation 
of cell cycle regulation(14,15). Patients with HPV-positive HNSCC are typically non-
smokers and tend to be younger and healthier then HPV-negative HNSCC patients(9,10). 
The division of HNSCC into two cohorts with distinct demographics, genomic features and 
prognostic outcomes (described below) on the basis of HPV status represents one of the 
most significant developments in head and neck cancer research and treatment. 
 
1.2.2 Lethality of head and neck squamous cell carcinoma 
It is estimated that 600,000 individuals worldwide, including 4700 in Canada 
(2017; Canadian Cancer Society), are diagnosed with HNSCC yearly(17). Of these, 
approximately 25% cases are thought to be driven by HPV(9,10). While many HPV-
positive patients experience favourable outcomes following treatment, about 20% fail 
treatment, with the majority having distant metastases(14,15). In stark contrast, HPV-
negative patients are at high risk of local, regional and distant relapses, with approximately 
50% of patients succumbing to the disease(18,19). This difference in survival likely reflects 
both the less favourable patient demographics of HPV-negative disease (generally older 
individuals, often with co-morbidities), as well as the fact that tumours are driven by the 
constant accumulation of many genomic aberrations over time. 
Importantly, even when treatment of HNSCC is successful, there can be significant 
long-term patient burdens, including the requirement for feeding tubes, tracheostomies, 
facial disfigurement and speech impairments(20). Patient quality of life is often impacted 
in a permanent way. Together, these data emphasize an urgent need for more effective 
therapies for both HPV-positive and HPV-negative HNSCC tumours. To develop safe and 
effective therapies for HNSCC patients, an improved understanding of the molecular 
biology driving HNSCC disease is needed, such that a balance between efficacy and 
tolerability/toxicity can be achieved.  
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1.2.3 Genetics of head and neck squamous cell carcinoma 
 In addition to demographic differences, HPV-positive and HPV-negative HNSCC 
are distinct at the molecular level. The tumour suppressor TP53 is mutated in 
approximately two-thirds of HPV-negative HNSCC tumours, while in HPV-positive 
tumours, p53 is rarely mutated(21-23). Rather, the viral oncoprotein E6 targets p53 for 
degradation(24). Although the mechanism of p53 impairment differs, in both cases loss of 
p53 activity results in dysregulation of cell cycle and impaired monitoring of genomic 
integrity, which leads to aberrant proliferation and defective DNA repair(5). In HPV-
negative HNSCC, the cell cycle regulator p16 (encoded by CDKN2A) is additionally 
inactivated in approximately 58% of cases. Along with mutation of p53, there is nearly 
universal loss of tumour suppressor function in HPV-negative HNSCC(22). Using The 
Cancer Genome Atlas’ (TCGA) HNSCC dataset of 504 patients, an “OncoPrint” diagram 
was generated to depict the amplifications, deletions and mutations commonly observed in 
HNSCC disease, including those discussed here and below (Fig. 1.3). 
 Other common genomic events in HPV-negative HNSCC include NOTCH1 loss-
of-function mutations in 1119% of tumours and NOTCH2 or NOTCH3 mutations in 
another 1114% of cases(21,22). Amplifications of the epidermal growth factor receptor 
(EGFR) are also frequent in HNSCC, observed in approximately 15% of HPV-negative 
cases(22). The poorly-characterized gene CSDM1 is deleted in up to 50% of HNSCCs, 
while FAT1, which plays a role in Wnt signalling, is mutated in 1223% of HPV-negative 
tumours(21,22,25). Additional mutations and deletions have been identified in apoptosis-
related genes (e.g. CASP8, DDX3X) and in histone methyltransferase-encoding genes, 
including EZH2 and NSD1(21,22). Finally, aberrations in the RAS-RAF-MEK-ERK 
(MAPK) signalling pathway have been identified, with activating HRAS mutations 
(specifically at codons 12 and 13) observed in approximately 5% of HPV-negative HNSCC 
cases (Fig. 1.3)(22).  
 While many genomic aberrations observed in HNSCC tend to be specific to either 
HPV-positive or -negative disease, Lawrence et al. (2015) highlighted alterations in the 
phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signalling  
Fig. 1.3. Genomic aberrations in head and neck squamous cell carcinoma
(HNSCC) primary tumours. Using data from The Cancer Genome Atlas
(TCGA) Project, 504 HNSCC tumours were profiled for gene copy number
aberrations (CNAs) and single nucleotide variations (SNVs). cBioPortal
(http://www.cbioportal.org/) was used to generate a visual “OncoPrint”. Each
patient tumour sample is represented by a single vertical grey line. HPV status
is indicated (blue; HPV-negative, red; HPV-positive). Projected effect of
genomic aberrations is indicated in legend. TSG = tumour suppressor gene,
Apoptosis = apoptosis-related gene, Histones = histone methyltransferase-
encoding genes, PI3K = member of the PI3K/Akt/mTOR signalling pathway.
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cascade to be uniquely present in both patient cohorts(22). PIK3CA, which encodes the 
p110 catalytic subunit of the Class IA PI3K enzyme is amplified or mutated in 34% of 
HPV-negative and 56% of HPV-positive tumours(22). Of the PIK3CA mutations, 73% are 
localized to the E542K, E545K and H1047R/L hotspots, which are known to promote 
activity (Fig. 1.4)(22). PIK3R1, which encodes the p85 regulatory subunit of the Class 
IA PI3K enzyme is mutated in a handful of HPV-negative and HPV-positive cases (1% 
and 3% of cases, respectively), while PTEN, which negatively regulates PI3K signalling, 
is down-regulated or deleted in 612% of cases(22).  
 
1.2.4 Treatment of head and neck cancer 
Although several improvements have been made in the treatment of head and neck 
cancer, including improved chemotherapy regimens and surgical techniques, survival for 
patients with HNSCC has only marginally improved over the last three decades(26). 
HNSCC is primarily treated using a combination of surgery, radiation and/or chemotherapy 
(typically platinum-based drugs such as cisplatin) (4,27,28).  
In addition to standard therapies, a single targeted agent, Cetuximab, has been 
approved by the Food and Drug Administration (FDA) for use in HNSCC patients(29,30). 
Cetuximab is a monoclonal antibody that targets EGFR, which, as mentioned, is amplified 
in a subset of HNSCC cases(21-23). To date, Cetuximab has provided benefit to patients 
with recurrent/metastatic or advanced HNSCC, paving the way for the implementation of 
additional targeted agents guided by the mutational spectra of HNSCC(31,32).  
 Currently, clinical trials are underway for numerous targeted agents and 
immunomodulatory agents(30,33). While loss-of-function aberrations in the tumour 
suppressors p53 and p16 are frequent in HNSCC, reactivation or replacement of these cell 
cycle regulators is challenging and preclinical success has been limited(34,35). Instead, 
targeted inhibition of oncogenic aberrations is actively being investigated. Targeting 
members of the PI3K/Akt/mTOR signalling pathway is considered to be one of the most  
Fig. 1.4. Schematic representation showing the functional domains of the
human PIK3CA gene. Hotspot mutation sites (which make up 73% of
PIK3CA mutations in HNSCC) are indicated (E542K, E545K, H1047R/L).
p85 BD = p85 binding domain, RBD = Ras binding domain, C2 = C2 domain.
p85 BD Catalytic DomainRBD C2
Helical
Domain
H1047R/LE542K
E545K
PIK3CA
9
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promising therapeutic strategies for HNSCC(33). This is due both to the prevalence of 
PI3K pathway alterations in HNSCC tumours, and because preclinical development of 
these agents to date has been extensive, owing to their relevance in other cancer types (e.g. 
breast cancer)(33). Indeed, there is a wealth of targeted PI3K pathway inhibitors in 
development; these are addressed in Section 1.3.5. Immunomodulatory agents are also 
increasingly investigated in HNSCC(36). The checkpoint inhibitor Nivolumab (Opdivo®) 
which binds and inhibits PD-1, is now funded in Canada for patients with recurrent or 
metastatic HNSCC(37,38). In order for targeted drugs to achieve their maximal benefit 
however, it is critical to understand which patients are likely to respond and which would 
do better with other therapies. We can expect that further elucidation of the molecular 
underpinnings of HNSCC disease will lead to additional therapeutic targets, as well as 
improved tailoring of existing treatment modalities for individual patients.  
 
1.2.5 Summary 
HNSCC is by far the most common type of head and neck cancer. These tumours 
are epithelial in histology with evidence of squamous differentiation. HNSCC can be 
divided into tumours driven by HPV infection and those that stem from more traditional 
risk factors, including smoking and alcohol consumption. HPV-positive tumours show 
fewer, consistent alterations, including p16 overexpression. In contrast, HPV-negative 
HNSCC is more heterogeneous. Many of these tumours show loss of either p53 or p16 
and/or mutations or amplifications of EGFR or NOTCH family members. Across all 
HNSCC tumours however, the PI3K pathway is frequently altered, particularly at the level 
of PIK3CA, which is either aberrantly activated by mutation, or amplified. Unfortunately, 
even with improvements in treatment modalities and the adoption of anti-EGFR targeted 
therapy, outcomes for HNSCC patients remain poor and toxicity associated with treatment 
is high. Therefore, an improved understanding of the molecular signalling pathways 
driving HNSCC and how to better target these signalling effectors is essential to more 
effectively treat individuals suffering from HNSCC.  
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1.3 PI3K/Akt/mTOR Signalling in Head and Neck Cancer 
1.3.1 Overview 
Cellular signalling is any process of communication that modulates the activities of 
cells and/or coordinates processes within cells for their lifespan. In cancer, control of 
essential cell signalling is often lost or dysregulated, resulting in uncontrolled cellular 
proliferation, evasion of cell death, increased angiogenic signalling and/or genome 
instability(39,40). These aberrant cellular activities are all considered to be “Hallmarks of 
Cancer”(39,40). The PI3K/Akt/mTOR pathway is centrally involved with managing 
protein translation, proliferation, survival and metabolism of cells. As many members of 
the PI3K pathway are considered to be either proto-oncogenes or tumour suppressors, 
dysregulation of PI3K signalling is known to drive tumorigenesis. This section will 
describe central members of the PI3K pathway, how this network is activated, how 
signalling can contribute to tumorigenesis and what potential exists for targeting PI3K 
signalling in HNSCC and other cancers.  
 
1.3.2 Pathway members and activation 
1.3.2.1  Receptors 
Receptors, including both receptor tyrosine kinases (RTKs) and G-protein coupled 
receptors (GPCRs) are signalling transducers localized to the cell surface(41,42). Both 
families of receptors transduce signals from the extracellular environment to the cytoplasm 
and nucleus, and are among those that activate the intracellular PI3K signalling pathway. 
 Structurally, RTKs are composed of an extracellular (N-terminal) ligand-binding 
domain, a transmembrane domain, and an intracellular catalytic domain. RTKs become 
active when ligands (e.g. growth factors, cytokines or hormones) bind the extracellular 
domain (Fig. 1.5a). Following binding, RTK monomers dimerize with other identical 
monomers (homodimerization), or with other receptor monomers (heterodimerization)(43). 
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Receptor dimerization induces phosphorylation of the intracellular tyrosine kinase domains 
of both receptors. These phosphorylated domains then recruit and further phosphorylate 
downstream targets, thereby activating one or more signal transduction cascades(43). 
Normally RTK activities are tightly controlled. However, RTKs have oncogenic potential 
and aberrant activation of RTKs drives various human cancers. RTKs can be divided into 
numerous sub-families, some examples include: epidermal growth factor receptors 
(EGFR), fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor 
receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), ephrin (Eph) 
receptors and the TAM family of receptors (TYRO3, AXL and MER-TK)(43,44). 
 GPCRs consist of seven transmembrane-spanning domains that associate with 
intracellular G proteins (Fig. 1.5b). Ligand binding to GPCRs results in disassociation of 
bound G proteins, freeing them to then act on their intracellular targets and transduce 
signalling. While GPCRs make up the largest signal-transducing protein family, their role 
in tumour biology is not as well studied as that of RTKs(45). Examples of GPCRs include: 
prostaglandin E2 receptors and beta-adrenergic receptors. Both GPCRs and RTKs are 
known to stimulate PI3K signalling; class IA PI3K isoforms mediate signalling 
downstream of RTKs, while class IB PI3K isoforms signal downstream of GPCRs(46). 
Classes of PI3K isoforms are described in the next section (Section 1.3.2.2).  
 
1.3.2.2 Phosphoinositide 3-kinases (PI3K)  
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that integrate 
signals from various growth factors and cytokines(47-49). PI3Ks activate signalling that 
controls many cellular processes, including cell proliferation, survival, growth, protein 
translation and metabolism(47-49). PI3K enzymes fall into three classes: Class I (A & B), 
Class II and Class III (Table 1.1)(47-49). Class I PI3K enzymes are most often implicated 
in human cancers, with Class IA being the most often associated with downstream 
signalling to Akt/mTOR(50). Class IB PI3K enzymes are typically associated with GPCR 
and small GTPase or G-protein (e.g. RAS) signalling(51). PI3K enzymes are heterodimers 
composed of a catalytic subunit (p110α (PIK3CA), β or δ) and a regulatory subunit (p85α  
Fig. 1.5. Cell surface signalling to Class I PI3K enzymes. Following
activation of receptor tyrosine kinases (RTK) (A) or G-protein coupled
receptors (GPCR) (B), PI3K complexes are recruited to the plasma membrane
where they become activated and produce PI(3,4,5)P3, leading to downstream
pathway activation.
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Table 1.1. Classes of PI3K enzymes. PI3Ks are heterodimers composed of
various combinations of catalytic and regulatory subunits.
Class Sub$Class Subunit Protein Gene Lipid%Substrates Products
I A Catalytic p110⍺ PIK3CA PtdInsPtdIns4PPtdIns(4,5)P2 PtdIns3PPtdIns(4,5)P2PtdIns(3,4,5)P3
p110β PIK3CB
p110δ PIK3CD
Regulatory p85⍺ PIK3R1
p55⍺ PIK3R1
p50⍺ PIK3R1
p85β PIK3R2
p55γ PIK3R3
B Catalytic p110γ PIK3CG
Regulatory p101 PIK3R5
II Catalytic PI3KC2⍺ PIK3C2A PtdInsPtdIns4P PtdIns3PPtdIns(3,4)P2
PI3KC2β PIK3C2B
PI3KC2γ PIK3C2G
III Catalytic Vps34 PIK3C3 PtdIns PtdIns3P
Regulatory Vps15 PIK3R4
14
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(PIK3R1), β or γ). Of all the PI3Ks, mutations in the Class IA genes PIK3CA  and PIK3R1 
are most well established to be associated with human cancer(48,52,53). In HNSCC, 
PIK3CA aberrations are by far the most frequent PI3K alteration documented(22). Class 
IA PI3K enzyme complexes composed of p110α (PIK3CA) and p85 will be the focus when 
PI3K or PI3K complexes are mentioned hereafter. 
PI3K complexes are pre-formed but inactive in the cytosol. These complexes 
interact with phosphorylated tyrosine residues of activated RTKs, either by direct means 
(e.g. via the Src homology 2 (SH2) domain of p85) or by indirect means (e.g. via an adaptor 
protein such as Insulin Receptor Substrate 1 (IRS1)) (Fig. 1.6)(54). In doing so, the p85-
mediated inhibition of p110 is relieved and the PI3K complex becomes catalytically 
active(55). The PI3K complex is now also in close proximity to its substrate: 
phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]. PI3K catalyzes the conversion of 
PI(4,5)P2 to phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3] by phosphorylating the 
γ’-hydroxyl group of PI(4,5)P2(56). PI(3,4,5)P3 then functions as a docking site at the 
membrane for kinases such as Akt (also known as protein kinase B, PKB) and  PDK1(56). 
Opposing PI3K is the phosphatidylinositol-3,4,5-trisphosphate phosphatase and 
tensin homolog (PTEN). PTEN catalyzes the conversion of PI(3,4,5)P3 back to PI(4,5)P2 
(Fig. 1.6)(57). PTEN therefore functions as a negative regulator of the cellular PI(3,4,5)P3 
concentration and downstream PI3K signalling. An additional regulator of PI3K activation 
comes from the RAS/RAF/MEK/ERK (MAPK) signalling pathway. p110 is able to 
directly associate with the well-known RAS oncoprotein (via its RAS-binding domain 
(RBD)) (gene structure shown in Fig. 1.4)(58). This interaction promotes the catalytic 
activity of p110, thereby permitting RAS-mediated activation of PI3K/Akt/mTOR 
signalling(58-60). 
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Fig. 1.6. Activation of the PI3K/Akt/mTOR signalling cascade. Following
activation of receptor tyrosine kinases (RTKs), PI3K is recruited to the
membrane to activate its catalytic activity. PI3K complexes are pre-formed
but inactive in the cytosol. At the membrane, PI3K generates PI(3,4,5)P3
which acts as a membrane-docking site for Akt kinases. Akt is recruited to the
membrane and activated by phosphorylation on Ser473 by mTORC2 and on
Thr308 by PDK1. Akt phosphorylates and de-stabilizes TSC1/2, promoting
activation of the Rheb GTPase. GTP-Rheb activates mTORC1 which then
phosphorylates p70S6K and 4E-BP1. Active PI3K signalling promotes
cellular growth, survival, protein synthesis and metabolism. The PI3K
pathway can be attenuated by PTEN, which reverts PI(3,4,5)P3 back to
PI(4,5)P2.
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1.3.2.3 3-Phosphoinositide dependent kinase 1 (PDK1) 
 3-phosphoinositide dependent kinase 1 (PDK1) is a key signalling effector 
downstream of PI3K. PDK1 is considered to be constitutively-active, as phosphorylation 
of its activation loop (Ser241) is catalyzed by PDK1 itself(61). Additionally, the Ser241 
site has been found to be poorly-accessible to phosphatases, making its de-phosphorylation 
inefficient(61). While PDK1 is constitutively-active, its ability to activate Akt relies on its 
proximity to it. Both PDK1 and Akt are recruited to the plasma membrane by PI(3,4,5)P3 
produced by PI3K(56). When both effectors localize to the plasma membrane, PDK1 
phosphorylates Akt (Fig. 1.6)(56).  
 
1.3.2.4 Akt kinases 
The three Akt kinases (1, 2 and 3) are encoded by different genes and have tissue-
specific expression patterns. Akt1 is ubiquitously expressed, Akt2 is expressed in insulin-
sensitive tissues (e.g. liver, adipose and muscle) and Akt3 is expressed in the brain and 
testes(62-64). All three Akt kinases have the same structure of protein domains(56). Like 
PDK1, Akt is recruited to the plasma membrane via its interaction with PI(3,4,5)P3(56). 
For maximal activity, Akt kinases require two activating phosphorylation events, described 
below(50,65,66). 
Following interaction with PI(3,4,5)P3 at the plasma membrane, the conformation 
of Akt changes(67). This change in confirmation allows for phosphorylation of Akt1/2/3 
on Ser473/474/472 of the C-terminal hydrophobic motif by mTOR complex 2 (mTORC2; 
discussed further in Section 1.3.2.6)(68). Phosphorylation on Thr308/309/305 of the kinase 
domain activation loop of Akt1/2/3 is then conferred by PDK1(69). Although there has 
been discussion surrounding the order and necessity of these two phosphorylation events, 
phosphorylation of Akt Ser473 tends to be regarded as the first phosphorylation event, 
which then stimulates Akt phosphorylation at Thr308 by PDK1, leading to full Akt 
activation(65,70). It is thought that phosphorylation of both Ser473 and Thr308 is 
necessary for maximal Akt activation(50,65,66).  
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1.3.2.5 Tuberous sclerosis complex (TSC1/2)  
The genes TSC1 and TSC2 encode proteins that heterodimerize to form the 
Tuberous Sclerosis Complex (TSC1/2). TSC1/2 functions as a negative regulator of the 
PI3K/Akt pathway, acting downstream of Akt and upstream of mTORC1 to limit cellular 
proliferation and growth (71). Specifically, TSC1/2 converts the GTPase Rheb (RAS-
homolog enriched in brain) to its inactive, GDP-bound state(72). The central function of 
Rheb is to activate mTORC1; therefore, when Rheb is GDP-bound, signalling through 
mTORC1 is off. Akt phosphorylates TSC2, destabilizing the TSC1/2 complex and 
preventing its activity. As a result, Rheb can bind GTP and subsequently activate mTORC1 
(Fig. 1.6)(72-74).  
 
1.3.2.6 Mechanistic target of rapamycin (mTOR) kinase complexes 
The mTOR protein kinase exists in two large multi-protein complexes: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Both complexes share the same 
catalytic subunit mTOR, the scaffolding protein mLST8 and the negative regulatory 
subunit DEPTOR(70). mTORC1 also includes RAPTOR (regulatory associated protein of 
mTOR) and PRAS40 (proline-rich Akt substrate of 40kDa) (Fig. 1.7a). mTORC1 is 
stimulated downstream of Akt, through activation by Rheb, as described. In addition, Akt 
phosphorylates PRAS40, preventing it from binding and otherwise blocking the activity of 
RAPTOR(75). Therefore, mTORC1 activation is dependent on upstream Akt activity at 
more than one level. Once activated, mTORC1 phosphorylates several proteins, but its two 
most well-known targets are the ribosomal protein S6 kinase 1 (p70S6K) and the 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) (Fig. 1.6, Fig. 
1.7a)(76). p70S6K phosphorylation leads to its activation, and the assembly of protein 
translation-related factors(77). Phosphorylation of 4E-BP1 prevents it from binding and 
sequestering the eukaryotic translation initiation factor 4E (eIF4E), which frees up this 
protein to aid in complex assembly at the 5’-end of mRNA strands(78). Through the 
phosphorylation and activation of p70S6K and 4E-BP1, as well as several other targets, 
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mTORC1 functions as a key mediator of protein translation and metabolism, specifically 
as a regulator of translation initiation (recruitment of ribosomes to mRNA), which is a rate-
limiting step in protein synthesis(77,78). 
mTORC2 is the lesser-known mTOR complex, is defined by the RICTOR subunit, 
but also contains PROTOR and mSin1, in addition to DEPTOR, mLST8 and mTOR (Fig. 
1.7b)(70). As mentioned, mTORC2 functions upstream of Akt; it phosphorylates Akt 
Ser473 to promote its activity(65,68). In addition to Akt activation, mTORC2 
phosphorylates protein kinase C alpha (PKC) and serum/glucocorticoid regulated kinase 
1 (SGK1) (Fig. 1.7b)(65,79-81). The upstream regulation of mTORC2 remains largely 
unclear, however PI(3,4,5)P3 levels have been cited to affect mTORC2 signalling(82). 
Because the mTORC2 substrates (Akt, SGK1 and PKCα) are known to respond to different 
growth factors, it is likely that several types of growth factor signals are capable of 
activating mTORC2. At present, mTORC2 remains largely unexplored; the regulation and 
function of mTORC2 represent an important area for future research, especially given its 
key role in the oncogenic PI3K network. 
 
1.3.2.7 Ribosomal protein S6 kinase 1 (S6K) and ribosomal protein 
S6 (S6) 
The ribosomal protein S6 kinase 1 (p70S6K or S6K; encoded by RPS6KB1) is one 
of the best studied effectors of mTORC1(83). While S6K is phosphorylated at numerous 
residues, phosphorylation of Thr389 by mTORC1 is absolutely required for S6K 
activity(83). Once active, S6K phosphorylates its substrate, the ribosomal protein S6 (rpS6 
or S6), which is a component of the 40S ribosome(83). S6 also has multiple 
phosphorylation sites, including Ser235, Ser236, Ser240 and Ser244. Among these 
residues, Ser240 and Ser244 are phosphorylated by S6K(83). Ser235 and Ser236 are 
phosphorylated by p90RSK, a downstream member of the MAPK pathway(83). Apart from 
activation of S6, one of the key activities of S6K is its participation in various negative  
Fig. 1.7. Specific co-factors of mTOR complexes 1 and 2. Both mTOR
complexes contain the catalytic subunit mTOR, the scaffolding protein
mLST8 and the negative regulatory subunit DEPTOR. mTOR complex 1
(mTORC1) (A) also contains RAPTOR and PRAS40. mTOR complex 2
(mTORC2) (B) also includes RICTOR, PROTOR and SIN1.
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feedback loops, including one which regulates the activity of mTORC2. Upon activation, 
S6K exerts negative feedback regulation on mTORC2 via phosphorylation of Thr1135 of 
RICTOR(70,83). Therefore, mTOR is uniquely positioned to function both upstream of 
Akt (in mTORC2) and downstream of Akt (in mTORC1). 
 
1.3.3 Signalling attenuation 
Signalling through the PI3K/Akt/mTOR network is controlled at multiple levels by 
negative regulators (e.g. PTEN, TSC1/2) and feedback loops (e.g. S6K-
RICTOR/mTORC2), as discussed above. Availability/abundance of ligands also affects 
the extent of signalling at the level of cell surface receptor activation(84). Other means of 
signalling attenuation include the activities of the lipid phosphatases PHLPP1 and PHLPP2 
(PH-domain and leucine-rich repeat protein phosphatases). PHLPP1 and PHLPP2 de-
phosphorylate Akt and S6K(85,86). In addition, AMP-activated protein kinase (AMPK) 
activates TSC2 by phosphorylation, thereby promoting TSC1/2 activity, which inhibits 
mTORC1(72). It is evident that multiple mechanisms exist to negatively regulate and 
therefore balance PI3K/Akt/mTOR signalling in cells. 
 
1.3.4 Aberrant PI3K pathway activation in HNSCC 
The PI3K/Akt/mTOR pathway exhibits oncogenic activation in many human 
cancers, including HNSCC. In HNSCC, both mutations in pathway members (single 
nucleotide variations; SNVs) and gene copy-number aberrations (CNAs) are common(21-
23). Beginning upstream, alterations in RTKs that activate PI3K signalling have been 
reported. These include amplifications of members of the ErbB family, such as EGFR 
(ERBB1) and HER2 (ERBB2)(22). In addition, FGFR1 is amplified in approximately 10% 
of HPV-negative HNSCCs(22). 
At the intracellular level, PIK3CA is altered in approximately 56% of HPV-positive 
and 34% of HPV-negative HNSCCs(21-23). Alterations are either gene amplifications or 
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SNVs, typically in a nucleotide at one of three hotspot codons (E542, E545, H1047)(21-
23).  PTEN, the negative regulator of PI3K pathway activity is lost in a subset of HPV-
negative HNSCCs, resulting in a lack of regulation of the PI(3,4,5)P3 pool size when PI3K 
is active(22). Using the TCGA database of 504 primary HNSCC tumours, we examined 
amplifications, deletions, mRNA expression and mutations in all PI3K/Akt/mTOR 
pathway members discussed in this thesis. In doing so, the PI3K/Akt/mTOR pathway was 
found to be altered in 406/496 (82%) of HNSCC tumours (Fig. 1.8). 
 Aberrant downstream PI3K signalling resulting from the alteration of one of more 
pathway members promotes many of the hallmarks of cancer (Fig. 1.9). To support the 
rapid cell cycle turnover, elevated mTOR activity enables high levels of protein 
translation(77,78,87). Akt/mTORC1 signalling also strongly promotes angiogenesis by 
activating pro-angiogenic genes (e.g. VEGF) in a hypoxia-inducible factor alpha (HIF1α 
& HIF2α)-dependent manner(88). Further, Akt negatively regulates pro-apoptotic proteins 
(e.g. BAD, BIM) through phosphorylation, or by phosphorylation of Forkhead Box O 
(FOXO) transcription factors to prevent their expression(89-91). By preventing pro-
apoptotic genes from being transcribed, Akt promotes cell survival. Given the multiple 
means through which PI3K/Akt/mTOR signalling can support cell survival and 
proliferation, it is evident that it is a critical driver of oncogenesis. 
 
1.3.5 Targeting the PI3K network 
Drug development of PI3K/Akt/mTOR pathway inhibitors has continued to 
increase over the past decade, as highlighted by the numerous clinical trials underway 
assessing a large number of distinct inhibitors(33). Current agents in development include 
irreversible pan-PI3K inhibitors (e.g. PX-866), reversible ATP-competitive pan-Class I 
PI3K inhibitors (e.g. GDC-0941, BKM120), isoform-selective PI3K inhibitors (e.g. 
INK1117 and BYL719 for p110, CAL-101 for p110), dual PI3K/mTOR inhibitors (e.g. 
BEZ235, GSK1059615, XL765, GDC-0890), mTOR inhibitors (allosteric inhibitors: 
Rapamycin, Sirolimus, Temsirolimus, Everolimus, Ridaforolimus, or catalytic inhibitors:  
Fig. 1.8. Genomic aberrations and RNA expression for PI3K/Akt/mTOR
pathway members in HNSCC primary tumours. Using data from The
Cancer Genome Atlas (TCGA) Project, 496 HNSCC tumours were profiled
for gene copy number aberrations (CNAs), single nucleotide variations
(SNVs) and RNA expression. cBioPortal (http://www.cbioportal.org/) was
used to generate a visual “OncoPrint”. Each patient tumour sample is
represented by a single grey vertical line. HPV status is indicated (blue; HPV-
negative, red; HPV-positive). Projected effect of genomic aberrations is
indicated in legend. 82% (406/496) of tumours surveyed contained some type
of genomic aberration or altered RNA expression.
Hpv status p16
PIK3CA
PIK3R1
PDK1
AKT1
AKT2
AKT3
TSC1
TSC2
MTOR
RPTOR
RICTOR
RPS6KB1
RPS6
47%
5%
8%
18%
14%
10%
11%
6%
10%
8%
19%
3%
8%
Genetic Alteration Inframe Mutation (putative driver) Inframe Mutation (unknown significance) Missense Mutation (putative driver)
Missense Mutation (unknown significance) Truncating Mutation (putative driver) Truncating Mutation (unknown significance)
Amplification Deep Deletion mRNA Upregulation mRNA Downregulation No alterations
Hpv status p16 Negative Positive No data
24
 
25 
 
AZD8055, OSI-027, INK128) and Akt inhibitors (allosteric inhibitors: MK-2206, or 
catalytic inhibitors: GDC-0068 and GSK690693)(33,92-94). Drugs in bold represent those 
tested in this thesis. A schematic of available agents targeting the PI3K pathway is shown 
in Fig. 1.10.  
The prevalence of activating PIK3CA aberrations in HNSCC tumours make PI3K 
itself an ideal target for inhibition as tumours harbouring PIK3CA or other PI3K alterations 
are thought to be ‘addicted’ to PI3K signalling for growth and survival. Isoform-selective 
PI3K inhibitors tend to show greater target inhibition and fewer adverse toxicities 
compared to pan-PI3K inhibitors(95,96). To date, pan and isoform-selective PI3K 
inhibitors target both wildtype and somatic mutant variants of PI3K(97,98). It continues to 
be debated as to whether this limits the therapeutic window for using PI3K inhibitors or 
whether inhibiting PI3K signalling in tumours is beneficial even when PI3K or the pathway 
is not specifically mutated or hyperactivated (Ruicci KM, et al., 2018, under review; 
Chapter 2 of this thesis)(33,97). Overall, the toxicity profile of PI3K inhibitors in clinics 
has been acceptable, without dramatic or unexpected toxicities. Most frequently, adverse 
symptoms include: hyperglycemia and gastrointestinal upset (vomiting, diarrhea)(98-100).  
Compounds targeting mTOR were among the first agents targeting the PI3K 
network to enter clinics(101). Rapamycin and its derivatives (known as ‘rapalogs’) are 
allosteric inhibitors of mTOR. While rapalogs have been found to show efficacy in 
particular settings, such as when combined with endocrine therapies, agents targeting the 
catalytic site of mTOR are increasingly the preclinical and clinical focus(33,102). Catalytic 
mTOR inhibitors are thought to have the significant advantage of being capable of 
inhibiting both mTORC1 and mTORC2, unlike the rapalogs which only affect 
mTORC1(33). To date, no specific inhibitors of mTORC2 exist. However, there is an 
increasing push for the development of an mTORC2-specific agent owing to its recognized 
role in mediating Akt activation and the prevalence of RICTOR amplification and 
overexpression in certain cancers(103-105).  
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Fig. 1.9. PI3K/Akt/mTOR signalling network and relevant drugs that
target each of the components of the pathway. Numerous compounds have
been developed to inhibit different nodes of the PI3K/Akt/mTOR signalling
pathway. These include PI3K inhibitors (these can be sub-divided on the basis
of their selectivity into: pan-PI3K inhibitors, isoform-specific inhibitors and
dual pan-PI3K/mTOR inhibitors), Akt inhibitors (including both allosteric and
catalytic inhibitors) and mTOR inhibitors (either allosteric inhibitors
(rapalogs; mTORC1-specific) or catalytic inhibitors (dual mTORC1/2)).
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1.3.6 MAPK signalling 
One of the signalling pathways most highly interconnected with PI3K/Akt/mTOR 
signaling is the RAS/RAF/MEK/ERK, or MAPK, pathway(58,106).  The MAPK 
signalling pathway is critically involved in the regulation of cell cycle progression, 
apoptosis and growth. The most upstream member, RAS, is a GTPase that interacts with 
activated RTKs and GPCRs through the Src-homology/Growth factor receptor-bound 
protein 2/Son of Sevenless (Shc/Grb2/SOS) complex (Fig. 1.11)(51). Following 
interaction with the Shc/Grb2/SOS complex, RAS undergoes a conformational change 
from an inactive to active state(107,108). The three predominant RAS isoforms are HRAS, 
KRAS and NRAS; each is relevant in particular contexts(109,110). RAF (rapidly 
accelerated fibrosarcoma) kinase is a downstream target of RAS that activates mitogen-
activated protein kinase kinases, such as MEK1/2(111). Activated MEK1/2 catalyzes the 
activation of extracellular signal-regulated kinases (e.g. ERK1/2), which are responsible 
for phosphorylation of a number of downstream targets, including p90RSK(111,112). As 
mentioned, p90RSK is another key activator of S6, apart from p70S6K(112-114). p90RSK 
phosphorylates S6 at Ser235 and Ser236(112-114).  
Constitutive MAPK signalling is observed in numerous cancer types(107,108). 
Like the PI3K/Akt/mTOR pathway, aberrant activation of MAPK signalling can occur by 
various means. This may include overexpression or activation of RTKs, or overexpression 
or genetic aberrations in one or more pathway members(107,108). RAS mutations, 
typically in a single isoform, are common in various cancers, including HNSCC where 
about 5% of cases contain HRAS alterations(22). In general, mutations in RAS lead to 
impaired GTPase activity, such that RAS remains in a GTP-bound state and is 
constitutively active(115). RAF alterations are uncommon in HNSCC but are frequently 
observed in melanoma, among other cancers(116).  
In terms of interconnectivity with the PI3K/Akt/mTOR pathway, the MAPK 
signalling cascade promotes PI3K signalling by several means. ERK is known to confer 
inhibitory phosphorylation to TSC2, leading to TSC1/2 inactivation and mTORC1 
activation(117). ERK and its substrate p90RSK also both phosphorylate RAPTOR,  
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Fig. 1.10. Activation of the RAS/RAF/MEK/ERK signalling cascade. The
RAS/RAF/MEK/ERK (MAPK) signalling pathway is highly interconnected
with the PI3K pathway. Upstream, the GTPase RAS associates with activated
RTKs and GPCRs via the Shc/Grb2/SOS complex and becomes active. RAF
is a downstream target of RAS and it activates kinases including MEK1/2.
MEK1/2 then catalyzes the activation of ERK1/2, leading to downstream
P90RSK activation. Collectively, the MAPK signalling pathway is critically
involved with regulating cell cycle progression, apoptosis and cell growth.
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promoting mTORC1 activity(118). Finally, as mentioned, RAS interacts with the catalytic 
subunit of PI3K complexes, stimulating activity(58-60). Therefore, the PI3K/Akt/mTOR 
and MAPK can be thought to signal in a parallel with each other; both driving cellular 
proliferation, survival and growth. 
 
1.3.7 Summary 
 PI3K/Akt/mTOR signalling is activated by cell surface RTKs and GPCRs that 
stimulate PI3K enzymes to generate PI(3,4,5)P3 which pools in the cytoplasm. PI(3,4,5)P3 
recruits downstream effectors such as PDK1 and Akt. Akt is activated by both PDK1 and 
mTORC2 to initiate a signalling cascade leading to the activation of the downstream kinase 
complex mTORC1. Effector kinases of mTORC1 promote cell survival, proliferation, 
angiogenesis and protein synthesis; cellular activities that fuel tumorigenesis. In HNSCC, 
PI3K signalling is altered in approximately 80% of cases(21-23,119,120). Therapeutic 
inhibition of PI3K signalling is therefore a major pre-clinical and clinical research interest. 
Numerous clinical trials are underway using PI3K and PI3K-pathway inhibitors (examples: 
NCT02506556, NCT01629615, NCT01297491, NCT03601507). The role of the 
PI3K/Akt/mTOR pathway as a central driver of oncogenesis in HNSCC is apparent and 
research to advance targeting this pathway by better understanding the molecular 
underpinnings of PI3K signalling in HNSCC necessary.  
 
1.4 Cancer Therapeutic Resistance 
1.4.1 Overview 
Over the past few decades, there has been growing enthusiasm for the clinical 
implementation of targeted cancer therapies. Such therapies are designed to specifically 
target cellular pathways and mechanisms known to be activated in tumour cells. It is 
believed that targeted therapies offer reduced side effects and improved efficacy compared 
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to traditional cytotoxic chemotherapies(121). As discussed previously, PI3K pathway 
targeted agents are at various stages of preclinical and clinical development(33). 
Unfortunately, despite the demonstrated efficacy of various PI3K pathway targeted drugs 
in HNSCC and other cancers, it is now recognized that, with few exceptions, resistance to 
targeted therapies is almost universally inevitable(122). Resistance to anti-cancer targeted 
drugs can be sub-divided into cases of innate resistance, and cases of acquired 
resistance(122). This section will address the challenges posed by both innate and acquired 
resistance in the management of human cancers and then will outline experimental 
approaches to studying therapeutic resistance and current strategies under investigation to 
overcome resistance. 
 
1.4.2 Innate resistance 
 Some cancers are unresponsive to targeted therapies from the very outset of drug 
administration; these can even include tumours in which the targeted oncogene is present 
and/or activated by a genomic aberration(122-124). Mechanisms supporting innate 
resistance to anti-cancer therapies vary widely and continue to be discovered, but often 
innate resistance is caused by the constitutive activity of signalling transducers downstream 
of the drug target(125). An example of this is seen in non-small cell lung cancer (NSCLC) 
with EGFR tyrosine kinase inhibitor (TKI) therapy, where about 30% of patients with 
activating EGFR mutations are non-responsive to EGFR inhibition. One of the established 
mechanisms of innate resistance to EGFR inhibition in these cases includes the presence 
of activating mutations in the downstream signalling effector KRAS(126).  
 While a particular tumour may be innately resistant to a targeted therapy as a whole 
(Fig. 1.12a), the heterogeneity known to exist in the majority of cancers means that 
alternatively, a subset of tumour cells within a single tumour may bear a genomic feature(s) 
conferring resistance, while the remaining tumour cells may be responsive (Fig. 1.12b)(122-
124). In this case, the tumour may shrink initially before slowly re-growing as cells with 
innate resistance become predominant(122-124). Even in these cases, the application of the 
targeted agent to stabilize tumour growth even for a short timeframe may have clinical  
Fig. 1.11. Schematic illustrating innate resistance to targeted cancer
therapy. (A) Tumour cells are non-responsive to the targeted agent
administered. The targeted pathway may be irrelevant to the survival of the
tumour cells, or the tumour may contain one or more genomic aberrations that
confer it a survival advantage despite drug administration. (B) A sub-
population of tumour cells in the primary contain a genomic feature that
confers resistance to the targeted agent being administered. While a portion of
the tumour responds to targeted therapy, the innately-resistant cell(s)
eventually dominate the tumour niche and a clinical relapse occurs.
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benefit when combined with other treatment modalities. However, for patients who are 
entirely non-responsive to targeted agents and derive no measurable benefit, biomarkers 
are critical in order to avoid unnecessary toxicity and expense. Biomarkers can include 
specific genomic aberrations (mutations, copy number changes), expression signatures 
(transcript or protein) or metabolic states(127). Most often, biomarkers are based on 
observations made in preclinical research or prior clinical experience and can predict for 
either response or non-response to a targeted drug(127).  
 
1.4.3 Acquired resistance 
Apart from cancers that are non-responsive to targeted therapies, nearly all cancers 
develop resistance over time to targeted therapies, even after promising initial responses 
(Fig. 1.13)(122). Acquired resistance can occur through many different mechanisms and 
elucidating mediators of resistance to particular therapies in different cancer types is the 
subject of intensive research. Known mechanisms of acquired resistance include mutations 
in the drug target, activation of parallel signalling pathways, amplification or constitutive 
activation of downstream effectors and changes in drug uptake or metabolism(128). 
Returning to the example of targeted EGFR inhibition, two acquired resistance 
mechanisms have been identified. The first is the acquisition of a T90M mutation in EGFR 
that increases the affinity of mutant EGFR for ATP, enabling ATP to out-complete the 
targeted drug(129,130). Alternatively, amplification of the MET receptor has been 
observed following prolonged EGFR inhibition, allowing tumour cells to survive by 
switching their signalling dependencies(131).  
In many instances, patients without a known biomarker predicting innate resistance 
may respond to a targeted drug for weeks to months prior to the detection of growing 
tumour(132). It is often difficult to determine whether the emergence of tumour following 
months of successful treatment reflects slow-growing cells that were innately resistant to 
therapy, or whether the selective pressure from the targeted agent led to the acquisition of 
a new genomic feature or signalling capability in even a single tumour cell that allowed 
tumour re-growth over time(122). Further, these scenarios (pre-existing cells with a  
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Fig. 1.12. Schematic illustrating acquired resistance to targeted cancer
therapy. A primary tumour is treated with a targeted agent over a period of
weeks to months. Despite an initial apparent response, the prolonged selective
drug pressure can induce changes in the tumour genetics, epigenetics,
transcriptome, proteome and/or metabolome that impart resistance to the
targeted drug. Over time, the sub-population of drug-resistant cells
accumulate and eventually cause a clinical relapse.
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genomic aberration, versus newly-arising mutations) are not mutually exclusive and both 
can lead to eventual treatment failure. Designing therapeutic approaches to overcome the 
inherent challenge of drug resistance is critical to achieving more durable patient outcomes. 
 
1.4.4 Experimental approaches to study resistance 
 With the recognition of the inevitability of resistance to targeted therapies, 
numerous experimental approaches have been established to interrogate mechanisms 
supporting drug resistance. By understanding the molecular underpinnings driving drug 
resistance, the design of rational combinations of therapies is possible. Experimental 
models used to study anti-cancer drug resistance include: cell line models and xenograft 
models (discussed below), as well as discovery-based screening methods (e.g. 
overexpression screens to evaluate which genes can drive cells to resistance, or 
knockdown/knockout screens to determine which signalling effectors either confer 
resistance, or sensitize cells to the drugs when lost).   
 Cell line models are most commonly used to study resistance. Drug-resistant cell 
lines can be generated to model the clinical setting or to serve as higher-level experimental 
models(133). Cell line models of acquired drug resistance typically entail the serial dosing 
of cells with the drug of interest for between 218 months, on average(133). Approaches 
to generate drug-resistant cells vary between studies; treatment may be pulsed or 
continuous, drug dosing may remain constant or be escalated over time and single cells 
maybe isolated to generate clonal resistant lines(133-136). In Chapter 4 of this thesis, 
acquired resistance to PI3K inhibition is explored using both HNSCC cell lines and patient-
derived xenograft (PDX) models, discussed below. 
 Xenograft models of drug resistance most often entail the implantation of cancer 
cells (cell line xenografts) or tumour tissue (patient-derived xenografts) into mice, which 
are then treated over time with the drug of interest. Owing to the established strengths of 
PDX models, including their ability to preserve the tissue architecture, pathological 
features and molecular characteristics of patient tumours, as well as their ability to 
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accurately model clinical response rates seen in patients, PDX models of acquired 
resistance are a promising preclinical platform that is increasingly employed(137,138). 
Following the generation of either in vitro or in vivo models, drug-resistant models are 
typically surveyed for altered features relative to their parental counterpart models. These 
could include changes in their mutational spectra, differences in transcript or protein 
expression, or altered metabolism.  
 
1.4.5 Strategies to overcome resistance  
The identification of resistance mechanisms to targeted anti-cancer agents has led 
to several strategies aimed at circumventing or overcoming resistance to achieve more 
durable patient responses(139). Drug combinations, combinations of treatment modalities 
and strategic changes in drug administration protocols are some of the predominant 
approaches currently used to address the inevitable occurrence of drug resistance. Much 
research in the past decade has focused on elucidating mechanisms of resistance to some 
of the leading targeted therapies. By anticipating the secondary oncogenic dependencies 
that develop as a result of treatment with specific targeted agents, effective combinations 
of agents may be designed. These drug combinations are intended to reflect the established 
molecular mechanisms associated with therapeutic resistance(139). It is presently debated 
as to whether second-line agents are best administered in combination with the primary 
agent (if the resistance mechanism they target is well-established and very likely to arise), 
or whether sequential therapy will more effectively control the emergence of drug-resistant 
tumour cells over time(140-142). Importantly, the resistance mechanisms that emerge to a 
particular agent may depend, in part, on the therapy regimen followed and this is an 
important point of consideration(143).  
Apart from combining targeted therapies to prevent drug resistance, maximizing 
the success of targeted drugs may come from combining them with other treatment 
modalities. These may include standard cytotoxic chemotherapies, radiation therapy, 
surgery or, increasingly, immunomodulatory agents(144). For agents with potent but 
 
38 
 
relatively short-term efficacy in patients, their best clinical use may be in the neoadjuvant 
setting, ahead of another treatment.  
1.4.6 Resistance to PI3K inhibition 
As discussed previously, PI3K/Akt/mTOR is the most frequently dysregulated 
pathway in HNSCC and targeting this signalling network is a significant preclinical and 
clinical avenue of study(21-23,33). Despite the number of PI3K inhibitors that have entered 
clinical trials, these agents have displayed generally limited efficacy as single 
agents(99,100,145). Of patients who show an initial response, the development of 
therapeutic resistance over time has been cited(132,134).  
Understanding resistance to PI3K inhibition is an area of active investigation for 
many solid tumour types, at the preclinical and clinical level(132,134-136,146). 
Mechanisms of resistance to PI3K inhibition that have been explored to date include 
elevated expression of RTKs, such as HER2, EGFR and AXL, which provide access to one 
or more secondary pathways and/or increase the relative magnitude of signalling through 
downstream pathways(134,147,148). Alternatively, increased activation of oncogenes, 
including Src, c-Jun and STAT3 has been observed in the setting of acquired resistance to 
PI3K/mTOR inhibition by BEZ235(135). Loss of pathway regulation is another 
established mechanism of acquired resistance to PI3K inhibition(132). Specifically, the 
genetic alterations in PTEN, leading to loss of expression have been observed(132). 
Finally, use of the pan-PI3K inhibitor BKM120 over time has been found to promote 
activation of IL-6/ERK signalling which promotes cellular survival, while administration 
of the -isoform specific PI3K inhibitor BYL719 has been shown to induce growth 
signalling through the PLC-PKC network, downstream of AXL RTKs(134). Numerous 
other examples of resistance exist, highlighting the number of distinct mechanisms and 
mediators of resistance to PI3K inhibition known to date. Given the multitude of resistance 
mediators already established, it seems apparent that drug resistance mechanisms are 
context-specific, on the basis of the particular drug used and/or cancer type; this means that 
specific investigations of drug resistance mechanisms for leading agents is warranted in 
each setting in which they are to be used(128).  
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1.4.7 Summary 
Drug resistance is the primary limiting factor associated with the use of targeted 
therapies for cancer treatment. Resistance may be broadly classed as innate or acquired, 
according to the time frame in which it emerges—either immediately/quickly (innately 
resistant), or over time (acquired resistance). Elucidating mechanisms of resistance is 
important to help understand the underlying molecular biology, which in turn, may guide 
the design of new agents, secondary therapies, or the implementation of drug 
combinations(128). As a wide range of pathways and signalling effectors have been shown 
to play roles in resistance to PI3K inhibition in various solid tumour types, specific 
investigations of how drug resistance develops in different contexts, including in the 
context of HNSCC disease, is necessary.  
 
1.5 Scope of Thesis 
As presented in this introductory chapter, PI3K/Akt/mTOR signalling is a central 
signalling axis in HNSCC. Further, this network is considered to be one of the foremost 
targets for therapeutic inhibition, owing to the number of patient tumours that show 
genomic aberrations or hyperactivation at some level of the pathway. For the PI3K network 
to achieve its promise as a therapeutic target in HNSCC, biomarkers of response and 
resistance are needed, as is an understanding of how the disease may respond over time to 
targeted inhibition.  
The overall focus of this thesis is to identify and explore some of the biomarkers of 
response and mediators of resistance to PI3K inhibition in HNSCC, as doing so may 
uncover novel therapeutic targets or mechanisms which modulate the response of HNSCC 
disease to therapy. I begin by focusing on PI3K inhibition in HSNCC from the perspective 
of biomarker identification and characterization (Chapters 2 & 3), then proceed to explore  
potential second-line targets (Chapters 3, 4 & 5) and examine the acquisition of drug 
resistance over time (Chapter 4). The goal is for these findings to contribute to the 
optimization of PI3K targeted agents for HNSCC patients. 
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Chapter 2  
 
2 A controlled trial of HNSCC patient-derived xenografts 
reveals broad efficacy of PI3K inhibition in controlling 
tumour growth 
2.1 Abstract 
Head and neck squamous cell carcinomas (HNSCCs) frequently harbor alterations 
in the PI3K/AKT/mTOR signalling axis, particularly in the PIK3CA gene. PI3K-targeted 
agents have therefore gained considerable preclinical and clinical interest as emerging 
therapies for HNSCC. Identification of predictive biomarkers of response would advance 
the clinical application of PI3K-targeted drugs for patients in order to achieve maximal 
benefit. To date, studies of drug biomarkers have largely focused on screening cell lines, 
with much more limited in vivo testing, usually only as validation. This approach has rarely 
enabled accurate predictions of clinical efficacy. Recently, clinical trials of PDX models 
(PDX clinical trials) have been introduced as a preclinical approach to interrogate 
interpatient response heterogeneity. Already, PDX clinical trial responses have been 
demonstrated to correlate closely with patient outcomes. Here, using both an HNSCC 
specific, 28-cell line panel and a PDX clinical trial of 80 xenografts derived from 20 unique 
HNSCC tumours, we systematically examine patterns of response to PI3K inhibition in 
HNSCC. We find EGFR, AKT1 and CSMD1 copy number aberrations, but not PIK3CA 
mutations, to be associated with responsiveness to PI3K-targeted drugs. Further, we reveal 
PI3K inhibition to be almost globally tumoristatic in HNSCC xenografts regardless of 
PIK3CA mutational status, emphasizing its potential as a stabilizing neoadjuvant therapy 
for HNSCC patients.  
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2.2 Introduction 
 Head and neck squamous cell carcinoma (HNSCC) affects over 600,000 individuals 
worldwide each year(1). These cancers are among the most drastic in terms of both disease- 
and treatment-associated toxicities, including the requirement for feeding tubes, speech 
impairments, tracheostomies and facial disfigurements(2). Indeed, the non-selective, 
conventional treatment modalities (surgery, radiation, chemotherapy) used to manage 
HNSCC are known to cause damage to normal tissue, in addition to systemic toxicities(2). 
For these reasons, there is an ongoing need for treatment options with increased efficacy 
and reduced toxicities. 
The discovery of driver genomic aberrations has revolutionized care for several 
cancers by providing specific targets for therapeutic inhibition, rather than using broad 
cytotoxic approaches(3). The prevalence of EGFR amplifications in HNSCC for example, 
led to the approval of the EGFR-targeting monoclonal antibody Cetuximab, which has 
provided benefit to patients with recurrent/metastatic or advanced HNSCC(4,5). More 
recently, activating phosphoinositide 3-kinase (PI3K)-pathway alterations, predominately 
in the p110-encoding PIK3CA gene, have been identified in ~80% of HNSCC tumours—
including both HPV-positive and HPV-negative cases(6-10). The PI3K/AKT/mTOR 
pathway is a central regulator of cell growth, protein synthesis, metabolism and 
survival(11). Since the PI3K-pathway is frequently activated in HNSCC and plays a 
principal role in tumorigenesis, inhibition of PI3K signalling is a logical therapeutic route. 
While PI3K-targeting small molecule inhibitors have shown early promise in HNSCC and 
other cancers, predictive biomarkers of response have not been clearly established. 
Tumours with hotspot PIK3CA mutations are thought to be more responsive to therapy 
with specific PI3K inhibitors, however this conclusion has been predominately supported 
by cell line studies and only limited numbers of in vivo models(8,12-14). More rigorous 
preclinical testing is needed to enable accurate predictions of clinical efficacy and to 
identify factors influencing patient responses.  
  Patient-derived xenograft (PDX) models have drawn increasing attention in 
preclinical oncology research owing to their ability to accurately recapitulate human 
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tumour biology, including histopathologic, genetic and epigenetic features of 
tumours(15,16). Further, the responses of PDXs to anti-cancer therapeutics have been 
found to closely correlate with response rates seen in patients(17). As a result, Phase II type 
clinical trials of PDX models (PDX clinical trials) have been recently introduced as an 
experimental approach to interrogate interpatient response heterogeneity. In the present 
study, we have systematically examined PI3K inhibition in HNSCC using a panel of 28 
cell lines and a PDX clinical trial of 80 xenografts derived from 20 unique, genomically 
characterized tumours. We demonstrate for the first time that while PIK3CA mutations may 
predict response in vitro, other genomic features (including copy number aberrations 
(CNA) in EGFR, AKT1 and CSMD1) are associated with responsiveness in vivo. Further, 
we highlight PI3K inhibition to be almost globally tumoristatic in HNSCC xenografts, 
emphasizing its potential for clinical implementation as a stabilizing preoperative or 
neoadjuvant therapy for HNSCC patients. 
 
2.3 Materials and Methods 
Further details are provided as Supplemental Methods (Section 2.7.1). 
  
2.3.1 Cell lines 
HNSCC cell lines were obtained from the sources listed (Supp. Table 2.1). All cell 
lines were cultured in DMEM/F12, with 10% fetal bovine serum (GIBCO), penicillin 
(100IU/mL; Invitrogen) and streptomycin (100μg/mL; Invitrogen), unless otherwise stated 
(Supp. Table 2.1). Cells were maintained in a 37°C humidified atmosphere with 5% CO2. 
Short tandem repeat profiling (The Center for Applied Genetics; Toronto) was used to 
confirm identity of all lines (Supp. Table 2.2). Genomic characterization of cell lines was 
completed as described in Supplemental Methods (Section 2.7.1). 
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2.3.2 Study approval 
 Mice were maintained and handled in accordance with the AUP 1542 approved by 
the University Health Network Animal Care Committee and in accordance with the CCAC 
regulations. Fresh surgical HNSCC specimens were received from consenting patients with 
primarily diagnosed or recurrent HNSCC who underwent surgery at Princess Margaret 
Cancer Centre between 2009 and 2014 under a University Health Network Research Ethics 
Board approved protocol (REB# 12-5639). 
 
2.3.3 Establishment of patient-derived xenografts 
Fresh HNSCC surgical specimens were received within 0.524 hrs of surgery and 
kept at 4C in PBS until engraftment no later than 24hrs post-resection. A piece of tumour 
was flash frozen in OCT embedding medium and stored at -80C for genomic profiling. 
Tumours were then divided into ~1mm3 pieces and implanted subcutaneously into the flank 
region of NOD/SCID/IL2R-/- (NSG) male mice. Once tumours reached 11.5cm in size, 
mice were sacrificed and tumours were dissected from the flank, dissociated in culture 
medium containing collagenase/hyaluronidase and DNASE 1 and passaged 
subcutaneously into 4 mice per tumour model (minimum 100,000 cells/mouse) in 1:1 
matrigel/PBS. Once tumours were palpable, measurements with calipers began. Tumours 
were classified as HPV-positive using immunohistochemistry (IHC) for p16.  
 
2.3.4 PDX clinical trial design and drug treatment 
Tumour models were enrolled into our PCT on a rolling basis once tumour volumes 
reached 80120mm3, without pre-selection on the basis of their genetic features or growth 
latency/doubling time. Four xenografts were established per tumour model and randomized 
to either daily (5x/week) BYL719 (Novartis; 50mg/kg) by oral gavage or a vehicle control 
(corn oil). A total of 20 unique HNSCC tumours were used to generate a total of 80 PDX 
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models. Control-arm mice were maintained until tumours reached a maximum size of 1.5 
cm in diameter or an alternative humane endpoint was reached as stated in the animal 
protocol. Animals were observed daily for their overall health. Mice were evaluated for 
tumour size and body weight every 24 days. Individual tumour volumes were calculated 
using the formula: [length x (width)2] x 0.52. Mean tumour volumes at each time point for 
the vehicle-treated and experimental arms were determined and used to calculate 
BestResponse and BestAvgResponse (described in Supplemental Methods (Section 
2.7.1)(17). 
 
2.3.5 PDX genomics 
 Genomic characterization of HNSCC tumours was completed as described by 
Karamboulas et al., Cell Reports, 2018 (under revision).  
 
2.3.6 Statistics 
 Analyses were performed with Prism® 7 GraphPad Software. Statistical hypotheses 
were tested using 2-tailed Welch’s t-tests. A p value of less than 0.05 was considered 
significant.  
 
2.4 Results and Discussion 
2.4.1 Characterization of HNSCC cell lines identifies genomic 
features observed in patients 
In an initial approach to examine the sensitivity of preclinical HNSCC models to 
PI3K inhibition, we measured, in a panel of 28 HNSCC cell lines, the mean inhibitory 
concentration (IC50) after 72 hours of drug treatment. We tested all cell lines with dual 
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PI3K/mTOR inhibitor BEZ235, pan-PI3K inhibitor GDC-0941 and PI3K inhibitor 
BYL719. Importantly, all cell lines underwent targeted sequencing for single nucleotide 
variations (SNVs) in 42 HNSCC-related genes (Supp. Table 2.3), as well as OncoScan 
SNP arrays to characterize CNAs. As in patients, aberrations in TP53, EGFR and CDKN2A 
were almost exclusively restricted to HPV-negative cell lines, while PIK3CA SNVs and 
CNAs were observed in both HPV-positive and negative lines (Fig. 2.1a). The majority 
(73%) of PIK3CA mutations in HNSCC occur in one of three hotspot regions of the helical 
(E542K, E545K) or kinase domains (H1047R/L) and lead to gain-of-function activation of 
PI3K(6,18). All six PIK3CA mutations detected in our panel were at canonical hotspots 
(Supp. Table 2.4). Overall, we found the genomic landscape of HNSCC cell lines to be 
representative of HNSCC patient tumours(6,7,14). 
 
2.4.2 In vitro PI3K inhibition highlights putative biomarkers of 
response 
Following treatment with PI3K inhibitors, cell lines showed a gradient of 
sensitivities. GDC-0941 and BEZ235 were broadly potent, while responses to BYL719 
were more variable. Clinically, pan-PI3K and dual PI3K/mTOR inhibitors, such as 
BEZ235 and GDC-041, have shown high rates of side effects, compromising their use(19). 
We therefore focused predominately on the -isoform specific inhibitor BYL719, which 
is in Phase II clinical development for HNSCC and offers both improved therapeutic 
efficacy and a reduced toxicity profile(19). 
When we stratified responses by PIK3CA gene status we found that, in line with 
previous studies, PIK3CA amplifications were not associated with response to PI3K 
inhibition (p = 0.568, Fig. 2.1b), while PIK3CA hotspot mutant cell lines were more 
sensitive (p = 0.026) (Fig. 2.1c)(12,14,20). Data for BEZ235 and GDC-0941 are shown in 
Supplemental Fig. 2.1. Notably, numerous WT PIK3CA cell lines were equally as sensitive 
to PI3K inhibition as PIK3CA mutant lines. BYL719 has equipotent activity against both 
WT and somatic mutant variants of PI3K(12); while as a group PIK3CA mutant lines  
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Fig. 2.1. Mutational landscape of HNSCC cell lines and genomic
aberrations associated with PI3K inhibitor response. (A) Main genomic
features and HPV status for 28 HNSCC cell lines. Box plots show log
distribution of cell line sensitivities to BYL719 when stratified by genomic
features. Cell lines with PIK3CA amplifications (B) were not differentially
responsive to PI3K inhibition (p = 0.568). Hotspot PIK3CA mutant cell lines
were significantly more sensitive to BYL719 (p = 0.026) (C). * represents p <
0.05, ** represents p < 0.01, ns = not significant, Welch’s t-test.
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were more sensitive, it is apparent that responsiveness to PI3K inhibition is not restricted 
solely to PIK3CA mutants and other biomarkers of response may exist. Further, early 
clinical reports of PI3K inhibition suggest that PIK3CA mutant tumours are not universally 
sensitive to PI3K inhibition(21). These observations collectively emphasize the complex 
relationship that exists between target mutations and response to targeted therapeutics. 
 
2.4.3 Preclinical assessment of BYL719 in a PDX clinical trial 
While cell lines fill an essential role in the preclinical setting to study cancer 
biology, it has been shown that not all biomarkers identified in vitro hold true in vivo and 
vice versa. Given the demonstrated correlation between PDX drug response and patient 
clinical responses, PDX studies are critical for obtaining preliminary determinations of 
drug efficacy and for more accurately modeling response rates likely to be seen in 
patients(17). We passaged 20 HNSCC tumours (clinical characteristics are shown in Table 
2.1) to generate 80 total xenografts that we randomized to either BYL719 (50mg/kg) or 
vehicle treatment (Fig. 2.2a). All tumours underwent targeted sequencing (Supp. Table 
2.5) and genomic features common to HNSCC (including PIK3CA hotspot mutations and 
amplifications, EGFR amplifications, CSMD1 deletions and HRAS mutations) were 
observed (Fig. 2.2b).  
Following treatment, we categorized responses relative to baseline size using the 
modified RECIST (mRECIST) criteria described by Gao et al., which is based on the 
Response Evaluation Criteria in Solid Tumours (RECIST)—a set of clinically-established 
criteria defining when cancer patients “respond”, remain unchanged (“stable”) or “progress” 
during treatment(17,22). It is important to note that in the majority of xenograft-based 
studies, treatment efficacy is evaluated by comparing experimental and vehicle-treatment 
arms, rather than by comparing tumour size post-treatment to baseline tumour size, as is 
done clinically(22). When referenced to baseline, the majority of our PDXs classified as 
having progressive disease (mPD) (15/20; 75%), while the remaining models classified as 
stable disease (mSD) (5/20; 25%) (Fig. 2.2c). Only one tumour model (18342) showed a  
  
Table 1. Clinical characteristics of patients whose tumours were used to generate patient derived xenografts that were included in the 2x2 BYL719 trial 
UICC Disease HPV Smoking Alcohol
T N M Stage Site Status History Consumption
18342 F 63 T4a N0 M0 IVA Lip & Oral CavityLower Alveolus & Gingiva nt Non-smoker Light
68624 M 69.5 T3 N1 M0 III Lip & Oral Cavity Tongue nt Active smoker Heavy
20853 M 72 T2 N2b M0 IVA Lip & Oral Cavity Tongue nt Ex-smoker Non-drinker
73262 M 66 T1 N1 M0 III Lip & Oral Cavity Floor of Mouth nt Active smoker Ex-drinker
73412 M 57 T2 N2b M0 IVA Lip & Oral Cavity Buccal Mucosa nt Non-smoker Light
64390 M 53 T3 N2c M0 IVA Lip & Oral Cavity Tongue - Active smoker Moderate
61391 M 67 T4a N2c M0 IVA Lip & Oral Cavity Hard Palate nt Ex-smoker Non-drinker
37760 M 60 T3 N2c M0 IVA Oropharynx Base of Tongue + Non-smoker Non-drinker Yes
61531 M 56 T2 N0 M0 II Lip & Oral Cavity Retromolar Trigone - Active smoker Moderate
35852 M 31 T1 N1 M0 III Lip & Oral Cavity Tongue nt Non-smoker Non-drinker
65400 F 79 T1 N0 M0 I Lip & Oral Cavity Tongue nt Ex-smoker Non-drinker
57255 M 73 T2 N2b M0 IVA Lip & Oral Cavity Tongue nt Ex-smoker Moderate
34994 M 58 T2 N1 M0 III Lip & Oral Cavity Tongue nt Ex-smoker Ex-drinker
65128 M 61 T1 N2b M0 IVA Lip & Oral Cavity Buccal Mucosa nt Non-smoker Non-drinker
61773 M 67 T4a N2c M0 IVA Lip & Oral Cavity Floor of Mouth nt Ex-smoker Non-drinker
68614 M 64.6 T3 N0 M0 III Larynx Glottis nt Ex-smoker Ex-drinker
73191 F 87 T2 N2b M0 IVA Lip & Oral Cavity Tongue nt Non-smoker Non-drinker
64842 M 64 T4a N2c M1 IVC Hypopharynx Post-Cricoid nt Ex-smoker Moderate
64482 M 61 T3 N1 M0 III Oropharynx Tonsil + Non-smoker Non-drinker Yes
60976 M 52 T2 N2b M0 III Lip & Oral Cavity Floor of Mouth nt Active smoker Heavy
M - male; F - female; nt - not tested
Recurrent
TNM Stage
Tumor ID Gender Age Subsite
Table 2.1. Clinical characteristics of patient tumours used to generate
xenografts for the PDX clinical trial of -isoform selective PI3K inhibitor
BYL719.
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Fig. 2.2. Preclinical assessment of BYL719 in an HNSCC PDX clinical trial.
(A) Schematic outlining the PDX clinical trial of BYL719. (B) Genomic features
for primary HNSCC tumours (n = 20) used to generate xenografts for the PDX
clinical trial. (C) Waterfall plot of response to BYL719 in HNSCC PDX models,
measured relative to baseline tumour size (BestAvgResponse). Red bars indicate
models achieving classification as ‘stable disease’, grey bars indicate models
with ‘progressive disease’. (D) Waterfall plot of response to BYL719 in PDX
models measured relative to the vehicle-treated arm. (E) Representative growth
curves for tumours classified as having progressive or stable disease following
treatment with BYL719. Growth of vehicle-treated tumours is indicated for
reference with a dotted line. PDX models with EGFR (F) or AKT1 (G)
amplifications showed greater reductions in tumour volume relative to baseline,
compared to WT models (p = 0.024 and 0.038, respectively). (H) PDX models
with CSMD1 deletions also had significantly better responses to BYL719
compared to WT models (p = 0.007). (I) No difference in response to BYL719
was observed between PDX models with PIK3CA hotspot mutations and WT
models (p = 0.61). * represents p < 0.05, ** represents p < 0.01, ns = not
significant, Welch’s t-test.
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dramatic reduction (30.27%) in tumour volume relative to baseline. Representative growth 
curves for xenografts with progressive and stable disease are shown (Fig. 2.2e). 
As a point of comparison, we also examined the change in tumour volume for all 
models at the endpoint of treatment, when referenced to their corresponding vehicle-treated 
arm (Fig. 2.2d). Here we found BYL719 to be biologically active in 19/20 models, with 
15/20 models showing a >50% difference in tumour volume following treatment with 
BYL719, versus when the same model received the vehicle. Therefore, while our PDX 
clinical trial suggests that PI3K inhibition alone is likely insufficient to induce complete 
or partial responses, it highlights perhaps the optimal implementation approach for 
BYL719 in HNSCC: as a stabilizing neoadjuvant therapy, effective across most tumour 
genotypes. In support of this observation, the first in-human study of BYL719 in solid 
tumours (including HNSCC) found that the majority of patients experienced disease 
stabilization from treatment, rather than partial or complete tumour regression(23).  
 
2.4.4 In vivo testing identifies genomic features associated with 
response to BYL719 
The discrepancy that exists between biomarkers of response identified in vitro and 
those supported in vivo may stem from how the efficacy of in vivo studies is assessed. To 
identify potential biomarkers of treatment response, we stratified the responses of PDX 
models—measured relative to baseline tumour size—based on the presence of common 
genomic aberrations. This approach revealed several genomic features associated with 
sensitivity to PI3K inhibition that have not been previously reported. 
Genomic aberrations associated with sensitivity to BYL719 included EGFR 
amplifications (p = 0.024, Fig. 2.2f), AKT1 amplifications (p = 0.038, Fig. 2.2g) and 
CSMD1 deletions (p = 0.007, Fig. 2.2h). HRAS mutant models were, in general, on the 
less-sensitive end of the response spectrum, but this difference in susceptibility was not 
statistically significant (p = 0.075, Supp. Fig. 2.2), despite being supported  by previous 
studies(21,24,25). While relatively little is known about CSDM1 in HNSCC apart from its 
 
69 
 
frequent deletion, it is an established tumour suppressor(26). The sensitivity of PDX 
models with CSMD1 deletions to PI3K inhibition may suggest that loss of its tumour 
suppressive properties directs increased reliance on the PI3K network, to some degree. In 
breast cancer, it has been shown that CSMD1 decreases the intracellular signaling potential 
of cancer cells, for instance through reduction of activating phosphorylation of kinases, 
including AKT1/2/3(26). EGFR is known to activate PI3K/AKT/mTOR signalling and 
AKT is an integral effector of the network, explaining, at least in part, the sensitivity of 
these models to PI3K inhibition, as well as highlighting how WT PIK3CA models may be 
equivalently sensitive to BYL719 as models with specific activating PIK3CA 
alterations(11).  
With regard to PIK3CA, we did not find hotspot PIK3CA mutations to be associated 
with responsiveness to BYL719 in our PDX clinical trial (p = 0.61, Fig. 2.2i). While our 
PDX clinical trial of 20 unique HNSCC models and 80 total mice is of substantial size for 
a Phase II-style trial, it is possible that our cohort represents only a subset of PIK3CA 
mutant HNSCC tumours; an even larger trial may clarify the utility of this biomarker. Such 
a cohort may also include additional HPV-positive tumours which are known to be 
enriched for PIK3CA alterations; however, as these tumours are frequently managed with 
chemoradiation, curating and successfully engrafting non-recurrent HPV-positive tumours 
will require a concerted effort.  
 
2.5 Concluding Remarks 
In conclusion, as noted in both our cell line studies and through the other genomic 
correlates of sensitivity identified in vivo, many WT PIK3CA models are sensitive to 
PI3K inhibition. Therefore, our findings suggest that numerous HNSCC patient 
genotypes can derive benefit from PI3K inhibition. We do not find PIK3CA mutations to 
be a requirement for drug sensitivity, nor do our findings support the expectation that PI3K 
inhibitors should be restricted solely to HNSCC patients with these alterations. Our study 
addresses the translational gap that presently exists between preclinical studies of PI3K 
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inhibition and clinical efficacy of these agents for HNSCC patients. PI3K targeting by 
BYL719 has already been shown to be disease-stabilizing in humans, supporting the 
potential of this drug in a restricted time window to avoid the acquisition of 
resistance(23,27). Moving forwards, we suggest PI3K-targeted agents be examined for 
their fit into clinical usage in the neoadjuvant setting, ahead of surgical management or 
radiation therapy. 
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2.7 Supplementary Materials 
2.7.1 Supplementary methods 
2.7.1.1 Genomic characterization of cell lines 
Genomic characterizations of HNSCC cell lines were carried out using Ion Torrent 
technologies to profile single nucleotide variants (SNV) in 42 genes recurrently altered in 
HNSCC primary tumours (Supplementary Table 2.1), and OncoScan SNPs arrays to 
profile copy number aberrations (CNA) (Agrawal et al., 2011; Lawrence et al., 2015; 
Stransky et al., 2011). Ion Torrent BAM files were back-converted to FASTQ format and 
realigned to the reference genome (hg19 with decoy) using picard (v1.121) and bwa 
(v0.7.12) respectively (http://picard.sourceforge.net) (Li et al., 2010). The Genome 
Analysis Toolkit (GATK, v3.4.0) was used to perform base recalibration and 
HaplotypeCaller was used to identify potential variants, where a hard filter was applied 
when selecting SNPs using the following expression: "QD < 10 || FS > 60 || MQ < 40 || DP 
< 100" (DePristo et al., 2011; McKenna et al., 2010; Van der Auwera et al., 2002). SNPEff 
(v3.5) was used to annotate SNPs and SNPs were filtered out if they were found in the 
dbSNP database (v42) and kept if they were found in the COSMIC database (v71) 
(Cingolani et al., 2014; Forbes et al., 2001; Sherry et al., 2001). For OncoScan arrays, 
BioDiscovery’s Nexus Express (version 2.0) was used to call CNAs, using the SNP-
FASST2 algorithm with default parameters and a minimum number of probes per segment 
of 10. Tumour ploidy was estimated using the Allele-Specific Copy Number Analysis of 
Tumours (ASCAT, v2.1) algorithm and relative copy number changes were computed by 
setting the cell line ploidy as the new baseline zero, with all copy number calls adjusted by 
this ploidy value (Van Loo et al., 2010). Gene-level CNAs were identified by overlapping 
copy number segments using RefGene (2014-07-15) and annotated using BEDTools 
(v2.21.0) (Van Loo et al., 2010). Cell lines’ HPV status was based on previous literature 
and was previously confirmed by our group (Akagi et al., 2014; Brenner et al., 2010; 
Hermsen et al., 1996; Hoffmann et al., 2008; Nichols et al., 2013; Ragin et al., 2004; White 
et al., 2007). 
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2.7.1.2 PI3K inhibitor cytotoxicity assays 
Three drugs targeting the PI3K/AKT/mTOR pathway were tested: α-isoform 
specific PI3K inhibitor BYL719 (Alpelisib), dual PI3K/mTOR inhibitor BEZ235 
(Dactolisib), and pan-class I PI3K inhibitor GDC-0941 (Pictilisib), all purchased from 
Selleckchem. All drugs were stored as 10mM stock solutions at –80°C.  
Cells were seeded in 96-well plates at 2400 cells/well. 24 hours (hrs) later, media 
was removed and replaced with drug-containing media over a range of doses for each drug 
(0100M for BYL719 and GDC-0941, 050M for BEZ235). Cells were exposed to drug 
for 72hrs before measuring viability. For each drug concentration, three replicates were 
completed per cell line. Cell viability was measured indirectly using the PrestoBlue® 
Reagent (Thermo Fisher Scientific). Media-only (no cells), cells-only (no drug), and 
DMSO-only wells (cells, vehicle control) were simultaneously read to establish 
background. To determine the half-maximal inhibitory concentration (IC50) values—
defined as the drug concentration at which the normalized relative fluorescence units 
(RFU) measurement reached 50%—media-only (no cells) values were subtracted from the 
RFU measures of each replicate to account for background signal. Normalized RFU values 
of drug-treated replicates were calculated as a percentage of the mean RFU of the DMSO-
only control replicates and then drug doses were transformed to a logarithmic scale. IC50 
values were subsequently calculated by non-linear regression (Prism® 7 Graphpad 
Software, Inc.). Cell lines that were not reduced to at least 50% viability were considered 
not susceptible to the drug in the concentration range tested and were assigned the 
maximum value tested. Of note, for all drugs tested, PE/CA-PJ49 cells never reached a 
50% reduction in viability and were not included for comparative purposes. 
 
2.7.1.3 PDX response calls 
The response of PDXs to BYL719 was determined by comparing the mean tumour 
volume change at time t to its baseline size: % tumour volume change = Volt = 100% x 
((Vt –Vinitial)/Vinitial). Specifically, we determined the ‘Best Average Response’ 
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(BestAvgResponse) by calculating the average of Vt from t = 0 to t, for each time point 
and then taking the minimum average found, where t > 10 days. This metric uniquely 
captures the durability and strength of response (Gao et al., 2015). To categorize responses, 
we used the modified RECIST (mRECIST) criteria established by Gao et al., which is 
based on the Response Evaluation Criteria in Solid Tumours (RECIST)—a set of 
clinically-established criteria defining when cancer patients “respond”, remain unchanged 
(“stable”) or “progress” during the course of their treatment (Therasse et al., 2000). The 
mRECIST criteria considers both the BestAvgResponse, described above, as well as the 
‘Best Response’ (BestResponse) which is the minimum value of Vt for t >10 (Gao et al., 
2015). All models included in our PDX clinical trial received a minimum of 14 days of 
treatment with BYL719.  
 
 
  
Supplementary Table 2.1. Sources and cell culture media for HNSCC cell
lines used in this study.
Supplementary Table 1. Sources and cell culture media for established HNSCC cell lines used 
in this study. 
 
Cell Line 
HPV 
Status 
Tumour Site 
(if available) 
Patient 
Information 
(if available) 
Growth Medium Source 
93-VU-147T Positive Floor of mouth Male, T4N2 DMEM/F12 VUMC 
HMS001 Positive Oropharynx (tonsil) Male DMEM/F12 
Harvard Medical 
School 
UM-SCC47 Positive Lateral tongue Male, T3N1M0 DMEM/F12 University of Michigan 
UPCI:SCC090 Positive 
Oropharynx (tongue 
base) 
Male, T2N0 DMEM/F12 
University of 
Pittsburgh 
UPCI:SCC154 Positive Oral cavity Male, T4N2 DMEM/F12 
University of 
Pittsburgh 
UD-SCC-2 Positive ------ ------ DMEM/F12 
Harvard Medical 
School 
Detroit 562 Negative Pharynx Female DMEM/F12 ATCC 
FaDu Negative Hypopharynx Male, 56 DMEM/F12 ATCC 
HSC2 Negative Oral cavity Male, 69 EMEM 
Japanese Cancer 
Research Resources 
Bank (JCRB) 
Cal27 Negative Tongue Male, 56 DMEM/F12 ATCC 
SCC-4 Negative Tongue Male, 55 DMEM/F12 ATCC 
SCC-9 Negative Tongue Male, 25 DMEM/F12 ATCC 
SCC-15 Negative Tongue Male, 55 DMEM/F12 ATCC 
SCC-25 Negative Hypopharynx Male, 56 DMEM/F12 ATCC 
SCC-61 Negative ------ ------ DMEM/F12 Yale 
Cal33 Negative Tongue Male, 69 
DMEM + 
HI FBS + NEAA 
DSMZ 
JHU006 Negative ------ ------ DMEM/F12 Johns Hopkins 
JHU011 Negative Larynx Male, T3N0 DMEM/F12 Johns Hopkins 
JHU029 Negative Oropharynx Male, T4N0 DMEM/F12 Johns Hopkins 
PCI6A Negative ------ ------ DMEM/F12 
University of 
Pittsburgh 
PCI6B Negative Oropharynx Male, T3N3M0 DMEM/F12 
University of 
Pittsburgh 
PCI13 Negative Oral cavity Male, T4N1M0 DMEM/F12 
University of 
Pittsburgh 
PCI30 Negative ------ ------ DMEM/F12 
University of 
Pittsburgh 
RF22A Negative ------ ------ DMEM/F12 
University of 
Pittsburgh 
RF15B Negative ------ ------ DMEM/F12 
University of 
Pittsburgh 
RF37A Negative ------ ------ DMEM/F12 
University of 
Pittsburgh 
BICR56 Negative Tongue Female DMEM + 2mM L-glu Public Health England 
PE/CA-PJ49 Negative Tongue Male, 57 IMDM + 2mM L-glu Public Health England 
 
DMEM, Dulbecco’s Modified Eagle Medium; VUMC, VU University Medical Center Amsterdam; ATCC, 
American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen; 
IMDM, Iscove’s Modified Dulbecco’s Medium; NEAA, non-essential amino acids; L-glu, L-glutamine 
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Supplementary Table 2.2. Short tandem repeat (STR) profiles of HNSCC
cell line panel.
 Supplementary Table 2. Short tandem repeat (STR) profiles of HNSCC cell line panel (The Centre 
for Applied Genomics (TCAG), Toronto ON). 
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93-VU-147T X,Y 11,11 8,11 9,12 11,12 12,12 6,6 8,8 17,17 15,20 12,13 28,29 21,21 15,15 12,15 24,24 
HMS001 X,Y 11,11 8,8 9,12 11,12 12,12 6,6 8,8 17,17 15,20 13,14 28,29 21,21 15,15 13,15 24,24 
UM-SCC47 X,Y 11,13 8,11 8,13 11,12 11,11 7,9.3 10,11 18,18 18,18 14,15 29,30 25,25 15,15 15,15 25,25 
UPCI:SCC090 X,Y 11,12 11,11 12,13 11,12 9,10 7,7 8,8 17,17 14,18 12,13 29,31 22,22 14,14 12,12 20,20 
UPCI:SCC154 X,Y 10,12 9,12 13,13 11,12 9,10 7,7 8,9 17,17 15,15 15.2,16 28,29 25,25 16,16 12,12 20,24 
Cal27 X,X 10,12 10,11 11,12 11,12 10,10 6,9.3 8,8 14,17 13,13 14,15.2 28,29 23,24 16,16 13,15 25,25 
Detroit 562 X,X 11,13 12,12 11,11 11,12 8,10 8,9 8,10 16,16 15,15 14,14 28,30 25,25 15,16 13,14 21,21 
FaDu ---- 12,12 8,9 11,11 12,12 11,12 8,8 11,11 15,17,18 16,16 14,16 31.2,31.2 19,19 17,18 13,13 25,25 
UD-SCC2 X,Y 11,12 8,8 11,13 10,11 8,9 8,9 8,10 18,18 ND ND 30,31.2 ND ND ND ND 
SCC-4 X,Y 11,11 11,13 12,12 13,13 9,11 9.3,9.3 8,8 15,17 15,15 12,14 32.2,32.2 16,24 18,18 14,14 21,22 
SCC-9 X,Y 11,11 9,9 10,11 12,12 8,8 8,9 9,11 17,17 12,14 12,14 28,28 19,21 15,15 13,13 20,25 
SCC-15 X,Y 10,13 9,14 12,15 12,12 10,11 9,9.3 8,8 15,17 16,16 15,15 30,31.2 16,23 16,16 10,13 19,24 
SCC-25 X,X 10,10 13,13 11,12 12,12 12,12 8,8 8,12 17,19 16,16 13,14 30,30 17,19 17,17 13,13 20,24 
SCC61 X,Y 10,12 10,12 9,11 12,13 8,12 7,9 8,8 16,17 ND ND 28,30 ND ND ND ND 
Cal33 X,Y 11,12 8,13 11,11 11,12 8,10 9,9.3 8,8 17,17 14,14 14,15.2 29,30 20,25 17,17 13,13 21,22 
JHU006 X,Y 10,10 11,11 12,12 12,12 9,10 6,6 8,8 14,16 16,16 14,14.2 31,31 17,25 13,13 13,14 19,19 
JHU011 X,X 10,12 12,12 9,14 9,12 11,11 6,9 8,9 16,17 13,15 13,14 31,31 17,26 18,18 13,13 23,23 
JHU029 X,Y 8,12 12,13 10,13 13,15 10,11 8,8 9,11 15,15 15,15 13,13 33.2,33.2 19,26 16,16 14,14 22,25 
PCI6A X,X 12,12 9,11 11,11 11,12 8,12 6,6 11,11 15,18 12,17 15,16.2 31.2,31.2 17,24 18,18 14,14 23,23 
PCI6B X,Y 10,11 10,11 12,13 12,12 12,13 6,7 8,9 16,18 16,16 12,14 32.2,32.2 23,24 18,18 13,14 20,20 
PCI13 X,X 10,14 10,11 11,11 11,14 11,12 9,9.3 6,8 13,17 16,16 13,15.2 29,30 24,24 14,14 12,13 22,22 
PCI30 X,Y 10,10 13,13 12,13 11,11 10,12 6,6 10,11 14,17 12,15 12,12 30,32.2 18,18 15,15 13,15 21,21 
RF15B X,Y 11,11 11,11 11,11 11,11 11,11 6,6 8,8 18,18 14,14 14,15.2 28,28 20,25 16,16 14,14 23,23 
RF22A X,X 10,10 8,12 9,11 12,12 8,9 6,6 8,11 15,18 18,18 14,15 28,28 17,20 16,16 11,13 22,24 
RF37A X,X 11,11 10,13,14 11,14 11,11 7,10 7,9.3 8,11 16,17 13,13 15,16 30,32.2 24,24 17,17 11,13 21,21 
BICR56 X,X 12,12 12,12 11,11 11,12 8,12 9,9.3 8,9 15,16 14,17 14,15 28,29 24,26 14,14 11,13 21,21 
PE/CA-PJ49 X,X 11,12 8,11 11,11 8,12 8,9 6,10 8,8 16,19 24,24 14,14 32,32 17,18 16,16 10,11 20,20 
HSC2 X,Y 12,13 11,12 12,12 10,12 9,12 6,7 8,8 16,18 ND ND 31.2,31.2 ND ND ND ND 
 
 ND: not determined 
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Supplementary Table 3. Custom gene list for Iontorrent technologies SNV analysis of 42 genes 
recurrently altered in HNSCC primary tumours (cite Stransky & Agarwal).  
 
 
Genes 
ARpp21 JUB 
B2M KEAP1 
BAPI KMT2D 
BICR2 KRAS 
CASP8 MET 
CCND1 MYC 
CCR9 NEK10 
CDK6 NF1 
CDKN2A NFE2LW 
CHEK2 NOTCH1 
CUL3 NOTCH2 
DDR2 NOTCH3 
E2F1 NRAS 
EGFR NSD1 
EPHA2 PIK3CA 
ERBB2 PIK3R1 
FADD PTEN 
FAT1 PTPRG 
FBXW7 RAC1 
FGFR1 RB1 
FGFR2 SOX2 
FGFR3 SRY 
FHIT TGFBR2 
GADL1 TP63 
HLA-A TRAF3 
HRAS TRAK1 
IFG1R YAP1 
 
 
 
Supplementary Table 2.3. Custom gene list for Ion Torrent technologies
SNV analysis of 42 genes recurrently altered in HNSCC primary tumours.
80
Supplementary Table 2.4. Specific hotspot mutations in the PIK3CA gene
detected in HNSCC cell lines.
 
 
Cell Line PIK3CA Hotspot Mutation 
SCC61 E542K 
PCI6A E545K 
JHU029 H1047L 
HSC2 H1047R 
D562 H1047R 
Cal33 H1047R 
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Supplementary Table 4. Gene list for targeted panel used to characterize primary HNSCC 
tumours from which PDX models were derived. 
 
 
Genes 
AJUBA FOLR1 PARD3 
AKT1 FOXL2 PHKG1 
ATR GLI1 PIK3CA 
B2M GSK3B PIK3CB 
BCL2L1 HES1 PIK3CG 
BCL6 HEY1 PIK3R4 
CASP8 HLA-A PKHD1 
CCND1 HMCN1 PLEC 
CDK6 HRAS PLSCR4 
CDKN2A HUWE1 PLXNA1 
CDKN2B JAG1 PMAIP1 
CREBBP JAG2 PPFIA1 
CSMD1 JAK2 PRKDC 
CTCF KDM6A PTCH1 
CUL3 KEAP1 PTK2 
DLL3 KLF5 RAC1 
DTX2 KRT5 RB1 
DTX4 LFNG RICTOR 
EGFR LRP1B SCN9A 
EP300 LYN SERPINE1 
EPHA2 MDM2 SMAD4 
EPHA3 MED12 SNX31 
EPHA6 MIB1 SOX2 
EPHB1 MLL1 STEAP4 
EPHB3 MLL2 TERT 
EPHB4 MLL3 TGFBR2 
EPPK1 MYC TGIF1 
ERBB2 NAP1L2 TNK2 
ERBB4 NCSTN TP53 
FADD NECAB1 TP63 
FAM123B NEURL2 TRAF3 
FAT1 NFE2L2 TYMS 
FBXW7 NFIB YAP1 
FCRL4 NOTCH1 YEATS4 
FGF3 NOTCH2 YES1 
FGFR1 NOTCH3 ZNF750 
FGFR3 NOTCH4  
FLG NSD1  
Supplementary Table 2.5. Gene list for targeted sequencing panel used to
characterize primary HNSCC tumours from which PDX models were derived.
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A.
Supplementary Fig. 2.1. Response of HNSCC cell lines to BEZ235 and
GDC-0941 when stratified by genomic features. Box plots show log
distribution of drug sensitivity to BEZ235 and GDC-0941 when cell lines are
stratified by common genomic aberrations. No differences in responses were
observed. (A) Loss-of-function CDKN2A alterations, (B) EGFR
amplifications, (C) PIK3CA amplifications, (D) Hotspot PIK3CA mutations.
ns = not significant,Welch’s t-test.
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Supplementary Fig. 2.2. Response of HRAS mutant HNSCC PDX models
to BYL719. Comparison of BestAvgResponse of HRAS mutant PDX models
versus WT models following treatment with BYL719 (p = 0.075). ns = not
significant, Welch’s t-test.
C
h
a
n
g
e
 i
n
 t
u
m
o
u
r 
v
o
lu
m
e
 (
%
)
(B
e
s
tA
v
g
R
e
s
p
o
n
s
e
)
84
 
85 
 
Chapter 3  
 
3 ERK-TSC2 signalling in constitutively-active HRAS 
mutant HNSCC cells promotes resistance to PI3K 
inhibition 
3.1 Abstract 
Objectives: The PI3K/Akt/mTOR pathway is frequently altered in head and neck squamous 
cell cancer (HNSCC), making this pathway a logical therapeutic target. However, PI3K 
targeting is not universally effective. Biomarkers of response are needed to stratify patients 
likely to derive benefit and exclude those unlikely to respond. 
Materials and methods: We examined the sensitivity of cell lines with constitutively-active 
(G12V mutant) HRAS and wild-type HRAS to PI3K inhibition using flow cytometry and 
cell viability assays. We then overexpressed and silenced HRAS and measured sensitivity 
to the PI3K inhibitor BYL719. Immunoblotting was used to determine activation of the 
PI3K pathway. MEK and mTOR inhibitors were then tested in HRAS mutant cells to 
determine their efficacy. 
Results: HRAS mutant cell lines were non-responsive to PI3K inhibition. Overexpression 
of HRAS led to reduced susceptibility to PI3K inhibition, while knockdown improved 
sensitivity. Immunoblotting revealed suppressed Akt phosphorylation upon PI3K 
inhibition in both wild-type and HRAS mutant cell lines, however mutant lines maintained 
phosphorylation of S6, downstream of mTOR. Targeting mTOR effectively reduced 
viability of HRAS mutant cells and we subsequently examined the ERK-TSC2-mTOR 
cascade as a mediator of resistance to PI3K inhibition.  
Conclusions: HRAS mutant cells are resistant to PI3K inhibition and our findings suggest 
the involvement of a signalling intersection of the MAPK and PI3K pathways at the level 
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of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in 
combination with MAPK pathway inhibition may be a promising therapeutic strategy for 
this subset of HNSCC tumours. 
 
3.2 Introduction 
Phosphoinositide 3-kinase (PI3K)/Akt/mTOR signalling regulates critical tumour 
cell functions, including cellular metabolism, survival, angiogenesis, growth and 
migration(1). Hyper-activation of PI3K signalling is frequently observed in head and neck 
squamous cell carcinomas (HNSCCs), with nearly 80% of tumours containing 
amplifications or mutations of PIK3CA and numerous additional tumours containing losses 
of tumour suppressor PTEN or amplifications of EGFR or Akt1/2/3(2-4). Owing to the 
prevalence of PI3K-pathway aberrations in HNSCC and the dependency of tumour cells 
on PI3K signalling for survival and growth, targeting this pathway is an attractive 
therapeutic strategy for HNSCC patients.   
 Early clinical studies of PI3K inhibitors Alpelisib (BYL719) and Buparlisib 
(BKM120) in HNSCC have shown tolerable toxicity profiles and “on-target” PI3K 
inhibition(5-7). However, the clinical efficacy of PI3K inhibitors to date has been limited 
and not all patients respond(7,8). The PI3K/Akt/mTOR network contains numerous 
feedback loops and crosstalk nodes with other pathways, providing innumerable 
opportunities for circumventing the effects of PI3K inhibition. Studies of the signalling 
loops and adjacent pathways that counteract PI3K inhibition will help focus the use of PI3K 
inhibitors for patients likely to achieve maximal benefit. Further, identifying mediators of 
innate resistance to PI3K inhibition may highlight potentially targetable signalling 
dependencies in these non-responsive tumours that can be exploited for therapy using 
appropriate inhibitors.  
 HRAS belongs to the RAS family of GDP/GTP-binding proteins that function as 
intracellular signal transducers. When bound to GTP, HRAS is active and interacts with 
various downstream effectors, including RAF, which stimulates a phosphorylation cascade 
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involving, mitogen-activated protein kinase kinases (e.g. MEK1) and extracellular signal-
related kinases (e.g. ERK1/2)(9). The RAS-RAF-MEK-ERK (MAPK) signalling pathway 
plays an integral role in cellular proliferation and survival and is highly interconnected with 
PI3K/Akt signalling(10). The RAS isoforms (HRAS, KRAS and NRAS) are frequently 
altered human cancer, with particular isoforms having relevance in specific cancers(11-
13). Alterations in HRAS are most prevalent in HNSCC, observed in ~6% of tumours(2). 
In general, aberrations in the RAS isoforms are activating, maintaining RAS in a GTP-
bound state by impairing its GTPase activity. As a result, stimuli-independent RAS 
signalling is perpetuated(11). RAS alterations have been used to define specific patient 
subsets in various cancers that respond differently to anti-cancer therapies and/or display 
distinct clinical features, such as rapidly progressive disease(14-16).  
 In the present study, we explored the constitutively-active HRAS G12V mutation 
in HNSCC as a biomarker for non-response to PI3K inhibition. We first established HRAS 
G12V to be a mediator of intrinsic resistance to PI3K inhibition and secondarily 
interrogated the mechanism. We observed persistent downstream mTORC1 signalling in 
G12V mutant cells, despite PI3K blockade. We then explored ERK-mediated TSC2 
inactivation and highlight mTOR inhibition, alone or in combination with MAPK pathway 
inhibition, to be a novel therapeutic susceptibility of HRAS G12V mutant tumour cells(17). 
 
3.3 Materials and Methods 
3.3.1 Cell culture 
Cell lines were obtained from the sources listed (Supp. Table 3.1). All cell lines 
were cultured in DMEM/F12, with 10% fetal bovine serum (GIBCO), penicillin (100 
IU/mL; Invitrogen) and streptomycin (100 μg/mL; Invitrogen), unless otherwise stated 
(Supp. Table 3.1). Cells were maintained in a 37°C humidified atmosphere with 5% CO2. 
We previously used short tandem repeat profiling (The Center for Applied Genetics; 
Toronto) to confirm cell line identities(18). T24 urinary bladder epithelial cells were used 
as a model cell line for human tumour cells with an endogenous HRAS mutation at codon 
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12, as to date there are no established HNSCC cell lines with HRAS mutations at codon 12 
or 13 documented, despite the detection of these aberrations in primary tumours.  
 
3.3.2 Immunoblotting 
Cell lysates were obtained using a radioimmunoprecipitation assay (RIPA) buffer. 
Cells were washed once in 1x PBS before lysis. Lysates were kept on ice for 15 min, then 
centrifuged 15 min at 14,000 rpm. Protein concentration was determined using a Bradford 
assay. Using 412% SDS-PAGE, 30 μg of protein was resolved for 1 hour (hr) at 200 V in 
1x MES buffer. Protein was transferred to a PVDF Blotting Membrane (GE Healthcare) 
for 1 hr, 14 V at room temperature. Membranes were blocked with 3% bovine serum 
albumin (BSA; Sigma-Aldrich) in 1x TBST. Membranes were then incubated overnight at 
4°C with primary antibodies (Supp. Table 3.2). Of note, owing to the high degree of 
sequence homology between the RAS isoforms, we used a specific G12V-mutant RAS 
antibody to detect mutant RAS in our cell lines. Immunoreactive bands were visualized by 
incubating membranes for 1 hr at room temperature with a peroxidase-conjugated anti-
rabbit IgG in 5% skim milk/1x TBST. Membranes were visualized following exposure to 
enhanced chemiluminescence reagent (LuminataTM Crescendo, Western HRP Substrate; 
Millipore).  
 
3.3.3 Cell viability assays 
 Cells were seeded in 96-well plates at 2,400 cells/well and cultured overnight. 
Drugs (Supp. Table 3.3) were then added at the indicated doses. Viability was determined 
indirectly using the PrestoBlue® Reagent (Thermo Fisher Scientific) at 0 and 72 hrs 
following drug treatment on a SynergyTM H4 Hybrid Reader (BioTek) with 560 nm 
excitation and 590 nm emission wavelengths. 
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3.3.4 Flow cytometry 
 To examine the effects of BYL719 on cell cycle, we treated cells with 5 M 
BYL719 for 24 hrs. Three biological replicates were prepared. Prior to harvesting, BrdU 
(GE Healthcare, cat. RPN201) was added at 1:1000 and incubated with the cells for 2 hrs. 
Cells were then trypsinized, pelleted and the supernatant was removed. Cells were 
suspended in 1xPBS and fixed by adding 95% ethanol drop-wise while vortexing. Cells 
were then pelleted and resuspended in 2 N HCl, 0.5% Tx-100 drop-wise while vortexing, 
followed by 0.1 M Na2B4O7 (pH 8.5), each for 30 min to allow permeabilization. Mouse 
anti-BrdU primary antibody (1:50, BD Biosciences lot. 347580) and FITC-conjugated 
horse anti-mouse secondary antibody (1:25, Vector Laboratories cat. FI-2000) were added 
respectively and incubated for 30 min per step, at room temperature and protected from 
light. Cells were then resuspended in a propidium iodide (PI; Biolegend®; Cat No. 421301) 
and RNase A (Bioshop Canada Inc., cat. RNA675) solution (PBS with 1% BSA, 0.25 
mg/ml PI, 0.25mg/ml RNAse A) overnight at 4C, protected from light. Cells were then 
incubated overnight at 4°C. Cells were passed through a cell strainer and then DNA content 
was measured by flow cytometry on a Beckman-Coulter CytomicsTM FC500 flow 
cytometer with at least 10,000 events counted per test(19). 
 
3.3.5 RNA interference 
For RNAi-mediated knockdown of gene expression, cells were seeded at 200,000 
cells/well into 6-well dishes in antibiotic-free media and allowed to attach overnight. The 
next day, Lipofectamine® RNAiMax was used to deliver 30pmol of either anti-HRAS 
siRNA (Thermo Fisher Scientific, Cat No.4390824.), anti-ERK1/2 siRNA (Cell Signalling 
Technology, Cat No.6560) or scrambled siRNA (Thermo Fisher Scientific; Cat No. 
4390843) in Opti-MEM®. Media was replaced 24 hrs post-transfection and cells were 
allowed to recover for an additional 48 hrs prior to collection and lysis, or subsequent drug 
testing. Knockdown was confirmed by immunoblotting and real-time quantitative RT-PCR 
(qRT-PCR), described below.  
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For drug testing, cells were seeded into 96-well dishes at 2,400 cells/well. BYL719 
was added the next day over a 10-point dose range (040 M) and cells were incubated for 
72 hrs. For each drug concentration, three replicates were completed per cell line. Cell 
viability was determined as described above. To calculate half-maximal inhibitory 
concentration (IC50) values, relative fluorescence units (RFU) measures were normalized 
to the vehicle treatment (DMSO only). IC50 values (defined as the concentration at which 
the normalized RFU reached 50%) were then calculated by non-linear regression. 
 
3.3.6 Quantitative Real-Time PCR (qRT-PCR) 
 Total RNA was extracted using AllPrep DNA/RNA Mini Kits (Qiagen). Eluted 
RNA was reverse transcribed to complementary DNA (cDNA) using QuantiTect Reverse 
Transcription Kits (Qiagen). qRT-PCR was then performed in 20 l reactions, using Power 
SYBR® Green PCR Master Mix (Thermo Fisher Scientific), 200 nM of each primer and 
100 ng cDNA. PCR conditions: 95°C for 10 min, followed by 45 cycles of 95°C for 10 
min, 95°C for 15 s, 61°C for 1 min, 72°C for 40 s, with a melt curve: 95°C for 10 s, 65°C 
for 5 s, 95°C for 50 s. Relative transcript abundance was determined using the delta-delta 
CT method with expression of human -actin used for normalization. Quantification was 
completed with 3 biological replicates, each run in technical duplicate. Primers (5’3’): 
HRAS (F -AGACCCGGCAGGGAGTG, R -GTCATCCGGTGGGCGTG), -actin (F -
AGAGCTACGAGCTGCCTGAC, R -AGCACTGTGTTGGCGTACAG). 
 
3.3.7 Generation of stable lines 
Plasmid DNA for constructs containing either wild-type HRAS (Addgene; 39503) 
or HRAS G12V (Addgene; 39504) was prepared by mini-prep (QIAprep® Spin Miniprep 
Kit; Qiagen). For overexpression studies, cells were plated at 300,000 cells/well into 6-
well dishes in antibiotic-free media and allowed to attach overnight. The next day, 5 g 
plasmid DNA was delivered in 5 l P3000 reagent in Opti-MEM® with 3.75 l 
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LipofectamineTM 3000 reagent (Thermo Fisher Scientific) in Opti-MEM®, following a 15 
min incubation at room temperature. The next day, new antibiotic-free media containing 
450 g/ml Geneticin® Selective Antibiotic (G418 Sulfate; Wisent) was added and cells 
were maintained under selection for approximately 4 weeks. Overexpression of wild-type 
HRAS and HRAS G12V was confirmed by immunoblotting at 72 hrs and 1 month using 
RAS and RAS G12V antibodies (Supp. Table 3.2), as described. Growth over time and 
IC50 values for BYL719 were determined as described above.  
 
3.3.8 Statistical analysis 
All analyses were performed with Prism® 7 GraphPad Software. Experimental 
groups were compared with controls using Student’s unpaired, two-tailed t-tests. Multiple 
groups were compared across a single condition using one-way ANOVA. P < 0.05 was 
used to define significant differences from the null hypothesis.  
 
3.4 Results 
3.4.1 Characteristics of HNSCC patient tumours with HRAS 
alterations 
 We examined the prevalence of HRAS aberrations and other commonly observed 
alterations in the context of 504 HNSCC patient tumour specimens curated by The Cancer 
Genome Atlas (TCGA; Fig. 3.1a) using their online interface (cbioportal.com). Tumours 
with HRAS mutations were found to be mutually exclusive from tumours bearing other 
common oncogenic aberrations, including PIK3CA amplifications and single nucleotide 
variations (SNV), PTEN deletions, EGFR amplifications, CCND1 (Cyclin D1) 
amplifications and MYC amplifications(2-4). Furthermore, we noted that the fraction of the 
genome altered (a metric reflecting the collective mutational load in the tumour) was lower 
in tumours with HRAS mutations, in contrast to other HNSCC tumours (Fig. 3.1a). 
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Fig. 3.1. HRAS is altered in a distinct subset of HNSCC patients. (A)
TCGA-curated HNSCC tumours (n = 504) were assessed for genomic
aberrations in HRAS and other oncogenes associated with HNSCC using
cBioPortal software. (B) Comparison of specific mutations in HRAS observed
in TCGA-curated HNSCC tumours. (C) Immunoblot confirming the presence
of RAS G12V in T24 cells.
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In HNSCC, the majority (42.4%) of mutations in HRAS are found at codon 12, 
followed by 36.4% at codon 13, as shown in Fig. 3.1b. Both of these hotspot sites are 
known to promote constitutive activity of HRAS by impairing its ability to hydrolyze 
GTP(11). We analyzed the following cell line databases: Cancer Cell Line Encyclopedia 
(CCLE), Catalogue of Somatic Mutations In Cancer (COSMIC) Cell Lines Project, 
American Type Culture Collection (ATCC); to date, no established HNSCC cell lines are 
known to contain activating HRAS mutations at either codon 12 or 13. We therefore used 
the tumour-derived epithelial cell line T24, which has an HRAS G12V mutation, as a 
model to interrogate the effect an endogenous HRAS mutation has on response to PI3K 
inhibition (Fig. 3.1c). 
 
3.4.2 HRAS G12V mutant cells are intrinsically resistant to PI3K 
inhibition 
We first examined the sensitivity of HRAS G12V mutant cells to the PI3K inhibitor 
BYL719 (Alpelisib; Novartis). Following 24 hrs of treatment, G12V mutant (T24) cells 
were unaffected, with no apparent differences in cell morphology (Fig. 3.2a). In contrast, 
a wild-type HRAS cell line (Cal33) showed fewer cells with a rounded morphology 
following treatment with BYL719. These observations were then quantified (Fig. 3.2b). A 
significant reduction in cell viability was observed in two wild-type HRAS cell lines (Cal33 
and SCC61) following treatment with BYL719, while the G12V mutant cell line T24 
showed no difference in viability following treatment. 
 Single-agent PI3K inhibition typically leads to cytostasis both in vitro and in vivo, 
rather than cell death or tumour shrinkage(5). Using flow cytometry, we therefore 
examined cell cycle distribution following BYL719 treatment in wild-type and HRAS 
G12V mutant cell lines. We found a significant reduction in proliferative (S-phase) cells 
following BYL719 treatment in wild-type Cal33 cells (Fig. 3.2c), while HRAS G12V 
mutant T24 cells showed no change in the proportion of proliferative cells. 
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Fig. 3.2. Cells with activating HRAS mutations are resistant to PI3K
inhibition. (A) Phase contrast images of wild-type HRAS (Cal33) and HRAS
G12V mutant (T24) cell lines following treatment with BYL719 (5m) for
24hrs. (B) Effect of BYL719 (5m) on cell viability following 72hrs of
treatment. (C) Cal33 and T24 cells were exposed to BYL719 (5M) for 24hrs
(3 replicates per line) before BrdU incorporation and labeling with propidium
iodide. A minimum of 10,000 events was counted per test. Proportion of cells
in each cell cycle phase is shown, + standard deviation. * represents p < 0.05,
** represents p < 0.01, *** represents p < 0.001, ns = not significant, unpaired
Student’s t-test. RFU = relative fluorescence units.
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3.4.3 HRAS G12V mediates resistance to PI3K inhibition  
To further address the relation between mutant HRAS G12V and insensitivity to 
PI3K inhibition, we silenced HRAS expression in wild-type and G12V mutant cells. As 
shown in Fig. 3.3a and b, knockdown of HRAS considerably reduced transcript levels 
(>80%), as well as protein expression of mutant RAS. HRAS silencing was associated with 
a significant increase in susceptibility of G12V mutant (T24) cells to PI3K inhibition by 
BYL719, while the sensitivity of wild-type HRAS cells was unaffected. These observations 
support the hypothesis that mutant HRAS G12V is involved with modulating the sensitivity 
to PI3K inhibition (Fig. 3.3c).  
We then performed the reciprocal experiments and stably overexpressed both 
HRAS and HRAS G12V in wild-type HRAS cells (Fig. 3.3d). While the morphology of 
Cal33:HRAS and Cal33:HRAS G12V cells was comparable to that of parental cells, 
overexpression of either HRAS or HRAS G12V led to a significant increase in the rate of 
cellular proliferation (Fig. 3.3e and f). Further, overexpression of either HRAS or HRAS 
G12V resulted in reduced susceptibility to PI3K inhibition by BYL719 (* p < 0.05 for 
Cal33:HRAS G12V) (Fig. 3.3g), suggesting that HRAS G12V plays a key role in making 
cells refractory to PI3K inhibition in vitro.  
 
3.4.4 mTOR inhibition blocks cell growth and signalling in HRAS 
G12V mutant cells 
To elucidate the underlying mechanism of resistance of HRAS G12V mutant cells, 
we analyzed potential differences in pathway inhibition by BYL719 between wild-type and 
G12V mutant cell lines. While phosphorylation of Akt (Thr308) was equally suppressed 
by BYL719 treatment across all lines, mTOR activity was not abolished upon PI3K 
inhibition in G12V mutant cells, as indicated by persistent phosphorylation of its 
downstream substrate ribosomal protein S6 (pS6) on residues Ser240/4 (Fig. 3.4a). 
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Fig. 3.3. HRAS G12V affects sensitivity to PI3K inhibition. (A) HRAS
transcript abundance following siRNA-mediated knockdown in Cal33 and
T24 cells (3 replicates, + standard deviation shown). siCT, short interfering
control (scrambled) RNA; siHRAS, short interfering RNA targeting HRAS.
(B) Immunoblot showing HRAS knockdown in T24 cells. (C) Normalized
IC50 values of Cal33 and T24 cells following 72hrs of treatment with BYL719
over a 10-point dose range (3 replicates per line). (D) Immunoblot showing
RAS and RAS G12V expression following stable transfection of HRAS and
HRAS G12V into Cal33 cells. (E) Phase contrast images of Cal33 at baseline
and following stable transfection of HRAS or HRAS G12V. Scale bar
represents 130M. (F) Cellular proliferation of indicated cell lines, measured
from 096hrs, + standard deviation. P value was determined for 96hrs only.
(G) Normalized IC50 values of Cal33 cells stably overexpressing HRAS or
HRAS G12V following 72hrs of treatment with BYL719 over a 10-point dose
range (3 replicates per line). * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001, ns = not significant, unpaired Student’s t-tests (A & C)
or one-way ANOVA (F & G).
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Fig. 3.4. PI3K-independent activation of mTOR in HRAS G12V mutant
cells. (A) Immunoblot of PI3K/Akt/mTOR pathway signalling with lysates
from indicated cell lines treated with 5M BYL719 for 36hrs. (B) Effect of
AZD8055 (5m) on cell viability following 72hrs of treatment. (C)
Immunoblot of S6 phosphorylation with lysates from indicated cell lines
treated with 5M AZD8055 for 36hrs. RFU = relative fluorescence units.
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Based on the persistent S6 signalling observed in HRAS G12V mutant cells 
following treatment with BYL719, we tested out the efficacy of the ATP-competitive 
mTOR inhibitor AZD8055. Treatment with AZD8055 dramatically reduced cellular 
viability of both wild-type HRAS cell lines and the G12V mutant cell line T24 (Fig. 3.4b). 
Further, use of the mTOR inhibitor AZD8055 abolished phosphorylation of S6 in all cell 
lines tested, regardless of HRAS status (Fig. 3.4c). 
 
3.4.5 ERK1/2 promotes mTORC1 activation via TSC2 inactivation 
Based on our results demonstrating sustained mTOR activation despite PI3K 
inhibition in HRAS G12V mutant cells, we hypothesized that the MAPK pathway may 
intersect with the PI3K pathway downstream of PI3K. It has been previously established 
that the MAPK pathway member ERK is capable of post-translational inactivation of the 
tuberous sclerosis (TSC) gene 2 (TSC2) by phosphorylation(17). TSC2 functions as a 
negative regulator of the PI3K/Akt pathway, where the TSC1-TSC2 complex acts 
downstream of PI3K/Akt and upstream of mTOR to limit cellular proliferation and 
growth(20,21). Functional inactivation of TSC2 therefore results in active mTOR 
signalling.  
In the context of constitutive RAS activation, we hypothesized that ERK-mediated 
phosphorylation of TSC2 may contribute to persistent mTOR activity that overcomes 
upstream PI3K inhibition (schematic shown in Fig. 3.5a). We silenced ERK1/2 in T24 
cells and examined phosphorylation of TSC2 post-knockdown (Fig. 3.5b). ERK1/2 
knockdown markedly reduced the level of TSC2 (Ser664) phosphorylation. Knockdown 
of ERK1/2 also resulted in reduced levels of phosphorylated mTOR (Ser2448; active form) 
(Fig. 3.5c), as well as a reduction in S6 phosphorylation (Ser240/4; Fig. 3.5d).  
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Fig. 3.5. ERK1/2 expression affects phosphorylation of TSC2, mTORC1
and S6. (A) Schematic representation of wild-type and constitutively-active
HRAS signalling cascades, with emphasis on ERK/TSC2 signalling.
Signalling downstream of HRAS G12V can be blocked using mTOR and
MEK inhibitors, but not by PI3K inhibition. (B) Immunoblot showing
reduced TSC2 phosphorylation (Ser664) following ERK1/2 knockdown in
T24 cells. siCT, short interfering control (scrambled) RNA; siERK1/2, short
interfering RNA targeting ERK1/2. (C) Immunoblot showing reduced mTOR
phosphorylation (mTORC1; Ser2448, active form) following ERK1/2
knockdown in T24 cells. (D) Immunoblot showing reduced S6
phosphorylation (Ser240/4) following ERK1/2 knockdown.
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3.4.6 Combined inhibition of mTOR and MEK reduces viability of 
HRAS G12V mutant cells 
  Finally, we assessed the efficacy of targeting either mTOR, MAPK pathway 
member MEK, or both simultaneously to control the proliferation of HRAS G12V mutant 
cells. In accordance with previous results, mTOR inhibition significantly reduced cellular 
viability (p < 0.01). MEK inhibition by the ATP-noncompetitive inhibitor Trametinib also 
reduced viability (p < 0.01), although less dramatically than AZD8055 (Fig. 3.6). As both 
the MAPK pathway and the downstream PI3K pathway appear to be involved with the 
survival of G12V mutant cells, we also tested the combination of BYL719 with Trametinib, 
as well as AZD8055 with Trametinib. Combined inhibition resulted in a greater reduction 
in cell viability compared to using any of the drugs alone (Supp. Table 3.4). The 
combination of AZD8055 with Trametinib however, was notably more effective than the 
combination of BYL719 with Trametinib, highlighting the critical role of downstream 
PI3K signalling specifically in helping maintain the viability of cells with constitutive 
MAPK signalling.  
 
3.5 Discussion 
Both the treatment of HNSCC, as well the disease itself, is associated with 
substantial toxicity owing to the complex facial and pharyngeal anatomy. Patients often 
experience facial disfigurement, the need for tracheostomies and/or feeding tubes, as well 
as lasting speech/swallowing impairments(22). For these reasons, defining candidacy 
requirements for targeted therapies will help prevent patients from experiencing 
unnecessary toxicity when they are unlikely to respond to particular agents(22). PI3K 
targeting is a logical therapeutic approach for HNSCC patients, given the prevalence of 
PIK3CA and other PI3K-pathway alterations in primary tumours and the wealth of agents 
in preclinical and clinical development. Accumulating evidence suggests that while PI3K 
inhibitors are biologically active in some HNSCC patients, a subset are non-
responsive(7,8,23). To date, most clinical trials of PI3K inhibitors in human cancers have  
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not required pre-selection on the basis of genomic features, such as PIK3CA mutations 
(NCT02077933, NCT03138070, NCT02620839).  
In the present study, we have demonstrated that epithelial tumour cells with 
mutations causing constitutive HRAS activity are insensitive to PI3K inhibition by the 
PI3K inhibitor BYL719. Specifically, PI3K inhibition did not affect cellular viability or 
cell cycle progression of G12V mutant cells, in contrast to wild-type HRAS lines. 
Furthermore, introduction or silencing of HRAS G12V directly modulated susceptibility 
of cells to BYL719. Constitutively-active HRAS maintains constant activation of the 
MAPK pathway, which exhibits considerable molecular crosstalk with the PI3K pathway. 
Both networks are pivotal players in coordinating proliferation, survival and migration of 
HNSCC cancer cells(10). Here we have found that cells with constitutively-active MAPK 
signalling (owing to the presence of HRAS G12V) may define a subset of HNSCCs that 
are non-responsive to PI3K inhibition. In support of this, we previously found that in a 
panel of 20 HNSCC patient-derived xenograft (PDX) models, the 5 models with activating 
HRAS mutations were all among the least responsive models to BYL719 treatment, 
showing no reductions in tumour size relative to baseline following treatment (Ruicci KM, 
et al., under review; Chapter 2). Although RAS proteins are known to bind and activate 
PI3K signalling directly, presumably leading to some dependence on PI3K signalling, we 
and others find RAS mutants insensitive to PI3K targeting(10,24,25). 
 At present, no alternative treatment strategies exist specifically for HNSCC patients 
with activating HRAS mutations(26). Our data suggest that PI3K inhibition is unable to 
abolish mTORC1 activity in HRAS G12V mutant cells, despite effective Akt blockade. 
The preservation of mTORC1 activity clearly represents a strategy of resistance to PI3K 
inhibitors. Based on this, we speculated whether the MAPK pathway might signal directly 
to mTOR, without involving PI3K or Akt. We confirmed that mTOR inhibition effectively 
reduced the viability of G12V mutant cells and suppressed downstream activation of the 
ribosomal protein S6. These findings highlight mTOR as a relevant signalling node for 
G12V mutant cells. 
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 Work by Ma et al. has positioned the RAS/MAPK pathway upstream of mTORC1 
based on the ability of MAPK pathway member ERK to phosphorylate and functionally 
inactivate PI3K pathway member TSC2, a negative regulator of PI3K signalling (Fig. 3.5a) 
(17). ERK-mediated TSC2 inactivation promotes mTORC1 activity, leading to 
proliferation and cell survival. Based on this established interaction, we hypothesized that 
in the setting of constitutively active MAPK pathway signalling, activated ERK may 
promote mTORC1 activity, enabling cells to survive, despite upstream PI3K targeting. 
We evaluated ERK silencing using RNA interference and found it to be associated 
with reduced phosphorylation of TSC2, mTORC1 and S6. The limited response of HRAS 
G12V cells to PI3K inhibition may therefore stem not from insufficient target inhibition 
(as BYL719 effectively blocked Akt activation), but from persistent mTOR activity, 
modulated at least in part by cross signalling from the MAPK pathway. While the 
mechanisms involved in mutant RAS-mediated circumvention of PI3K targeted therapy 
are likely heterogeneous and context-specific, our study provides evidence that 
downstream PI3K targeting—specifically at the level of mTORC1—may be a therapeutic 
susceptibility for HRAS-driven tumours. Indeed, mTOR inhibition is being actively 
explored in the context of several RAS-driven cancers(27-29). As RAS-driven tumours 
often exhibit differential responsiveness to anti-cancer therapies, specific clinical 
consideration may be warranted(14-16).  
In summary, we have shown mutant HRAS G12V to be a predictive marker of non-
response to PI3K targeted therapy; this observation may help guide patient candidacy for 
PI3K targeted agent trials for HNSCC patients. mTOR may be a new therapeutic 
susceptibility for targeting in RAS-driven cancers, alone or in combination with MAPK 
pathway inhibition. If genomic analysis before treatment with a PI3K inhibitor is not 
possible clinically, monitoring levels of S6 phosphorylation (Ser240/4) after initial 
treatment may be useful in predicting whether PI3K inhibition is effective or whether the 
addition of an mTOR-targeted agent may be helpful in achieving improved patient 
responses. 
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Supplementary Table 3.1. Sources and cell culture media for established
HNSCC cell lines used in this study.Supplementary Table 1. Sources and cell culture media for established HNSCC cell lines used 
in this study. 
 
Cell Line 
HPV 
Status 
Tumour Site 
(if available) 
Patient 
Information 
(if available) 
Growth 
Medium 
Source 
SCC-61 Negative ------ ------ DMEM/F12 Yale 
Cal33 Negative Tongue Male, 69 
DMEM + 
HI FBS + NEAA 
DSMZ 
T24 NA Urinary Bladder Female, 81 DMEM/F12 
University of 
Pittsburgh 
 
DMEM, Dulbecco’s Modified Eagle Medium; DSMZ, Deutsche Sammlung von Mikroorganismen und 
Zellkulturen; NEAA, non-essential amino acids; HI, heat-inactivated; NA, not applicable 
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Supplementary Table 3.3. Targeted inhibitors used in this study.
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Supplementary Table 3.4. P values comparing viability of T24 cells
following treatment with the indicated inhibitors. Comparisons were done by
one-way ANOVA followed by Tukey’s multiple comparisons tests.
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Chapter 4  
 
4 Involvement of TYRO3 and AXL receptors and MAPK 
signalling in acquired resistance to PI3K inhibition in 
head and neck squamous cell carcinoma 
4.1 Abstract 
Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway is 
common in head and neck squamous cell carcinoma (HNSCC). Despite many pre-clinical 
and clinical studies, outcomes from targeting the PI3K pathway have been underwhelming 
and the development of drug resistance poses a significant barrier to patient treatment. In 
the present study, we examined mechanism(s) of acquired resistance to the PI3K inhibitor 
BYL719 (Alpelisib) in HNSCC cell lines and patient-derived xenograft (PDX) models. 
Prolonged treatment with BYL719 led to upregulation of TAM family receptor tyrosine 
kinases (RTKs) TYRO3 and AXL and activation of the MAPK signalling pathway. 
Knockdown of TYRO3 and/or AXL sensitized BYL719-resistant cells to PI3K inhibition, 
while blockade of P90RSK in the MAPK pathway also reduced viability of BYL719-
resistant cells. In vivo, resistance to BYL719 emerged following 2035 days of treatment 
in all five unique PDX models tested. TYRO3 and phopsho-P90RSK (Ser380) were 
detected in BYL719-resistant PDX tissues and, using a cell line derived from a treatment-
naïve xenograft, we observed upregulation of TAM RTKs and MAPK pathway activation, 
highlighting the consistency of our observations between experimental platforms. Whereas 
AXL has been previously noted as a key mediator of resistance to a variety of anti-cancer 
drugs, its family member TYRO3 has not been implicated. Our results highlight pan-TAM 
inhibition as a promising avenue for combinatorial or second-line therapy alongside PI3K 
inhibition. These findings advance our understanding of the role that TAM RTKs play in 
HNSCC and suggest a means to prevent, or at least delay, resistance to PI3K inhibition and 
improve outcomes for HNSCC patients.  
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4.2 Introduction 
Head and neck squamous cell carcinoma (HNSCC), which arises in the mucosa of 
the oral cavity, pharynx and tongue, is the 6th most common cancer worldwide(1). Despite 
advances in available treatments (surgery, radiation, chemotherapy), survival rates at 5 
years remain poor. Further, even patients who respond well to treatment are typically left 
with impairments in their abilities to speak, swallow and breathe, as well as facial 
disfigurements(2). The development and clinical implementation of targeted therapeutics 
is needed to improve the survival outcomes and relieve the toxic burden presently 
associated with HNSCC treatment.  
The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway is a major growth 
signalling pathway that regulates a variety of cellular processes, including protein and lipid 
synthesis, proliferation and cell survival(3). The PI3K pathway is the most frequently 
dysregulated pathway in HNSCC, across both HPV-positive and HPV-negative HNSCC 
tumours(4-6). Dysregulation of PI3K signalling—stemming from activating mutations or 
amplifications of PIK3CA—leads to constitutive activation of PI3K signalling that can 
promote tumour development and progression(5-7). Given the prevalence of PI3K pathway 
alterations in HNSCC and the role this network plays in tumorigenesis, inhibiting this 
pathway is a logical therapeutic approach(7).  
Various inhibitors that target one or more of the PI3K isoforms have entered clinical 
trials(7). To date however, PI3K inhibitors have displayed limited efficacy as single agents. 
These drugs have typically lead to cytostasis, rarely inducing tumour cell death or 
shrinkage(7,8). Moreover, in patients who initially respond to targeted inhibition of PI3K, 
acquired resistance over time has been cited(9).  
Acquired resistance to PI3K inhibition is an area of active research(9-13). In 
ovarian cancer, elevated expression of receptor tyrosine kinases (RTKs), including HER2 
and EGFR, as well as increased activation of Src, c-Jun and STAT3 have been implicated 
in mediating resistance to PI3K inhibition by BEZ235(11). In breast cancer, genetic 
alterations in PTEN resulting in loss of expression have been identified in a patient who 
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initially achieved a clinical response to PI3K inhibition before progressing rapidly(9). Only 
a limited number of studies to date have examined acquired resistance to PI3K inhibition 
in HNSCC. Of these, resistance to the pan-PI3K inhibitor BKM120 has been shown to 
involve positive feedback activation of IL-6/ERK signalling, while resistance to the -
isoform specific PI3K inhibitor BYL719 has been associated with growth signalling 
through the PLC-PKC network, downstream of the RTK AXL(12,14). It is evident that a 
number of distinct mechanisms and mediators of resistance to PI3K inhibition exist and 
may be context-specific according to the drug used and/or cancer type.  
BYL719 (Alpelisib) is an -isoform specific PI3K inhibitor that has been shown to 
exhibit “on-target” PI3K inhibition and anti-cancer efficacy(7,8,15). BYL719 targets the 
p110 catalytic subunit of the Class IA PI3K enzyme encoded by PIK3CA(16). Due to the 
prevalence of genomic aberrations in PIK3CA observed in HNSCC, including gain of 
function mutations and amplifications, BYL719 is a particularly relevant drug. Further, by 
targeting only the -isoform, BYL719 has shown better tolerability than other, broader-
acting PI3K inhibitors, with generally manageable side effects (e.g. hyperglycemia)(8). In-
human activity of BYL719 has recently been reported and phase II clinical trials are 
ongoing(8). To date, there have been few investigations of how resistance to PI3K 
inhibition by BYL719 is acquired in the context of HNSCC(12). Further, most studies have 
been limited to in vitro investigations and have not made use of patient-derived xenograft 
models to explore resistance and/or validate their findings(12,17).  
To capitalize on the promise of PI3K inhibitors in HNSCC, it is essential to 
understand resistance mechanisms that may be acquired over time; this will enable the 
design of drug combinations that will be both tolerable and durable(18). In the present 
study, we explored acquired resistance to BYL719 using both HNSCC cell lines and 
HNSCC patient-derived xenografts (PDXs). We observed elevated expression of the AXL 
RTK, in line with other studies, but we also identified its family member TYRO3 to be 
elevated in BYL719-resistant HNSCC models(12). Further, we interrogated MAPK 
pathway activation downstream of AXL and TYRO3 as a critical network for 
circumventing PI3K inhibition. Collectively our findings emphasize TYRO3 and AXL as 
key mediators of acquired resistance to PI3K inhibition in HNSCC, through the MAPK 
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pathway. Pan-TAM RTK inhibition may be a promising second-line therapy for HNSCC 
patients receiving PI3K-targeted agents.  
 
4.3 Materials and Methods 
4.3.1 Cell lines and chemical compounds 
Cell lines were obtained from the sources listed (Supp. Table 4.1). All cell lines 
were cultured in DMEM/F12, with 10% fetal bovine serum (GIBCO), penicillin 
(100IU/mL; Invitrogen) and streptomycin (100μg/mL; Invitrogen), unless otherwise 
stated. We previously used short tandem repeat profiling (The Center for Applied Genetics; 
Toronto) to confirm identity of all lines (Ruicci KM et al., 2018, under review; Chapter 2). 
Resistant cell lines were obtained after chronic exposure to increasing concentrations of 
BYL719 for ~34 months. All cells were maintained in a 37°C humidified atmosphere at 
5% CO2. The inhibitors BYL719 and BI-D1870 were purchased from Selleckchem. 
Compounds were dissolved in DMSO for in vitro experiments. 
 
4.3.2 Establishment of patient-derived xenografts 
Mice were handled in accordance with the AUP 1542 approved by the University 
Health Network Animal Care Committee and in accordance with the CCAC regulations. 
Xenografts were established and handled as described previously (Chapter 2). Details are 
provided as Supplemental Methods (Section 4.7.1).  
Once tumour volumes reached 80120mm3 mice were randomized to either daily 
(5x/week) BYL719 (Novartis; 50mg/kg) by oral gavage or a vehicle control (corn oil). 
Individual tumour volumes were calculated using the formula: [length x (width)2] x 0.52. 
Where possible, STR profiling was used to confirm matching identifies of primary 
tumours, xenograft tumours, patient blood and PDX-derived cell lines (if applicable) 
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(Supp. Table 4.2). Tumours were classified as HPV-positive using immunohistochemistry 
(IHC) for p16.  
 
4.3.3 Dose response curves 
Cells were seeded in 96-well plates at 2,400 cells/well and cultured overnight. 
Drugs were then added over 10-point ranges (040M). Viability was determined 72hrs 
later using the PrestoBlue® Reagent (Thermo Fisher Scientific) on a SynergyTM H4 Hybrid 
Reader (BioTek) with 560nm excitation and 590nm emission wavelengths. For each dose, 
viability values were normalized to no-drug controls and average viability for each dose 
was calculated. To determine the half-maximal inhibitory concentration (IC50) values, 
normalized relative fluorescence values of drug-treated replicates were calculated as a 
percentage of the mean RFU of the control replicates and then drug doses were transformed 
to a logarithmic scale. IC50 values were subsequently calculated by non-linear regression. 
Values are plotted as mean + standard deviation (SD) using Prism® 7 Graphpad Software.  
 
4.3.4 Clonogenic survival assay 
Parental and resistant cell lines were counted and seeded at 500 cells per well into 
24-well dishes. Cells were allowed to adhere for 48hrs and then cells were treated with 
media containing 5M BYL719. For the next 714 days, cells were monitored and media 
replaced every 3 days until visible colonies were formed. Colonies were rinsed with 1x 
PBS, fixed with cold 100% methanol (MeOH) and stained with 0.5% crystal in 25% 
MeOH/1x PBS. The colonies were then gently washed with water and air-dried. Visible 
colonies were counted.  
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4.3.5 Reverse phase protein arrays (RPPA) 
Following treatment with BYL719 (5M for 24hrs), cells were prepared for RPPA 
analysis as follows: 10cm plates were washed twice with cold 1x PBS. Cold lysis buffer 
(containing: 1% Triton X-100, 50mM HEPES pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM 
EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol and 1% 
freshly-added protease and phosphatase inhibitors) was added to the plates which were 
then incubated 20mins on ice with occasional shaking. Lysed cells were centrifuged at 14 
000rpm for 10mins at 4C. Protein concentration was determined by Bradford Assay. 
Lysates were combined with sample buffer (40% glycerol, 8% SDS, 0.25M Tris-HCl pH 
6.8 and 1/10 volume -mercaptoethanol –added just before use) at 3 parts lysate : 1 part 
sample buffer. Samples were boiled for 5 mins and stored at -80C.  
Samples were submitted to MD Anderson’s Functional Proteomics RPPA Core 
Facility. Briefly, lysates were serially diluted and arrayed onto nitrocellulose-coated glass 
slides. Samples were probed with 307 antibodies and visualized by DAB colorimetric 
reaction. Slides were then scanned and spot densities quantified by Array-Pro Analyzer. 
All data points were normalized for protein loading and transformed to a linear value. We 
restricted our analysis to the top 50% of differentially-expressed proteins for each cell line. 
Values were then log-transformed and median-centered data. Unsupervised average 
hierarchical clustering using the Spearman rank correlation with Cluster3.0 software was 
then performed. Heatmaps were subsequently generated using JavaTreeView1.1.1.  
 
4.3.6 Immunoblotting & co-immunoprecipitation 
Cell lysates were prepared and analyzed by immunoblotting as described 
previously(19). A list of primary antibodies used is provided in Supp. Table 4.3.  
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4.3.7 Tissue microarray (TMA) and immunohistochemistry 
TMAs were constructed for two of the xenograft models. In brief, the FFPE block 
for each tumour was sectioned and stained with hematoxylin & eosin (H & E) to examine 
the presence of human tumour. Guided by these sections, a Manual Tissue Arrayer (MTA-
1; Beecher Instruments Inc.) was used to punch out 34 cylindrical cores of 0.6mm 
diameter from each sample. Cores were arrayed into recipient paraffin blocks. Eleven 
control tissues (tonsil, stomach, prostate, pancreas, lung, kidney, skin, thyroid, spleen, 
adipose, liver) were also included on each block. Cores were sealed into recipient blocks 
by heating at 40C for ~40mins. Blocks were sectioned into 1.5M sections and affixed to 
glass slides. Every ninth slide was stained with H & E to provide a tissue structure 
reference. Additional details are available in the MTA-1 Instruction Manual 
(www.beecherinstruments.com). IHC staining was completed in collaboration with the 
Department of Pathology & Laboratory Medicine and the Molecular Pathology Core 
Facility (Western University). Tissues were examined using an Aperio ScanScope® slide 
scanner and staining quantification was performed with Fiji software. 
 
4.3.8 Flow cytometry for cell surface expression of RTKs 
Parental and resistant cells were collected by trypsinization, washed in 1x PBS and 
counted. Single-cell suspensions were incubated in a 5% BSA solution containing anti-
AXL or TYRO3, PE-conjugated antibodies at 1:50 (R & D Biosystems) for 40mins at room 
temperature in the dark. Cells were passed through a cell strainer to collect single cells and 
were protected from light until they were quantified using a Beckman-Coulter Cytomics 
FC500 flow cytometer with at least 10,000 events counted per test. Histograms were used 
to compare intensity of staining between unstained, parental and resistant cell line samples. 
Median fluorescence intensity was calculated for each sample and t-tests were used to 
quantify differences.  
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4.3.9 RNA interference 
Knockdown of AXL and TYRO3 was performed using specific pooled siRNAs 
purchased from Dharmacon (Cat No’s. L-003104-00-0005 and L-003183-00-0005, 
respectively), as described previously(19). Scrambled control siRNA (siCT) (Thermo 
Fisher Scientific; Cat No. 4390843) was also used. Knockdowns were confirmed by 
immunoblotting. 
For drug testing, cells were seeded into 96-well dishes at 2,400cells/well. BYL719 
was added the next day at 5M and cells were incubated for 72hrs. Cell viability was then 
determined indirectly using the PrestoBlue® Reagent (Thermo Fisher Scientific) on a 
SynergyTM H4 Hybrid Reader (BioTek) with 560nm excitation and 590nm emission 
wavelengths. For each condition, BYL719-treated cells were compared with normalized 
untreated cells to determine the relative effect of RNAi-mediated knockdown. 
 
4.3.10 Generation of PDX-derived cell line 
Using cells dissociated from first passage xenograft tumours, we attempted to 
establish cell lines from the patient tumours used to generate the PDX models that went on 
to be treated out to resistance with BYL719 (Supp. Fig. 4.1a). Specifically, the cell lines 
were attempted from tumour tissues that were never treated with either BYL719 or the 
vehicle agent. A cell line (called PDX-C Cell Line) was successfully established for one 
model, PDX-C (Supp. Fig. 4.1b). STR profiling, immunoblotting and flow cytometry for 
cell surface expression of EpCAM (CD326) were all completed as described previously, 
validating the cell line as a human epithelial line from the same patient as the PDX-C 
xenograft (Supp. Fig. 4.1c, Supp. Table 4.2).  
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4.3.11 Statistical Analysis 
All analyses were performed with Prism® 7 GraphPad Software. Experimental 
groups were compared with controls using Student’s unpaired, two-tailed t-tests. Multiple 
groups were compared across a single condition using one-way ANOVA. P < 0.05 was 
used to define significant differences from the null hypothesis.  
 
4.4 Results 
4.4.1 BYL719 inhibits growth and PI3K signalling in HNSCC cells 
Prior to exploring acquired resistance to PI3K inhibition, we first validated the 
efficacy of BYL719 in HNSCC cell lines. BYL719 treatment reduced signalling through 
both the PI3K and MAPK pathways in Cal33 and 93VU-147T cells (Fig. 4.1a), as indicated 
by reduced levels of phosphorylated (p)-Akt (Thr308), pERK1/2 (Thr202/Tyr204) and 
pP90RSK (Ser380). Based on previous studies, we hypothesized that the mechanism of 
action for BYL719 in HNSCC would involve cell cycle arrest(7). Following 24hrs of 
treatment with BYL719, we observed a significant reduction in the proportion of 
proliferating (S-phase) Cal33 cells (Fig. 4.1b). Finally, to determine whether BYL719 was 
also able to induce cell death through apoptosis, we examined PARP cleavage (Fig. 4.1c). 
Following BYL719 treatment, cleaved PARP was readily detectable. 
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Fig. 4.1. BYL719 inhibits growth and PI3K signalling in HNSCC cells.
(A) Immunoblot of PI3K and MAPK pathway members Akt, ERK1/2 and
P90RSK following treatment with 5M BYL719 for 36hrs. (B) Flow
cytometric analysis of Cal33 cells treated with BYL719 (5M) for 24hrs (3
replicates per line) before BrdU incorporation and labeling with propidium
iodide. Approximately 10,000 events were counted per test. Proportion of
cells in each cell cycle phase is shown, + standard deviation. * represents p <
0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents p <
0.0001, ns = not significant, unpaired Student’s t-test. (C) Immunoblot for
PARP cleavage in Cal33 cells treated with BYL719 (5M) for 24hrs, or
Staurosporine (2M) for 3hrs, as a positive control.
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4.4.2 Genomically-distinct HNSCC cell lines develop resistance to 
BYL719 
To identify pathways associated with acquired resistance to BYL719, we exposed 
three genomically-distinct HNSCC cell lines (Fig. 4.2a) to increasing concentrations of 
BYL719 over a 34 month period (schematic shown in Supp. Fig. 4.2), ultimately yielding 
cell lines significantly more resistant to BYL719 than their parental counterparts (Fig. 4.2b 
and c). To verify the durability of the resistant cell lines, parental and resistant cells were 
challenged to grow as single cell colonies in the presence of BYL719. Whereas BYL719 
treatment led to a significant reduction in the number of colonies formed by all three 
parental cell lines, it was much less effective in resistant cell lines. In BYL719-resistant 
Cal33 and FaDu cells there was no difference in the number of colonies formed between 
untreated and BYL719-treated cells. Although the BYL719-resistant 93VU-147T cells 
exhibited a modest reduction in colony formation following BYL719 treatment, the 
difference was much less than that of the parental line (Fig. 4.2d). Thus, cell lines treated 
for a prolonged period with BYL719 exhibit increased tolerance for this PI3K inhibitor. 
To determine whether BYL719 continued to block signalling through the 
PI3K/Akt/mTOR pathway in drug-resistant cells, we used immunoblotting to examine Akt 
phosphorylation following BYL719 treatment in parental and resistant cell lines. Across 
all three resistant cell lines, BYL719 treatment suppressed Akt Thr308 phosphorylation, 
indicating its sustained efficacy (Fig. 4.3a). 
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Fig. 4.2. Genomically-distinct HNSCC cell lines become resistant to PI3K
inhibition over time. (A) Genomic features and IC50 values for Cal33, 93VU-
147T and FaDu cell lines. (B) Phase contrast microscopy images of parental
and resistant HNSCC cell lines, with and without 5M BYL719 treatment for
24hrs. (C) Dose response curves comparing sensitivity of parental and
resistant cell lines over 10 doses of BYL719. (D) Colony formation assays
comparing tolerance of parental and BYL719-resistant cell lines to BYL719
treatment over time. Number of colonies was counted and graphed. *
represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, ns = not
significant, unpaired Student’s t-test.
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4.4.3 Expression of AXL and TYRO3 is elevated in BYL719-
resistant cells 
To examine a broad array of signalling pathways that could mediate resistance to 
PI3K inhibition in HNSCC cells, we performed reverse phase protein arrays (RPPAs) on 
lysates from Cal33, 93VU-147T and FaDu parental cells and their resistant counterpart cell 
lines (Fig. 4.3b). In both Cal33 and 93VU-147T cells resistant to BYL719, RPPAs 
suggested that expression of the membrane-bound RTK AXL was elevated relative to 
parental cells. As mentioned, AXL has been previously shown to mediate resistance to 
various anti-cancer agents, including EGFR, HER2 and PI3K-targeted therapies(12,20-22). 
AXL is part of a three-member RTK sub-family known as the ‘TAM family’ of receptors 
(TYRO3, AXL, MER-TK) (23-26). Interestingly, expression of TYRO3 was also elevated 
in our RPPA analysis in both Cal33 and 93VU-147T BYL719-resistant cells. To our 
knowledge, TYRO3 has never been implicated in PI3K-inhibitor resistance, nor in HNSCC 
as an effector of therapy response. In general, much less is known about TYRO3, including 
the role it plays in cancer development and progression(25-27). No apparent change in 
protein expression of AXL or TYRO3 was observed between parental and resistant FaDu 
cells.  
We confirmed the elevated protein expression of AXL and TYRO3 in BYL719-
resistant Cal33 and 93VU-147T cells, relative to parental cells by immunoblotting (Fig. 
4.3c). We also examined expression of the third member of the TAM RTK family, MER-
TK, which was not included in the RPPA. MER-TK was only weakly detectable in all three 
HNSCC cell lines, in contrast to its high abundance in HEK293T cells (long exposure blots 
shown in Supp. Fig. 4.5a-c). Due to the low protein expression of MER-TK and the 
absence of a difference in expression of it between parental and resistant cells, we did not 
examine it further. We also preliminarily examined transcript expression of AXL and 
TYRO3 using qRT-PCR, which suggested a possible increase in expression of AXL in 
Cal33 and 93VU-147T cells, and elevated expression of TYRO3 in 93VU-147T and FaDu 
cells after long-term treatment with BYL719 (Supp. Fig. 4.3a and b). Based on our 
findings, we hypothesized that overexpression of TYRO3 and/or AXL receptors may play 
a role in mediating resistance to PI3K inhibition.  
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4.4.4 HNSCC PDX models develop resistance to BYL719 
following prolonged treatment  
 In parallel with our cell line models, we generated 5 PDX models from HNSCC 
patient tumours (clinical characteristics for patients are outlined in Table 4.1). Histological 
comparison of PDXs and their corresponding primary tumours (where available) revealed 
a high degree of similarity in their cellular morphology (Supp. Fig. 4.4). In all 5 PDX 
models, treatment with BYL719 significantly suppressed tumour growth for the first 2035 
days, relative to the vehicle agent (Fig. 4.4a, boxed regions). However, beyond this initial 
response period, BYL719-treated tumours began to resume growth or exhibit an increased 
rate of growth over time (Fig. 4.4a). Thus, PDX models behave similarly to cell lines in 
that they also develop resistance to PI3K inhibition by BYL719 over time. 
Ki67 staining was used to examine the proliferative activity of vehicle-treated 
tumours, BYL719-sensitive tumours (not treated to resistance) and BYL719-resistant 
tumours. Most vehicle-treated and BYL719-resistant tumours exhibited strong positive 
Ki67 staining, whereas BYL719-sensitive tumours showed weaker staining (representative 
sections shown in Fig. 4.4b).  
 We next analyzed the expression of AXL and TYRO3 in PDX models using IHC. 
While no visible difference in AXL expression was detected for either of the models 
examined (Fig. 4.5a), TYRO3 abundance following prolonged treatment with BYL719 
was markedly elevated in both PDX models (Fig. 4.5b).  
 
4.4.5 TYRO3 and AXL overexpression mediate resistance to 
BYL719 
Since expression of AXL and TYRO3 were both elevated in BYL719-resistant 
models, we proceeded to determine the relative expression of both receptors at the cell 
surface in parental and resistant cells. Flow cytometric analysis demonstrated a significant 
increase in both AXL and TYRO3 surface levels in BYL719-resistant Cal33 and 93VU- 
Table 4.1. Clinical features of HNSCC patients used to generate PDX models
of acquired drug resistance.
PDX ID Gender Age 
TNM Stage Disease 
Site 
Subsite 
HPV 
Status 
Smoking 
History 
Alcohol 
Consumption 
Recurrent T N M 
 
PDX-A M 72 T2 N2b M0 
Lip & Oral 
Cavity 
Tongue nt Ex-smoker Non-drinker No 
PDX-B M 60 T3 N2c M0 Oropharynx 
Base of 
Tongue 
+ Non-smoker Non-drinker Yes 
PDX-C M 44 T2 N1 M0 
Lip & Oral 
Cavity 
Tongue - Non-smoker Non-drinker No 
PDX-D F 87 T2 N2b M0 
Lip & Oral 
Cavity 
Tongue nt Non-smoker Non-drinker No 
PDX-E M 63 T4 N2b M0 Hypopharynx 
Piriform 
Sinus 
- NA NA NA 
 
 
 
 
 
un: unknown
nt: not tested
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Fig. 4.4. HNSCC PDX models develop resistance to BYL719 following
prolonged treatment. (A) Growth curves for PDX models treated over time
with BYL719. 5 mice per arm received either BYL719 (50mg/kg) or a vehicle
agent (corn oil). * represents p < 0.05, ** represents p < 0.01, unpaired
Student’s t-test. Boxed out region highlights early treatment days where
BYL719-treated tumours showed static growth relative to the vehicle
treatment. (B) Representative IHC sections showing Ki67 staining PDX
tissues treated with the vehicle agent (corn oil) or BYL719 (endpoint either
while still responding or treated out to the emergence of resistance). Scale bar
represents 100uM.
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Fig. 4.5. Expression of TYRO3 and AXL in PDX models with acquired
resistance to PI3K inhibition. (A) Representative IHC sections showing
AXL staining in PDX-C and PDX-E models. Quantification completed using
Fiji software is shown below. ns = not significant, unpaired Student’s t-test.
(B) Representative IHC sections showing TYRO3 staining in PDX-C and
PDX-E models. Quantification was completed using Fiji software is shown
below. * represents p < 0.05, unpaired Student’s t-test. Scale bars represent
100uM.
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147T cells, compared to parental cells (Fig. 4.6a). No difference in TYRO3 expression was 
observed between parental and resistant FaDu cells, while AXL surface expression was 
lower in BYL719-resistant cells.  
To assess whether the upregulation of TYRO3 and/or AXL expression plays a 
causative role in mediating resistance to PI3K inhibition, we used siRNAs to silence each 
receptor in BYL719-resistant cells. Knockdown of either TYRO3 or AXL re-sensitized 
BYL719-resistant cells to a level almost comparable to the parental (baseline) sensitivity 
(Fig. 4.6b and c). This was true across all three cell lines, even FaDu which was re-
sensitized to BYL719 despite lacking any apparent differences in total protein expression 
or cell surface localization of either AXL or TYRO3. 
 
4.4.6 The MAPK pathway is activated in BYL719-resistant models 
 As the expression of MAPK pathway members ERK1/2 and P90RSK was reduced 
by PI3K inhibition in parental cells (Fig. 4.1a), we analyzed the activation status of several 
MAPK pathway members (Fig. 4.7a) in our resistant cells. Beginning upstream, we 
examined expression of the scaffold protein GAB2 that mediates signalling from the 
adaptor protein Grb2 on intracellular RTK domains to RAS. GAB2 expression was 
elevated in BYL719-resistant 93VU-147T cells (as suggested in the RPPA), although no 
difference was apparent in Cal33 or FaDu cells (Fig. 4.7b, block 1). The next differentially-
expressed pathway member was phosphorylated MEK1 (Ser298) which was apparent in 
BYL719-resistant Cal33 cells (Fig. 4.7b, block 2). Moving down the MAPK pathway, 
elevated activating phosphorylation of ERK1/2, P90RSK and S6 was detected in all 3 
resistant cell lines (Fig. 4.7b, block 3), confirming an induction of MAPK pathway 
activation upon prolonged treatment with BYL719. 
 Given the upregulation of pP90RSK observed in the resistant cell lines and its 
described involvement in HNSCC oncogenesis, we proceeded to examine the expression 
of pP90RSK (Ser380) in our PDX models using IHC(28,29). We observed a non-
significant trend towards elevated pP90RSK (Ser380) expression in BYL719-resistant  
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Fig. 4.6. TYRO3 and AXL modulate sensitivity to BYL719. (A) Flow
cytometric analysis of AXL and TYRO3 in parental and resistant HNSCC cell
lines. Median fluorescence intensity (MFI) was measured and graphed for
three biological replicates. * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001, **** represents p < 0.0001, ns = not significant. One-
way ANOVA. (B) siRNA-mediated knockdown of AXL (siAXL) and
TYRO3 (siTYRO3) in Cal33, 93VU-147T and FaDu cells. siCT = scrambled
control siRNA. Letters denote samples that differ from other samples by p <
0.05 or greater. (C) Immunoblot of AXL and TYRO3 expression following
siRNA-mediated knockdowns. siCT = scrambled control siRNA.
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Fig. 4.7. Activation of the MAPK signalling pathway in BYL719-resistant
cell lines and PDX models. (A) Schematic representation of PI3K and
MAPK pathways, with crosstalk activating mTORC1 shown. (B) Immunoblot
with indicated parental and BYL719-resistant lysates examining activation of
the MAPK pathway. (C) & (D) Representative IHC sections showing
pP90RSK (Ser380) staining in PDX-E (C) and PDX-C (D) models.
Quantification was completed using Fiji software and is shown below. ***
represent p < 0.01, ns = not significant, unpaired Student’s t-test. Scale bars
represent 50uM.
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PDX-E tissues and a significant increase in expression of pP90RSK (Ser380) in PDX-C 
tissues (Fig. 4.7c and d). 
 
4.4.7 Inhibition of MAPK signalling improves response to BYL719 
To evaluate the effect of MAPK signalling on resistant cells’ responsiveness to 
BYL719, we targeted the downstream MAPK pathway member P90RSK using the small 
molecule inhibitor BI-D1870, alone and in combination with BYL719(30). In all three 
BYL719-resistant cell lines, BI-D1870 treatment resulted in a significant reduction in cell 
viability (Fig. 4.8a). Interestingly, only in FaDu cells was BI-D1870 more effective than 
BYL719 as a single agent. However, in all cell lines, when BI-D1870 and BYL719 
treatments were combined, the effect on cell viability was most maximized.  
 
4.4.8 Knockdown of TYRO3 and AXL reduces MAPK pathway 
activation 
We next evaluated the relation between expression of TYRO3 and AXL and MAPK 
pathway activation. Following knockdown of both TYRO3 and AXL in BYL719-resistant 
cells, we used immunoblotting to detect phosphorylated (active form) members of the 
MAPK pathway, including ERK1/2, P90RSK and S6 (Fig. 4.8b). In Cal33 cells, silencing 
of either TYRO3 or AXL was associated with reduced phosphorylation of P90RSK 
(Ser380) and S6 (Ser235/6), while only TYRO3 silencing reduced ERK1/2 
(Thr202/Tyr204) phosphorylation. In 93VU-147T cells, TYRO3 knockdown reduced 
phosphorylation of ERK1/2 and P90RSK, while AXL knockdown did not have an apparent 
effect on MAPK pathway activation. Finally, in FaDu cells, AXL knockdown decreased 
levels of phosphorylated ERK1/2, while both AXL and TYRO3 knockdown resulted in 
reduced phosphorylation of P90RSK. 
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Fig. 4.8. Inhibition of MAPK signalling improves response to BYL719.
(A) Effect of P90RSK inhibitor BI-D1870 and BYL719 (5M each) on
viability of BYL719-resistant cell lines. One-way ANOVA. Letters denote
samples that differ from other samples by p < 0.05 or greater. (B) Immunoblot
of MAPK pathway members following knockdown of AXL and TYRO3.
siCT = scrambled control siRNA.
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4.4.9 Baseline expression of AXL and TYRO3 is not associated 
with sensitivity to PI3K inhibition 
To determine whether expression of TYRO3 and/or AXL was associated with PI3K 
inhibitor sensitivity at baseline (i.e. without prolonged drug exposure), we examined the 
protein expression of both receptors in a panel of 25 HNSCC cell lines. We previously 
characterized the sensitivity of all 25 lines to BYL719 and ordered the cell lines 
accordingly (Ruicci KM et al., 2018, under review; Chapter 2). While expression of both 
proteins varied between cell lines, we did not observe an apparent trend in the expression 
of either TYRO3 or AXL that correlated with sensitivity to BYL719 (Fig. 4.9). Given an 
absence of a correlation between baseline TAM RTK expression and response to PI3K 
inhibition, it appears the involvement of TYRO3 and AXL in drug response is contingent 
on either the specific activity of the receptors, or on a relative upregulation of the receptors 
during the course of treatment. 
 
4.4.10 Activation of MAPK signalling and elevated TAM family 
expression in a PDX-derived cell line 
 Finally, in parallel with our in vitro and in vivo models of acquired resistance to 
PI3K inhibition, we generated a BYL719-resistant cell line from the parental PDX-derived 
cell line (PDX-C cell line) we established (described in methods). This model system 
provided the unique opportunity to use an early-passage tumour-derived cell line to 
validate the data from both our in vitro studies using established HNSCC cell lines and our 
in vivo studies using PDX models. The BYL719-resistant PDX-C-derived cell line had ~3-
fold increase in IC50 (2.3M versus 6.3M), relative to its parental counterpart (Fig. 4.10a). 
Immunoblotting revealed elevated expression of AXL in the BYL719-resistant cell line, 
while TYRO3 expression appeared stable (Fig. 4.10b). Downstream, elevated 
phosphorylation of MAPK pathway members ERK1/2 and P90RSK was also detected, 
confirming our previous cell line and PDX-based findings. (Fig. 4.10c). 
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4.5 Discussion 
In this study, we showed that PI3K inhibition exhibits anti-tumour efficacy in 
HNSCC models by dampening PI3K signalling, inducing PARP cleavage and reducing the 
proportion of actively-proliferating cells. As targeted PI3K inhibition is under active 
clinical investigation for HNSCC patients, we proceeded to evaluate the efficacy of PI3K 
inhibition over time using BYL719. We showed in both in vitro and in vivo assays that 
HNSCC escapes the anti-tumour activity of BYL719 over a period of weeks to months. 
This acquisition of drug resistance is associated with upregulation of the RTKs TYRO3 
and AXL, which leads to an apparent increase in downstream signalling through the MAPK 
network. While AXL has been described in various settings to function as a mediator of 
acquired drug resistance, the involvement of its family member TYRO3 is previously 
unrecognized(12,20,21,31,32). 
 AXL and TYRO3 are two members of the three-membered TAM family of RTKs, 
which also includes MER-TK(26). Although none of the TAM RTKs are considered to be 
strong oncogenes, all three have demonstrated transforming potential and it is increasingly 
recognized that their overexpression contributes to resistance to both standard and targeted 
chemotherapies(25). AXL is by far the best-studied TAM RTK and has an established role 
in supporting tumorigenesis through its positive effects on cellular survival, migration, 
proliferation and invasion, and in mediating acquired resistance(25). To date, 
overexpression of AXL has been implicated in resistance to imatinib (BCR-Abl, c-Kit and 
PDGFR inhibitor), lapatinib (HER2 inhibitor), erlotinib (EGFR inhibitor) and cetuximab 
(EGFR-targeting monoclonal antibody), as well as resistance to the chemotherapeutics 
doxorubicin, cisplatin and etoposide (VP-16) in a variety of solid tumour types and blood 
cancers(20,21,25,31-33). In contrast, TYRO3 overexpression has only been shown to 
mediate taxol resistance in ovarian cancer(34).  
 In our HNSCC models, upregulation of both AXL and TYRO3 total protein was 
detected, as was a relative increase in cell surface localization in BYL719-resistant versus 
parental samples. The involvement of AXL and TYRO3 in resistance to PI3K inhibition 
is underscored by the fact that knockdown of either or both receptors significantly 
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sensitized cells to BYL719 treatment. Upregulation of AXL and TYRO3 in response to 
long-term BYL719 treatment was apparent in 2 of the 3 HNSCC cell lines we surveyed 
(Cal33 and 93VU-147T), however in all three cells lines, receptor knockdown resulted in 
increased susceptibility to PI3K inhibition. This may suggest that while total expression 
did not vary detectably in FaDu cells, the activity of the receptor may have changed via 
another mechanism; this is an avenue for further study.  
Across a large panel of HNSCC cell lines, we did not observe a trend between 
protein expression of TYRO3 or AXL, and sensitivity to PI3K inhibition. This leads us 
to believe that the involvement of AXL and TYRO3 in PI3K inhibitor resistance is likely 
based on a relative increase in expression/surface localization or altered receptor activity, 
rather than a baseline expression level. At present it is not well known how expression of 
AXL and TYRO3 is regulated; given the emerging role of TAM RTKs in cancer and drug 
response however, this is an area of active research(26,27). Hypoxia and HIF-1 
expression has been associated with AXL expression while certain microRNAs (miRNAs) 
are also thought to mediate of TAM RTK expression(35-38).  
Downstream of AXL and TYRO3, numerous intracellular signalling pathways have 
been associated with cancer progression and drug resistance(26,27). Re-activation of Akt 
signalling and activation of the NF-B pathway are two such examples(31,32). In the 
context of HNSCC specifically, PLC-PKC signalling downstream of AXL has been 
identified following PI3K inhibition(12). Our data provide clear evidence of MAPK 
pathway activation, consistent across all cell lines surveyed. Further, targeted inhibition of 
the downstream MAPK pathway member P90RSK, alone and in combination with 
BYL719, resulted in a significant reduction in cell viability of BYL719-resistant HNSCC 
cells, emphasizing the relevance of this pathway in circumventing PI3K inhibition. Our 
observations are in accordance with previous findings that have demonstrated RSK family 
members to be mediators of resistance to PI3K pathway inhibition in breast cancer, and to 
be capable of promoting disease progression in HNSCC specifically(28,29). 
Other studies have reported that residual mTORC1 activity following PI3K 
inhibition is involved with limiting its anti-tumour efficacy(39,40). The activation of 
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MAPK signalling observed in our BYL719-resistant HNSCC cell lines supports this 
finding, as the MAPK pathway intersects with the PI3K pathway at several downstream 
points that promote mTORC1 or S6 activity (Fig. 4.7a)(41). Additionally, Chandarlapaty 
et al. (2011) described a direct association between inhibition of PI3K/Akt signalling and 
upregulation of RTKs, such as HER3 and IGF-1R(42). The pattern of receptor 
upregulation/activation and intracellular signalling converging on mTORC1/S6 may be a 
shared feature of acquired resistance to PI3K pathway inhibition across different cancer 
types(12,42). However, the particular mechanism and mediator(s) adopted by tumour cells 
are likely cancer- and/or drug-specific.  
 Recently, PDX models have emerged as a leading preclinical platform through 
which to interrogate drug efficacy, interpatient response heterogeneity and, more recently, 
to elucidate mechanisms of drug resistance(17,43,44). In our study, we confirmed our in 
vitro findings of TYRO3 and AXL upregulation and MAPK pathway activation upon 
prolonged PI3K inhibition in a panel of unique HNSCC PDX models treated for up to 
100 days with BYL719.  
 Based on our collective findings, pan-TAM inhibition emerges as a logical 
combinatorial or second-line treatment target alongside PI3K inhibition in HNSCC. 
While AXL inhibitors are already in active development owing to its identified role in drug 
resistance, our findings reveal its family member TYRO3 to be similarly relevant(25). We 
would therefore speculate that the use of a dual AXL/TYRO3 or pan-TAM inhibitor (e.g. 
LDC1267) would be more effective and durable over time(25). To date, no-specific 
TYRO3 inhibitors are available. Targeting the MAPK pathway is an alternative approach, 
as we demonstrated with the P90RSK inhibitor BI-D1870. However, MAPK pathway 
inhibition has had variable efficacy to date and acquired resistance to inhibitors of the 
MAPK pathway has been documented, in some cases involving TAM RTKs(45,46). 
Upstream targeting of AXL and TYRO3 therefore seems to be the most logical approach. 
In summary, our findings identify TYRO3 and AXL upregulation and MAPK 
pathway activation as a consequence of prolonged PI3K inhibition both in vitro and in 
vivo and emphasize the potential of a therapeutic approach involving not only AXL 
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inhibition, but pan-TAM RTK inhibition in order to prevent, or at least delay, resistance to 
PI3K inhibitors for HNSCC patients.  
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4.7 Supplementary Materials 
4.7.1 Supplementary methods 
4.7.1.1 Quantitative Real-Time PCR (qRT-PCR)  
qRT-PCR analysis was completed as described previously17. Primers (5’ to 3’): 
AXL (F -AGGGCCGGGGACAGC, R -AGCCTGCGTGCCCCT), TYRO3 (F -
CCGCCGCAGGTCTGAAG, R -ACCCACTGGATGTCAGGCTC), -actin (F - 
AGAGCTACGAGCTGCCTGAC, R - AGCACTGTGTTGGCGTACAG).  
 
4.7.1.2 Establishment of patient-derived xenografts 
 Fresh surgical HNSCC specimens were received from consenting patients with 
primarily diagnosed or recurrent HNSCC who underwent surgery at the London Health 
Sciences Centre or Princess Margaret Cancer Centre between 2009 and 2014 under a 
University Health Network Research Ethics Board approved protocol (REB #12-5639). 
Specimens were received within 0.524hrs of surgery and kept at 4C in PBS until 
engraftment no later than 24hrs post-resection. Tumours were divided into ~1mm3 pieces 
and implanted subcutaneously into the flank region of NOD/SCID/IL2R-/- (NSG) male 
mice. Once tumours reached 11.5cm in size, mice were sacrificed and tumours were 
dissected from the flank, dissociated in culture medium containing 
collagenase/hyaluronidase and DNASE 1 and passaged subcutaneously into 10 mice per 
tumour model (minimum 100,000 cells/mouse) in 1:1 matrigel/PBS. Once tumours were 
palpable, measurements with calipers began. Tumours were classified as HPV-positive 
using immunohistochemistry (IHC) for p16.  
Once tumour volumes reached 80120mm3 mice were randomized to either daily 
(5x/week) BYL719 (Novartis; 50mg/kg) by oral gavage or a vehicle agent (corn oil). Mice 
were maintained until tumours reached a maximum size of 1.5 cm in diameter or an 
alternative humane endpoint was reached as stated in the animal protocol. Animals were 
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observed daily for their overall health. Mice were evaluated for tumour size and body 
weight every 24 days. Individual tumour volumes were calculated using the formula: 
[length x (width)2] x 0.52. Where possible, STR profiling was used to confirm matching 
identifies of primary tumours, xenograft tumours, patient blood and PDX-derived cell 
lines, if available (Supp. Table 4.2).  
 
 
. 
 
  
Supplementary Table 1. Sources and cell culture media for established HNSCC cell lines used 
in this study. 
 
Cell Line 
HPV 
Status 
Tumour Site 
(if available) 
Patient 
Information 
(if available) 
Growth Medium Source 
93-VU-147T Positive Floor of mouth Male, T4N2 DMEM/F12 VUMC 
FaDu Negative Hypopharynx Male, 56 DMEM/F12 ATCC 
Cal33 Negative Tongue Male, 69 
DMEM + 
HI FBS + NEAA 
DSMZ 
 
DMEM, Dulbecco’s Modified Eagle Medium; VUMC, VU University Medical Center Amsterdam; ATCC, 
American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen; 
IMDM, NEAA, non-essential amino acids 
Supplementary Table 4.1. Sources and cell culture media for established
HNSCC cell lines used in this study.
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Supplementary Table 4.2. Short-tandem repeat (STR) profiling results
confirming matching identities of primary tumour, blood, xenograft tumours
and cell lines, where available.
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Blood 
X,Y 10,12 11,13 11,12   28,32.2   11,11 10,10   6,9.3 8,11 16,16 
PDX-C 
Primary 
X,Y 10,12 11,13 11,12   28,32.2   11,11 10,10   6,9.3 8,11 16,16 
PDX-C 
C4 
X,Y 10,12 11,13 11,12 11,13 14,14 28,28 17,18 15,15 11,11 10,10 13,13 25,25 6,9.3 8,11 16,17 
PDX-C 
C5 
X,Y 10,12 11,13 11,12   28,32.2   11,11 10,10   6,9.3 8,11 16,17 
PDX-C 
B2 
X,Y 10,12 11,13 11,12   28,28   11,11 10,10   6,9.3 8,11 16,17 
PDX-C 
B3 
X,Y 10,12 11,13 11,12 11,13 14,14 28,28 17,18 15,15 11,11 10,10 13,13 25,25 6,9.3 8,11 16,17 
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Cell Line 
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PDX-E 
C4 
X,X 12,12 12,12 9,9   30,30,2   12,13 11,11   7,9.3 11,11 17,17 
PDX-E 
B2 
X,X 12,12 12,12 9,9 10,18 12,16 30,30,2 19,19 17,17 12,13 11,11 13,13 22,23 7,9.3 8,11 17,17 
PDX-E 
B3 
X,X 12,12 12,12 9,9   30,30,2   12,13 11,11   7,9.3 8,11 17,17 
PDX-E 
B4 
X,X 12,12 12,12 9,9 10,18 12,16 30,30,2 19,19 17,17 12,13 11,11 13,13 22,23 7,9.3 8,11 17,17 
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Supplementary Fig. 4.1. PDX-C cell line development and
characterization. (A) Schematic outlining the derivation of cell line from
PDX-C. (B) Phase contrast microscopy image of PDX-C cells. (C) Flow
cytometry for cell surface expression of EpCAM (CD326) in PDX-C cells.
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Supplementary Fig. 4.3. qRT-PCR results for expression of AXL (A) and
TYRO3 (B) in parental and BYL719-resistant HNSCC cells. 2 biological
replicates, each run in technical duplicate are shown.
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Supplementary Fig. 4.4. Histological comparison of PDX tissues and their
corresponding primary tumours (where available), stained with H&E. Scale
bar represents 50uM.
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Supplementary Fig. 4.5. (A) – (C) Immunoblot of MER-TK expression in
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positive control for MER-TK expression.
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Chapter 5  
 
5 Disruption of the RICTOR/mTORC2 complex enhances 
the response of head and neck squamous cell 
carcinoma cells to PI3K inhibition 
5.1 Abstract 
PI3-kinase (PI3K) is aberrantly activated in head and neck squamous cell 
carcinomas (HNSCC) and plays a pivotal role in tumorigenesis by driving Akt signalling, 
leading to cell survival and proliferation. Phosphorylation of Akt Thr308 by PI3K-PDK1 
and Akt Ser473 by mTOR complex 2 (mTORC2) activates Akt. Targeted inhibition of 
PI3K is a major area of preclinical and clinical investigation as it reduces Akt Thr308 
phosphorylation, suppressing downstream mTORC1 activity. However, inhibition of 
mTORC1 releases feedback inhibition of mTORC2, resulting in a resurgence of Akt 
activation mediated by mTORC2. While the role of PI3K-activated Akt signalling is well-
established in HNSCC, the significance of mTORC2-driven Akt signalling has not been 
thoroughly examined. Here we explore the expression and function of mTORC2 and its 
obligate subunit RICTOR in HNSCC primary tumours and cell lines. We find RICTOR to 
be overexpressed in a subset of HNSCC tumours, including those with PIK3CA or EGFR 
gene amplifications. Whereas overexpression of RICTOR reduced susceptibility of 
HNSCC tumour cells to PI3K inhibition, genetic ablation of RICTOR using CRISPR/Cas9 
sensitized cells to PI3K inhibition, as well as to EGFR inhibition and cisplatin treatment. 
Further, mTORC2 disruption led to reduced viability and colony forming abilities of 
HNSCC cells relative to their parental lines and induced loss of both activating Akt 
phosphorylation modifications (Thr308 and Ser473). Taken together, our findings establish 
RICTOR/mTORC2 as a critical oncogenic complex in HNSCC and rationalize the 
development of an mTORC2-specific inhibitor for use in HNSCC, either combined with 
agents already under investigation, or as an independent therapy.  
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5.2 Introduction 
 Activating Akt phosphorylation drives cell proliferation, motility, survival and 
protein synthesis in numerous cancers, including head and neck squamous cell cancer 
(HNSCC) which affects over 550 000 individuals worldwide each year(1,2). In HNSCC, 
both human papillomavirus (HPV)-positive and HPV-negative tumours show frequent 
direct activation of Akt, or indirect activation via the PI3K pathway, which serves as an 
upstream activator of Akt(3-5). Accordingly, regulation of Akt is an area of interest for 
both preclinical and clinical cancer research. 
 Many studies have focused on PI3K-PDK1 signalling as the primary means of Akt 
activation, via phosphorylation of Akt (Thr308)(6). Inhibition of PI3K blocks Akt 
phosphorylation at Thr308, leading to decreased downstream signalling to mTORC1 and 
a reduction in cell growth and survival(6). However, PI3K/Akt/mTORC1 suppression 
relieves feedback inhibition to upstream network effectors, including mTOR complex 2 
(mTORC2), causing a recovery of Akt signalling(7). As a result of this compensatory 
signalling adaptation, the efficacy of PI3K pathway inhibition is diminished(6). To more 
effectively inhibit Akt signalling in cancer, consideration of these inherent feedback loops 
is required. 
 mTORC2 (previously known as PDK2) was the second major Akt kinase to be 
identified and is best known for contributing to Akt activation via phosphorylation of Akt 
at Ser473(8). When PI3K/Akt/mTORC1 signalling is active, the mTORC1 effector 
p70S6K (S6K) directly phosphorylates the RICTOR subunit of mTORC2 (Thr1135) to 
downregulate mTORC2-mediated Akt activation(6,7,9). However, in the case of inhibition 
of PI3K/Akt/mTORC1 signalling, feedback inhibition of mTORC2 is lost and the complex 
becomes active(6,7,9) (schematic shown in Fig. 5.1a). mTOR is therefore uniquely 
positioned to be both activated by Akt (via mTORC1) and to activate Akt (via mTORC2). 
To date, the importance of mTORC2-mediated Akt signalling in HNSCC has not be 
examined in relation to targeting the PI3K pathway. 
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mTORC1 and 2 are structurally-distinct multi-protein complexes, with mTORC1 
containing RAPTOR and PRAS40, and mTORC2 containing RICTOR, SIN1 and 
PROTOR as its distinguishing subunits(10,11). Given the different subunits and substrates 
of the two mTOR complexes, it is increasingly recognized that these complexes are distinct 
in their physiological roles and have different consequences to their activation and 
dysregulation in cancer(12). RICTOR (rapamycin-insensitive companion of mTOR) has 
been found to be overexpressed in various cancers (e.g. gastric and lung) and to be capable 
of cooperating with other driver mutations to stimulate cellular proliferation(12-14). 
Furthermore, in both glioblastoma and breast cancer, RICTOR/mTORC2 has been 
implicated as a mediator of disease progression and therapy resistance(12,15).  
 While relatively little is known about the intricacies of mTORC2 signalling in 
HNSCC, there is substantial interest in targeting the PI3K pathway (e.g. via targeted 
inhibition of PI3K, Akt, or mTORC1). Presently however, patient responses to PI3K 
inhibition have been variable and relatively short-lived(16-18). Here, we have explored 
RICTOR/mTORC2 in HNSCC tumour cells and interrogated the role of mTORC2 in 
modulating response to PI3K inhibition. As no specific inhibitors of mTORC2 exist to date, 
we have generated a novel gene knockout model of RICTOR using CRISPR/Cas9 to 
determine how loss of RICTOR/mTORC2 activity affects the therapeutic response of 
HNSCC tumour cells to PI3K inhibition, as well as to EGFR inhibition and cisplatin 
treatment. 
 
5.3 Materials and Methods 
5.3.1 Tissue microarray and immunohistochemistry 
Study approval was obtained from the University of Western Ontario Research 
Ethics Board (HSREB 103886).  A retrospective search of the London Health Sciences 
Centre pathology database was performed to identify pre-treatment oropharyngeal cancer 
biopsy specimens and clinicopathological factors were extracted through a retrospective 
chart review. A tissue microarray (TMA) was constructed from 1mm core punches of 
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primary site biopsy specimens. 4µM sections were cut and tested for RICTOR expression 
using immunohistochemistry (IHC) (ab70374; 2g/ml). RICTOR expression was scored 
by two clinical pathologists (PP and CJH) based on a combination of staining intensity 
(none (0), weak (1), moderate (2), strong(3)) and extent of staining (incomplete, complete). 
Disagreements in scoring were resolved by consensus. Quantitative reverse transcription 
PCR (qRT-PCR) was used to test for HPV types 16 and 18 in DNA extracted from formalin 
fixed samples as previously described(19). RICTOR expression was compared to 
clinicopathologic variables by using Fisher’s Exact tests and Chi-Square tests. Survival 
curves stratified by RICTOR expression were generated and compared using log-rank tests. 
 
5.3.2 Immunoblotting and co-immunoprecipitation 
Cell lysates were prepared and analyzed by immunoblotting as described 
previously(20). A list of primary antibodies is provided in Supp. Table 5.1.  
For co-immunoprecipitation (co-IP), cells were cultured in 15cm dishes then 
washed with cold 1x PBS, pelleted and re-suspended in buffer (50mM Tris-Cl, pH 7.5, 
100mM NaCl, 5% glycerol). Cells were again pelleted and lysed in 150300l of buffer 
containing: 50mM Tris-Cl pH 7.5, 100nM NaCl, 5% glycerol, 1% NP-40, 5mM NaF, 1mM 
PMSF, 1mM DTT and 1% Protease/Phosphatase inhibitors; Sigma-Aldrich) for 15mins on 
ice. Cells were pelleted and the protein content of the supernatant was determined by 
Bradford Assay. 800g1mg protein in 150200l lysis buffer was used for co-IP analysis. 
mTOR primary antibody (Supp. Table 5.1) was added to samples at 1:100. Samples were 
incubated, rotating, overnight at 4C. Protein G DynabeadsTM (Invitrogen; 10003D) were 
then added and incubated 2hrs rotating at 4C. Adhered protein complexes were collected 
using a magnet and washed several times by moving the beads through lysis buffer. 5x 
sodium dodecyl sulfate (SDS) was added and incubated 10mins at 70C to disrupt binding 
between the beads and proteins. Proteins were then analyzed by immunoblotting, as 
described. Membranes were visualized following exposure to enhanced 
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chemiluminescence reagent (LuminataTM Crescendo or LuminataTM Forte, Western HRP 
Substrate; Millipore) on a BIORAD ChemiDocTMMP Imaging System. 
 
5.3.3 Quantitative Real-Time PCR (qRT-PCR) 
Total RNA was extracted using AllPrep DNA/RNA Mini Kits (Qiagen). Eluted 
RNA was reverse transcribed to complementary DNA (cDNA) using QuantiTect Reverse 
Transcription Kits (Qiagen). qRT-PCR was then performed in 20μl reactions, using 2X 
Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific), 200nM each of 
forward and reverse primers and 100ng cDNA. PCR conditions: 95°C for 10 min, followed 
by 45 cycles of 95°C for 10mins, 95°C for 15s, 59°C for 1min, 72°C for 40s, with a melt 
curve: 95°C for 10s, 65°C for 5s, 95°C for 50s. Relative transcript abundance was 
determined using the delta-delta CT method with expression of human -actin used for 
normalization. Primers (5’ to 3’): RICTOR (F -AGTACGAGGGCGGAATGACA, R -
TGATACTCCCTGCAATCTGGC), -actin (F - AGAGCTACGAGCTGCCTGAC, R -
AGCACTGTGTTGGCGTACAG). 
 
5.3.4 RICTOR overexpression studies 
Plasmid DNA for a construct containing myc-tagged RICTOR (Addgene; 11367) 
was prepared by mini-prep (QIAprep® Spin Miniprep Kit; Qiagen). For transfection, cells 
were plated into 6-well dishes (300 000 cells/well) in antibiotic-free media and allowed to 
attach overnight. The next day, 5g plasmid DNA was delivered in 5l P3000 reagent in 
Opti-MEM® with 3.75l LipofectamineTM 3000 reagent (Thermo Fisher Scientific) in 
Opti-MEM®, following a 15min incubation at room temperature. The next day, new 
antibiotic-free media was added and cells were allowed to recover for 12 days. Cells were 
then collected or re-plated for downstream assays. Overexpression of RICTOR was 
confirmed by immunoblotting.  
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5.3.5 CRISPR/Cas9-mediated deletion of RICTOR  
Further details are provided as Supplemental Methods (Section 5.8.1). 
As no mTORC2-specific inhibitors exist to date, CRISPR/Cas9 was used to delete 
a region of the RICTOR gene sequence, with the goal of diminishing the activity of 
mTORC2. Two single guide (sg)RNA oligo sequences targeting RICTOR exon 5 were 
designed and ligated into a pSpCas9(BB)-2A-GFP (Addgene; 48138)-CMV vector 
(PX458-CMV). Plasmid DNA was prepared using a QIAprep® Spin Miniprep Kit 
(Qiagen) and ligations were verified by Sanger Sequencing (London Regional Genomics 
Centre). FaDu and Cal27 HNSCC cells were seeded in 24-well dishes (50 000 cells/well) 
and 1g total plasmid DNA was delivered using Lipofectamine 3000 Reagent (Thermo 
Fisher Scientific) in Opti-MEM® (FaDu) or using FuGENE® HD Transfection Reagent 
(Promega Corporation) (Cal27). PCR with Phusion® High-Fidelity DNA Polymerase was 
used to genotype exon 5. PCR amplicons were run on 2% agarose gels and the detection 
of a ~100bp difference in product size was used to assess the presence of a deletion. 
Limiting dilutions were then used to deliver 1 cell/well in 96-well plates. Once single cell 
colonies covered >50% of the well, a pipette tip was used to wipe through the monolayer. 
Collected cells were deposited into PCR tubes and used to genotype RICTOR exon 5. 
Colonies with putative deletions were expanded for downstream assays and Sanger 
Sequencing. 
 
5.3.6 Clonogenic survival assays 
Cells were seeded at 500 cells/well into 24-well dishes. Cells were allowed to 
adhere for 48hrs at which time half of the wells for each cell line were treated with media 
containing 5M of the PI3K inhibitor BYL719 (Alpelisib), 1M cisplatin or 2.5M of the 
EGFR inhibitor erlotinib. For the next ~10 days, cells were monitored and drug-containing 
media replaced as needed until visible colonies formed. Plates were then rinsed with 1x 
PBS, fixed with cold 100% methanol (MeOH) and stained with 0.5% crystal in 25% 
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MeOH/1x PBS. Plates were washed with water and air-dried. Number of colonies was 
quantified using Fiji software. 
 
5.3.7  Cell viability assays 
Cells were seeded in 96-well plates in drug-free media at 2400 cells/well. 24hrs 
later, media was removed and replaced with drug-containing media over a 10-point dose 
range for each drug 040M). Cells were incubated for 72hrs at 37°C in 95% air and 5% 
CO2. Cell viability was then measured indirectly using the PrestoBlue® Cell Viability 
Reagent (Thermo Fisher Scientific), following a 1hr incubation at 37°C using a SynergyTM 
H4 Hybrid Reader (BioTek) with 560nm excitation and 590nm emission wavelengths. For 
each dose, viability values were normalized to no-drug controls and average viability for 
each dose was calculated. Values are plotted as mean + SEM using Prism® 7 Graphpad 
Software.  
 
5.3.8 Statistical analysis 
All analyses were performed with Prism® 7 GraphPad Software. Experimental 
groups were compared with controls using Student’s unpaired, two-tailed t-tests. Multiple 
groups were compared across a single condition using one-way ANOVA. Significance of 
clinicopathological features was assessed as described. P < 0.05 was used to define 
significant differences from the null hypothesis.  
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5.4 Results 
5.4.1 RICTOR/mTORC2 is overexpressed in a subset of HNSCC 
primary tumours 
We began by examining the prevalence of genomic aberrations and altered RNA 
expression of mTORC2 components in HNSCC patient tumours (Fig. 5.1b). While 
DEPTOR was found to be most frequently amplified, it is not unique to mTORC2(10,11). 
RICTOR, which is only found in mTORC2, was also amplified in a subset of cases (5.2%, 
n = 496 total cases examined) and overexpressed in others (62/496, 12.5%). RICTOR has 
been found to be overexpressed and/or amplified in various other cancers and to cooperate 
with other driver mutations to stimulate cellular proliferation(12-14). Because we were 
interested in the effect mTORC2 signalling has on the therapeutic efficacy of PI3K 
inhibition in HNSCC tumour cells, we made use of the cBioPortal interface to evaluate 
whether aberrations in these genes (RICTOR and PIK3CA) tend to co-occur or be exclusive 
from one another. We found PIK3CA and RICTOR aberrations to significantly co-occur in 
HNSCC tumours (Fig. 5.1c). In addition, we noted aberrations in RICTOR to also 
significantly co-occur with those in EGFR, which is also frequently altered in HNSCC 
tumours and functions at the cell surface to transduce signalling to oncogenic pathways, 
including the PI3K pathway (Fig. 5.1c) (3,21). The co-occurrence of RICTOR aberrations 
with prominent HNSCC driver alterations is important, as RICTOR overexpression is 
associated with increased mTORC2 activity(22). If patients with PIK3CA and EGFR-
altered HNSCC tumours are to be candidates for either PI3K or EGFR inhibitors, it may 
be a relevant therapeutic consideration that a subset of these tumours also have alterations 
in, or show overexpression of RICTOR and therefore have mTORC2 activity that may 
continue to drive Akt activation(22,23). Although RICTOR aberrations did not affect 
survival in the entire TCGA cohort, in both PIK3CA amplified and EGFR amplified 
HNSCC tumour subsets, there is a trend towards a shorter time to relapse in cases with 
RICTOR aberrations versus in those without (Fig. 5.1d).  
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Fig. 5.1. RICTOR/mTORC2 in HNSCC primary tumours. (A) Schematic
representation of PI3K/Akt/mTOR signalling cascade with emphasis on
negative feedback inhibition of RICTOR/mTORC2 by S6K. (B) Oncoprint
showing prevalence of single nucleotide variations (SNV), copy number
aberrations and transcript expression of mTOR complex 2 subunits in TCGA-
curated HNSCC tumours, generated using cBioPortal software. (C)
Evaluation of mutual exclusivity or co-occurrence of genomic aberrations in
RICTOR and PIK3CA, as well as in RICTOR and EGFR (generated based on
TCGA-curated HNSCC tumours using cBioPortal). (D) Kaplan-Meier
survival analyses of TCGA-curated HNSCC cases. Cases were stratified
according to presence or absence of RICTOR gene amplification, SNV and
mRNA overexpression (>2 standard deviations above average expression) in
HNSCC as whole, or in subsets of HNSCC cases with either PIK3CA or
EGFR amplifications. Cases with RICTOR alterations are represented in red.
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5.4.2 Relation between RICTOR expression, clinicopathological 
variables and survival 
We used IHC to assess the expression of mTORC2 subunit RICTOR in clinical 
HNSCC TMAs composed of 130 HNSCC patients from our institution. RICTOR was 
expressed variably across the tumour tissues surveyed, with the majority of samples having 
strong and complete expression of RICTOR (score of 3), consistent with other studies that 
have found positive RICTOR IHC staining in the majority of HNSCC cases examined (Fig. 
5.2a) (24). RICTOR was detected in both the cytoplasm as well as the nucleus in some 
cases(25). Eleven patients were scored as having weak, incomplete staining (8.5%; score 
= 1), 30 were scored as moderate, incomplete staining (23.1%; score = 2) and 89 were 
scored as strong, complete staining (68.5%; score =3). No samples were assigned a score 
of 0. Scores 0/1, and 2/3 were grouped together for analyses a priori. Based on Chi-squared 
and Fisher’s exact tests, we found RICTOR expression positively related to tumour site (p 
= 0.0018) (Supp. Table 5.2). Analysis for survival (disease-free and overall) revealed no 
differences between RICTOR expression groups (Supp. Fig. 5.1a and b). 
 
5.4.3 Activated Akt and RICTOR are elevated in HNSCC cell lines 
Nineteen HNSCC cell lines (including 5 HPV-positive lines, denoted ‘+’) were 
profiled for the expression of RICTOR and other PI3K pathway members (Fig. 5.2b). Cell 
lines were arranged according to their sensitivity to PI3K inhibition by BYL719 
determined previously (Ruicci KM, et al. 2018, under review; Chapter 2). RICTOR, p110 
(encoded by PIK3CA) and EGFR were readily detected in all lines surveyed. In general, 
the expression pattern for RICTOR, EGFR and p110 followed the same pattern between 
cell lines. Akt phosphorylated at Ser473 was detected in most cell lines at baseline, with 
fewer cells displaying Akt phosphorylated at Thr308. Interestingly, both Akt Thr308 and 
Ser473 appeared to be in higher abundance in cell lines less sensitive to BYL719.  
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5.4.4 Feedback relief following PI3K inhibition leads to Akt Ser473 
accumulation 
Inhibition of PI3K signalling is known to relieve negative feedback from S6K to 
RICTOR (Thr1135) (schematic shown in Fig. 5.1a). To evaluate how loss of negative 
feedback to RICTOR/mTORC2 affected Akt phosphorylation in HNSCC tumour cells, we 
examined Akt phosphorylation following PI3K inhibition by BYL719 (2M) for up to 
96hrs (Fig. 5.3a). While Akt Thr308 phosphorylation was variably suppressed, Akt Ser473 
phosphorylation was steadily restored over time, as expected, based on the relief of S6K-
RICTOR negative feedback(26). 
 
5.4.5 RICTOR overexpression promotes resistance to PI3K 
inhibition 
 RICTOR overexpression is associated with elevated activity of the mTORC2 
complex(22). To evaluate the effect of elevated mTORC2 activity on the response of 
HNSCC cells to PI3K inhibition, myc-tagged RICTOR was exogenously expressed in two 
HNSCC cell lines. In both cell lines, RICTOR protein appeared elevated. However, 
increased RICTOR was only associated with increased Akt (Ser473) phosphorylation in 
Cal27 cells (Fig. 5.3b). When cell viability was measured following treatment with 
BYL719, 93VU-147T cells overexpressing RICTOR showed increased viability over a 
range of drug doses, indicative of a reduced response to PI3K inhibition relative to the 
control cells (Fig. 5.3c). Cal27 cells overexpressing RICTOR also appeared to show 
increased viability relative to baseline, however this was not significant and only apparent 
at lower drug doses.   
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Fig. 5.3. Feedback relief following PI3K inhibition leads to Akt Ser473
accumulation. (A) Immunoblot showing time-dependent re-accumulation of
phosphorylated Akt (Ser473) following PI3K inhibition by BYL719 (5M).
(B) Immunoblot with indicated antibodies following transfection of HNSCC
cells with myc-tagged RICTOR. (C) Proliferation after 72hrs of HNSCC cell
lines at baseline compared to following transfection of myc-tagged RICTOR
upon increasing doses of BYL719 (040M). * represents p < 0.05, **
represents p < 0.01, ns = not significant.
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5.4.6 Generation of RICTOR knockout cells using CRISPR/Cas9 
Although both mTORC1-selective and dual mTORC1/2 inhibitors exist, there are 
currently no mTORC2-selective inhibitors(21). The efficacy of mTORC2-specific 
inhibition in the context of HNSCC therefore remains unknown. We addressed this by 
generating a genetic knockout of RICTOR using CRISPR/Cas9 technology. Specifically, 
we targeted exon 5 of RICTOR using two custom single-guide RNAs (Fig. 5.4a, additional 
detail in Supp. Fig. 5.2). Although the protein domain structure of RICTOR is not 
definitively known, exon 5 (codons 88130) is thought to be part of a HEAT domain, 
which is believed to mediate RICTOR-mTOR binding similar to RAPTOR-mTOR binding 
in mTORC1 (Supp. Fig. 5.3)(27). 
The predicted deletion products for our CRISPR/Cas9 model are shown in Fig. 
5.4b. RICTOR deletion was attempted in two HNSCC cell lines: Cal27 and FaDu. Both 
cell lines are among the least-sensitive to PI3K inhibition (Fig. 5.2a), and FaDu contains a 
PIK3CA amplification. As we noted PIK3CA-amplified TCGA tumours that also 
harboured RICTOR aberrations tended to relapse more quickly, testing the effect of 
mTORC2 loss in this setting was of interest. Following the transfection of the single-guide 
(sg)RNAs into FaDu and Cal27 cells, single cell clones were generated by limiting 
dilutions and expanded before verifying deletion of exon 5 by PCR. Three clonal cell lines 
are shown per parental line (Fig. 5.4c). We used Sanger Sequencing to validate the deletion 
of exon 5 in each cell line. Sequences were aligned to the wild-type RICTOR gene 
sequence, confirming the presence of the predicted deletion (Supp. Fig. 5.5). As a control, 
we also amplified and sequenced the top 2 off-target putative binding sites for both guide 
RNAs used; no mutations were detected.  
We proceeded to evaluate RICTOR expression by immunoblotting in each putative 
knockout line. Immunoblotting revealed that in all knockout lines RICTOR protein was 
still detectable at the correct size (200kDa; Fig. 5.4d) with no apparent truncated protein 
versions visible at smaller sizes (Supp. Fig. 5.4). This was true for knockout cell lines with 
identical exon 5 deletions in both alleles (FaDu E5-3Y and E5-3dd, Cal27 E5-J14 and E5-
H9) and for RICTOR knockout cell lines with the predicted deletion in 1 allele and a  
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Fig. 5.4. Deletion of RICTOR exon 5 disrupts the interaction between
RICTOR and mTOR. (A) Schematic illustrating design of single-guide
RNAs and primers for CRISPR/Cas9-mediated deletion of exon 5 of
RICTOR. (B) Predicted genotypes and base pair sizes for genomic PCR
amplicons of RICTOR following CRISPR/Cas9 targeting of RICTOR. (C)
Agarose gel images showing RICTOR amplicons in cell populations (FaDu,
Cal27 cells) transfected with guides targeting RICTOR or an empty vector
(PX458-CMV). (D) Immunoblot of RICTOR expression in parental and
mutant cell lines (E5-XX lines). (E) Immunoblot showing co-
immunoprecipitation of RICTOR and mTOR in FaDu and Cal27 cells, but no
detectable interaction in any of the putative RICTOR knockout cell lines.
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smaller deletion in the other allele (FaDu E5-2F and Cal27 E5-B3). In some cell lines (e.g. 
E5-B3, E5-H9 and E5-3dd), RICTOR protein appeared to be in lower abundance than in 
parental lines, however in all cell lines a 200 kDa band was visible. Of note, the RICTOR 
antibody used targets a region coded within exon 31 (Leu1121) of RICTOR. It is 
conceivable that, even with deletion of the 42-codon exon 5 (residues 88130), an altered 
protein may still form. Relative to the total size of RICTOR, which contains 1732 codons, 
loss of 42 codons would result in a size difference of just 4.62 kDa.  
 
5.4.7 RICTOR exon 5 deletion disrupts RICTOR/mTOR binding 
We next sought to evaluate whether the biological activity of RICTOR in the 
knockout cell lines was still intact. We used co-immunoprecipitation (co-IP) to evaluate 
binding between mTOR and RICTOR. While mTOR/RICTOR binding was readily 
detected in parental FaDu and Cal27 cells, no apparent interaction between mTOR and 
RICTOR was detected in any of the knockout lines tested (Fig. 5.4e). This observation 
suggests that exon 5 of RICTOR must interact with mTOR to produce the mTORC2 
complex. 
 
5.4.8 RICTOR/mTORC2 loss reduces colony forming ability and 
cell line growth 
Having confirmed the absence of mTORC2 formation in RICTOR knockout cells, 
we proceeded to characterize the clonal knockout cell lines generated from both FaDu and 
Cal27 parental cells. Morphologically, FaDu RICTOR knockout cells and parental cells 
appeared similar (Fig. 5.5a), whereas Cal27 RICTOR knockout cells tended to grow in 
smaller, dense colonies, rather than in ‘sheets’ as seen for the parental cells (Fig. 5.5b). In 
terms of colony forming ability, both FaDu and Cal27 RICTOR knockout lines were 
drastically impaired when challenged to grow as single colonies, with significantly fewer  
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Fig. 5.5. Deletion of RICTOR exon 5 alters cell growth and colony
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colonies present in RICTOR knockout Cal27 and FaDu cells relative to parental cells (Fig. 
5.5c-d). 
 
5.4.9 Activating phosphorylation of Akt is lost in RICTOR knockout 
cell lines 
 We next examined the status of mTORC2 readouts by immunoblotting. No 
phosphorylated Akt was detected in any knockout line—neither Akt Ser473, nor Akt 
Thr308 (Fig. 5.6a and b), although there was no loss of endogenous Akt. The temporal 
sequence of Akt phosphorylation is somewhat debated in the literature, but the predominant 
view is that Akt Ser473 phosphorylation typically precedes Thr308 phosphorylation and 
that its presence boosts the subsequent phosphorylation of Thr308(10). Based on our 
results, it appears that the lack of Akt Ser473 phosphorylation (due to impaired mTORC2 
activity) impairs Akt Thr308 phosphorylation to the extent that it is absent or nearly 
undetectable(10,28). Using the HNSCC cohort (n = 346) from The Cancer Proteome Atlas 
(TCPA) it is apparent that phosphorylation of Akt Ser473 and Akt Thr308 are tightly 
correlated (p = 7.7526 x 10-19) in HNSCC tumours (Supp. Fig. 5.6a). To verify that the 
Akt Thr308 kinase PDK1 was still present in RICTOR knockout cells, we evaluated PDK1 
expression by immunoblotting and detected it in all lines (Supp. Fig. 5.6b). Apart from 
Akt, we also examined phosphorylation of NDRG1. NDRG1 is an established readout for 
activity of serum/glucocorticoid regulated kinase 1 (SGK1), which is a direct 
phosphorylation target of mTORC2(29). SGK1 has been reported to be difficult to detect 
reliably by western blot, therefore its substrate NDRG1 is typically surveyed(29). 
Phosphorylation of NDRG1 was lost in most RICTOR knockout clones, with the exception 
of E5-3dd. Phosphorylation of the ribosomal protein S6 was also variably reduced across 
the knockout cell lines, as was phosphorylation of mTORC1 (Ser2448; active form) (Fig. 
5.6a and b). 
While Akt Ser473 and Thr308 phosphorylation was absent at baseline in all 
RICTOR knockout lines, we proceeded to determine whether, under a condition of cellular  
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stress, activated Akt could be detected. We conducted a serum starvation assay in which 
each cell line was starved for 48hrs and then serum-stimulated for 2hrs. In parental FaDu 
and Cal27 cells, starvation reduced Akt phosphorylation at both sites, which was then 
rescued by serum stimulation (Fig. 5.6c). In contrast, in all knockout lines analyzed, serum 
starvation followed by stimulation was unable to induce any level of Akt phosphorylation 
at either phosphorylation site, suggesting total impairment of mTORC2 in phosphorylating 
Akt Ser473 and confirming the necessity of Ser473 phosphorylation for subsequent 
phosphorylation of Akt at Thr308. 
 
5.4.10 RICTOR/mTORC2 loss sensitizes HNSCC cells to PI3K 
inhibition 
 Due to the recovery of mTORC2 activity that occurs following PI3K/Akt/mTORC1 
axis inhibition, we proceeded to examine whether co-targeting mTORC2 alongside PI3K 
inhibition may enhance its anti-cancer efficacy. As mentioned, no specific inhibitors of 
mTORC2 exist to date. We therefore made use of our RICTOR knockout cell lines and 
interrogated their relative responsiveness to PI3K inhibition. In the presence of the PI3K 
inhibitor BYL719, we found RICTOR knockout lines to be impaired in their ability to form 
colonies. Because RICTOR knockout cells showed poor colony forming ability even 
without drug treatment (Fig. 5.5c), we normalized the number of colonies following 
BYL719 treatment to the number of colonies present in corresponding untreated wells for 
each clonal line (Fig. 5.7a and b). In FaDu cells, the cell line E5-3Y (which has complete 
RICTOR exon 5 loss in both alleles) showed a significantly enhanced response to BYL719 
(p < 0.01). In terms of sensitivity to BYL719, we evaluated cellular viability of parental 
and RICTOR knockout cells in response to BYL719 across a 10-point dose range. For both 
FaDu and Cal27, all RICTOR knockout cell lines showed increased sensitivity to BYL719 
(Fig. 5.7c and d). 
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Fig. 5.7. RICTOR/mTORC2 loss improves response of HNSCC cells to
PI3K inhibition. (A) & (B) Colony formation assays of parental and
RICTOR knockout cell lines with/without 5M BYL719 for 10 days. Number
of colonies was quantified using Fiji software. Error bars represent SD. n = 3.
(C) & (D) Proliferation after 72hrs of parental versus RICTOR/mTORC2
knockout HNSCC cells upon increasing doses of BYL719 (040M). Error
bars represent standard error of mean (SEM). * represents p < 0.05, **
represents p < 0.01, ns = not significant.
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5.4.11 RICTOR/mTORC2 loss improves response of HNSCC cells 
to erlotinib and cisplatin 
 To extend the applicability of mTORC2 as a target in HNSCC, we lastly examined 
the efficacy of the EGFR inhibitor erlotinib and the alkylating chemotherapy agent 
cisplatin in cells lacking mTORC2 activity. EGFR is an established therapeutic target in 
HNSCC as it is known to be frequently amplified(3). Cisplatin is one of the most 
frequently-used chemotherapies for HNSCC patients and mTORC2 has previously 
emerged as a mediator of resistance to cisplatin therapy in ovarian cancer(30). In both FaDu 
and Cal27 cells, RICTOR knockout resulted in significantly fewer colonies able to grow 
in the presence of cisplatin (Fig. 5.8a). In Cal27, both RICTOR knockout cell lines tested 
showed significantly reduced cellular viability when treated with cisplatin, relative to the 
parental line (Fig. 5.8b). In FaDu cells, E5-3Y cells showed a significant reduction in 
viability following cisplatin treatment. 
 In response to erlotinib, FaDu cells lacking mTORC2 activity showed reduced 
cellular viability as well as significantly impaired colony forming assay relative to the 
parental cell line (Fig. 5.8c and d). Cal27 cells lacking mTORC2 activity showed 
significant reductions in colony forming ability with erlotinib treatment, however cell 
viability was not measurably reduced (Fig. 5.8c and d). 
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Fig. 5.8. RICTOR/mTORC2 loss sensitizes HNSCC cells to erlotinib and
cisplatin treatment. (A) Colony formation assays of parental and RICTOR
knockout cell lines with/without 1M cisplatin for 10 days. Number of
colonies was quantified using Fiji software. Error bars represent SD. n = 3.
(B) Proliferation after 72hrs of parental versus RICTOR/mTORC2 knockout
HNSCC cells upon increasing doses of cisplatin (040M). Error bars
represent SEM. (C) Colony formation assays of parental and RICTOR
knockout cell lines with/without 2.5M erlotinib for 10 days. Number of
colonies was quantified using Fiji software. Error bars represent SD. n = 3.
(D) Proliferation after 72hrs of parental versus RICTOR/mTORC2 knockout
HNSCC cells upon increasing doses of erlotinib (040M). Error bars
represent SEM. * represents p < 0.05, ** represents p < 0.01, *** represents p
< 0.001, **** represents p < 0.0001, ns = not significant.
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5.5 Discussion 
 mTOR integrates oncogenic PI3K/Akt signalling and downstream pathways 
regulating cell growth, metabolism, survival and protein synthesis(6). mTOR itself exists 
in two structurally and functionally distinct multi-protein complexes—mTORC1 and 
mTORC2(10). Whereas mTORC1 is activated downstream of PI3K/Akt, the lesser-known 
mTORC2 functions upstream of Akt(10). Inhibition of PI3K/Akt/mTORC1 is known to 
cause a recovery of mTORC2 activity, due to loss of feedback inhibition(10,11). As such, 
it is thought that re-activation of mTORC2 may play a role in dampening the therapeutic 
effect of PI3K inhibition and may therefore serve as an important oncogenic inhibitory 
target. 
 The studies presented here examine RICTOR/mTORC2 signalling in HNSCC 
specifically, where PI3K inhibition is one of the leading targeted therapies currently under 
investigation(21,31). To date, efficacy of PI3K inhibitors, both preclinically and in clinical 
trials, has been variable; recovery of mTORC2-mediated Akt activation following PI3K 
inhibition may be a central adaptive resistance mechanism limiting their 
efficacy(10,11,32). In both HNSCC primary tumours and a panel of HNSCC cell lines, we 
detected abundant RICTOR expression, the defining subunit of mTORC2. Elevated 
expression of RICTOR is known to promote increased mTORC2 activity and RICTOR is 
essential for the catalytic activity of mTOR(22). Previous studies have similarly found oral 
squamous cell carcinomas to exhibit positive RICTOR IHC staining in the majority of 
cases surveyed (68%)(24). We observed genomic aberrations in RICTOR and PIK3CA to 
significantly co-occur in HNSCC tumours; as patients with PIK3CA aberrations are 
thought to be optimal candidates for PI3K inhibition therapy, the prevalence of RICTOR 
amplifications or RNA overexpression in this cohort may have therapeutic 
implications(32). The possibility that RICTOR amplification may affect 
PI3K/Akt/mTORC1 inhibition is already under evaluation in three phase II clinical trials 
with the dual mTORC1/2 inhibitor AZD2014 (NCT03106155, NCT03166904, 
NCT03061708)(32). In these trials, RICTOR is being assessed for amplification and/or for 
protein overexpression by IHC(32).  
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Further support for RICTOR/mTORC2 activity modulating response to PI3K 
inhibition is provided by our observation that across HNSCC cell lines, phosphorylated 
Akt (Thr308 and Ser473) was highest in cell lines that were less-susceptible to PI3K 
inhibition. Akt Ser473 phosphorylation is mediated by mTORC2 directly and Akt Thr308 
phosphorylation, although not mediated by mTORC2, is thought to be “primed” by 
phosphorylation of Ser473(10). These observations collectively suggest that the activity of 
mTORC2 may influence the sensitivity of HNSCC tumour cells to PI3K inhibition. 
 As there are no mTORC2-specific inhibitors available presently, and relatively 
little overall is known about mTORC2 compared to mTORC1 and other PI3K pathway 
effectors, we used CRISPR/Cas9 to delete a region of RICTOR and disrupt the function of 
mTORC2. Our goal was to then interrogate the impact of mTORC2 impairment both at 
baseline, as well as when combined with PI3K inhibition and other chemotherapies. 
Following deletion of RICTOR exon 5, the interaction between RICTOR and mTOR was 
abolished, despite the detection of substantial levels of RICTOR. This observation 
identifies the region encoded by exon 5 as essential for permitting the interaction of 
RICTOR with mTOR, and therefore essential to the formation of mTORC2(27). 
Consistent with impaired mTORC2 formation, RICTOR deletion eliminated all 
activating Akt Ser473 phosphorylation. Importantly, phosphorylation of Akt Thr308 was 
also absent in all RICTOR knockout lines. Our results therefore highlight the importance 
of Ser473 phosphorylation for subsequent Thr308 phosphorylation(10). Further, these 
observations lead us to speculate as to whether blockade of mTORC2 alone may be 
sufficient to substantially impair Akt activity and therefore serve as a key therapeutic 
target. The selection of mTORC2 as an anti-cancer target is additionally supported by the 
impaired cell growth and colony forming ability of RICTOR knockout cells. 
Relative to parental cells, RICTOR/mTORC2 knockout cells showed, in most 
cases, significant improvements in responsiveness to PI3K inhibition, EGFR inhibition and 
cisplatin treatment. Several recent preclinical studies have demonstrated mTORC2 
inhibition to be critical for the efficacy of various targeted agents, including the HER2 
inhibitor lapatinib and CDK4/6 inhibitors(9,12). Our findings contribute to a growing body 
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of evidence highlighting mTORC2 as a central signalling node and a promising target or 
co-target in cancer. 
To date, most studies addressing PI3K/Akt/mTOR signalling have focused on 
either PI3K inhibition, or on downstream mTORC1 inhibition(6). While inhibitors of PI3K 
and mTORC1 have demonstrated therapeutic efficacy in certain contexts, a gradual re-
accumulation of Akt Ser473 phosphorylation is typically observed, leading to a 
restoration/reactivation of PI3K signalling(32). Increasingly, mTOR kinase inhibitors 
targeting both mTORC1 and mTORC2 are being investigated, although to date no specific 
mTORC2 inhibitors have been established(33,34). If toxicity associated with dual 
mTORC1/2 inhibition is limiting, then specific inhibition of mTORC2 may be a promising 
therapeutic avenue, particularly given its ability to diminish activating Akt Ser473 and 
Thr308 phosphorylation alike(10). 
In summary, our analyses of HNSCC patient tumours and cell lines, combined with 
a novel CRISPR/Cas9-mediated genetic knockout of RICTOR reveal a key oncogenic role 
for RICTOR/mTORC2 in HNSCC. We find RICTOR/mTORC2 blockade to impair 
cellular viability and growth and to enhance the efficacy of PI3K and EGFR inhibitors, as 
well as cisplatin. These observations support the ongoing push for the development of a 
specific mTORC2-targeting agent for use in cancer treatment and for further investigations 
centred on understanding the regulation and cellular activities of mTORC2. 
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5.8 Supplementary Materials 
5.8.1 Supplementary methods 
5.8.1.1 CRISPR/Cas9-mediated deletion of RICTOR  
Owing to a paucity of mTORC2-specific inhibitors, CRISPR/Cas9 was used to 
mutate RICTOR, with the goal of diminishing the activity of mTORC2. A 132 base pair 
(bp) region encompassing exon 5 of the RICTOR  gene was selected for targeted deletion 
(Supp. Fig. 5.2a). Two single guide (sg)RNA oligo sequences were designed: one 
‘upstream’ and one ‘downstream’, such that the region between them was considered the 
‘targeted’ region for deletion. Complimentary oligos were ordered for each guide sequence 
and annealed guides were ligated into a pSpCas9(BB)-2A-GFP (Addgene; 48138)-CMV 
vector (PX458-CMV). Ligated plasmids were transformed and single colonies were grown 
overnight. The following day, plasmid DNA was prepared using a QIAprep® Spin 
Miniprep Kit (Qiagen). Successful ligation of guide RNAs into PX458-CMV was verified 
by Sanger Sequencing (London Regional Genomics Centre).  
For transfection, FaDu and Cal27 HNSCC cells were plated at 50 000 cells/well in 
24-well dishes. The next day, 1g of plasmid DNA (500ng of the upstream guide, 500ng 
of the downstream guide) was delivered using Lipofectamine 3000 Reagent (Thermo 
Fisher Scientific) in Opti-MEM® (for FaDu) or using FuGENE® HD Transfection 
Reagent (Promega Corporation) (for Cal27). Twenty-four hours later, media was replaced 
and cells were allowed to recover for 24hrs. 
Transfected cells were then collected and genomic DNA was extracted using 
AllPrep DNA/RNA Mini Kits (Qiagen). PCR using Phusion® High-Fidelity DNA 
Polymerase was then completed to genotype exon 5 with specific primers designed to flank 
the ‘targeted’ region. 20l reactions were prepared, containing 5x Phusion GC Buffer, 
0.4l of 10mM dNTPs, 0.5l of 20M forward and reverse primers and 0.2l Phusion. 
PCR conditions: 98°C for 30s, followed by 40 cycles of 98°C for 10s, 58°C for 10s, 72°C 
for 20s, then 72°C for 5mins. PCR amplicons were run on 2% agarose gels and the 
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detection of a ~100bp difference in product size was used to assess the presence of a 
deletion in at least a subset of cells. Limiting dilutions were then used to achieve a 
concentration of 10cells/1ml, such that in a 96-well plate, with 100l/well, ~1 cell would 
be added to each well. Following dilution, plates were incubated at 37C and media 
changed as needed. Colonies were first visible after ~1 week. Once single cell colonies 
covered >50% of the well surface area, a pipette tip was used to wipe the bottom of the 
well and then wiped all around the base of a PCR tube. These tubes were subsequently 
used for PCR to genotype RICTOR exon 5 (as described) and products were run on agarose 
gels. Colonies with putative homozygous or heterozygous deletions were expanded for 
downstream assays and Sanger Sequencing (London Regional Genomics Centre) to 
determine the exact deletion regions. Primers (5’ to 3’): RICTOR (F -
TTGAAACCTGTGCAGCAAAA, R -CGTCCAACACACAATGCTCA). 
 
 
  
Supplementary Table 5.1. Antibodies used in this study.
200
Negative (0) / Moderate, incomplete (2) / p  value
Weak, incomplete (1) strong, near complete (3)
Age <60 69 (53.1) 4 65 0.3461
>=60 61 (47.9) 7 54
Gender Male 99 (76.2) 8 91 0.723
Female 31 (23.8) 3 28
Site Tonsil 92 (70.8) 3 89 0.0018 *
Base of Tongue 24 (18.5) 4 20
Other 14 (10.8) 4 10
T Classification 1 31 (23.8) 2 29 0.8377
2 48 (36.9) 4 44
3 28 (21.5) 2 26
4 23 (17.7) 3 20
N Classification 0 20 (15.4) 1 19 0.7342
1 22 (16.9) 2 20
2 78 (60.0) 7 71
3 10 (7.7) 0 10
Overal Stage 1 6 (4.6) 0 6 0.8631
2 9 (7.0) 1 8
3 19 (14.6) 2 17
4 96 (73.8) 8 88
Smoking never smokers 28 (21.5) 4 24 0.686
1-9 py 8 (6.2) 1 7
10-19 py 13 (10.0) 1 12
>20 py 75 (57.7) 5 70
Unknown 6 (4.6) 0 6
Alcohol < 21 drinks 88 (67.7) 7 81 0.7378
(drinks/wk) >21 drinks 38 (29.2) 4 34
Unknown 4 (3.0) 0 4
Recurred No 104 (80.0) 9 95 0.99
Yes 26 (20.0) 2 24
HPV Negative 43 (47.8) 1 42 0.618
Positive 46 (51.1) 3 44
* Significant features; p < 0.05
RICTORClinicopathological variables n (%)
Supplementary Table 5.2. Clinical and pathological characteristics of 130
patients with HNSCC and association with RICTOR expression
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Supplementary Fig. 5.1. (A) Overall survival of HNSCC cases (n= 130)
from the London Health Sciences Centre (LHSC), stratified by RICTOR IHC
score (scores 0 & 1, versus 2 & 3). Cases scored as having RICTOR
expression of 2 or 3 (n = 119) are represented in red. (B) Disease-free survival
of HNSCC cases (n= 130), stratified by RICTOR IHC score (scores 0 & 1,
versus 2 & 3). Cases scored as having RICTOR expression of 2 or 3 (n = 119)
are represented in red.
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Supplementary Fig. 5.2. Schematic illustrating design of single-guide RNAs
and primers for CRISPR/Cas9-mediated deletion of exon 5 of RICTOR.
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Supplementary Fig. 5.3. (A) Schematic representation of the protein-coding
domains of the human RICTOR gene. (B) Schematic representation of the
protein-coding domains of the human MTOR gene, with putative interacting
HEAT domains of RICTOR and mTOR shown. Adapted from Zhou P, et al.,
J Comp Bio, 2015.
HEAT HEAT RBD PH HEATP H W  D  40
WD
40
A.
B.
RICTOR
MTOR
HEAT FRBFAT KINASE FATC
exon 5
204
P
a
re
n
ta
l
E
m
p
ty
 V
e
c
to
r
E
5
-3
Y
E
5
-3
d
d
E
5
-2
F
FaDuCal27
P
a
re
n
ta
l
E
m
p
ty
 V
e
c
to
r
E
5
-H
9
E
5
-J
1
4
E
5
-B
3
RICTOR
Supplementary Fig. 5.4. Immunoblot of RICTOR expression in parental and
putative RICTOR knockout cell lines (E5-XX lines). Full-length gel shown in
order to evaluate the presence of any truncated proteins forming following
RICTOR exon 5 deletion.
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FaDu
Cal27
Cal27          1 NNNNN------------------GNTTGCGGTTAGCTTTATTAAATGAAGCAAAAGAAGT  
E5-J14         1 TTGTATTTTGTTTGTTTTCANACAG-----------------------------------  
E5-H9          1 TAG---------------------------------------------------------  
E5-B3T         1 TTGTATTTTGTTTGTTTTCATACAGTTGCGGTTAGCTTTATTAAATGAAGCAAAAGAAGT 
E5-B3B         1 NNNNN------------------N------------------------------------ 
 
 
Cal27         43 GCGAGCAGCAGGGCTACGAGCGCTTCGATATCTCATCCAAGACTCCAGTATTCTCCAGAA  
E5-J14        26 ------------------------------------------------------------  
E5-H9          4 ------------------------------------------------------------  
E5-B3T        61 GCGAGCAGCAGGGCTACGAGCGCTTCGATATCTCATCCAAGACTCCAGTATTCTCCAGAA  
E5-B3B         7 ------------------------------------- ----------------------- 
 
 
Cal27        103 GGTGCTAAAATTGAAAGTGGACTATTTAATA GCTAGGTAAATTTCCTAGACTTGTTTATA  
E5-J14        26 -----------N-------------------GNTAGGTAAATTTCCTAGACTTGTTTATA  
E5-H9          4 -------------------------------- CTAGGTAAATTTCCTAGACTTGTTTATA  
E5-B3T       121 GGTGCTAAAATT-------------------GCTAGGTAAATTTCCTAGACTTGTTTATA  
E5-B3B         7 ----------------------------------------------- NNNNTTGTTNANA 
 
 
Cal27        163 TATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTTGTA  
E5-J14        56 TATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTTGTA  
E5-H9         32 TATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTTGT N 
E5-B3T       162 TATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTTGTA  
E5-B3B        20 TATTTTTGA-ATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTTGTA  
 
 
 
 
 
 
 
 
FaDu          1 ACTTGTATTTTGTTTGTTTTCATACAG TTTGCGGTTAGCTTTATTAAATGAAGCAAAAGA  
E5-3Y         1 ACTTGTATTTTGTTTGTTTTCATACAG ---------------------------------  
E5-3dd        1 ACTTGTATTTTGTTTGTTTTCATACAG ---------------------------------  
E5-2FT        1 ANNTNTNTTTTNTNNNTTNTNNNNCNNTTTGCGGTTAGCTTTATTAAATGAAGCAAAAGA  
E5-2FB        1 GCT---------------------------------- ----------------------- 
 
 
FaDu         61 AGTGCGAGCAGCAGGGCTACGAGCGCTTCGATATCTCATCCAAGACTCCAGTATTCTCCA  
E5-3Y        28 ------------------------------ ------------------------------  
E5-3dd       28 ------------------------------------------------------------  
E5-2FT       61 AGTGCGAGCAGCAGGGCTACGAGCGCTTCGATATCTCATCCAAGACTCCAGTATTCTCCA  
E5-2FB        4 ------------------------------------------------- ----------- 
 
 
FaDu        121 GAAGGTGCTAAAATTGAAAGTGGACTATTTAA TAGCTAGGTAAATTTCCTAGACTTGTTT  
E5-3Y        28 -------------------------------- TAGCTAGGTAAATTTCCTAGACTTGTTT  
E5-3dd       28 -------------------------------- TAGCTAGGTAAATTTCCTAGACTTGTTT  
E5-2FT      121 GAAGGTGCTAAAATTGAAAGTGGNCTATT --TTAGCTAGGTAAATTTCCTAGACTTGTTT  
E5-2FB        4 ------------------------------------- AGGTAAATTTCCTAGACTTGTTT 
 
 
FaDu        181 ATATATTTTTGAAATTTTGTGTTGAGTTTTTAGCA NNCNNNCCATAAAGTGTATAGATTT 
E5-3Y        56 ATATATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTT  
E5-3dd       56 ATATATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCTGCCATAAAGTGTATAGATTT  
E5-2FT      179 ATATATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGCCT NCCATAAAGTGTATAGATTT 
E5-2FB       27 ATATATTTTTGAAATTTTGTGTTGAGTTTTTAGCATGC NTGCCATAAAGTGTATAGATTT 
 
 
 
 
 
 
Supplementary Fig. 5.5. Sequencing alignments for (A) FaDu and (B) Cal27
cell lines. RICTOR knockout cell lines underwent Sanger Sequencing and
were aligned to their parental counterparts, revealing deletions of variable
sizes in the RICTOR gene sequence spanning exon 5. The wild-type gene
sequence is at the top of each panel, indicated in bold text.
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Supplementary Fig. 5.6. Correlation between abundance of Akt (Thr308)
and Akt (Ser473) in HNSCC primary tumour samples (A). Data curated by
and accessed through The Cancer Proteome Atlas (TCPA). (B) Immunoblot
of PDK1 expression in parental and RICTOR knockout cell lines (E5-XX
lines).
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Chapter 6  
 
6 Discussion 
6.1 Overview 
 The genomic characterization of HNSCC has revealed a heterogenous disease 
landscape(1-3). Across both HPV-positive and -negative tumours however, the 
PI3K/Akt/mTOR signalling network has emerged as the most frequently-altered actionable 
target(1-3). As HNSCC disease and current treatment modalities impart significant lasting 
toxicity to patients (including impairments to speech, swallowing, breathing and facial 
appearance), new therapies are urgently needed. Owing to the prevalence of PI3K pathway 
aberrations in HNSCC tumours, the preclinical and clinical development of targeted 
inhibitors is an active area of research(4-6). Early data has demonstrated the efficacy of 
targeted PI3K inhibition for HNSCC treatment, however responses to date have been 
collectively underwhelming(7,8). My research, presented in this thesis focuses on 
characterizing PI3K inhibition in HSNCC from the perspectives of biomarker 
identification (Chapters 2 & 3), elucidating second-line targets (Chapters 3, 4 & 5) and 
understanding the acquisition of drug resistance over time (Chapter 4). The goal of this 
research is to contribute to the optimization of PI3K targeted drugs for HNSCC patients.  
 
6.2 Summary of Findings 
We began our investigation (Chapter 2) by interrogating a large panel of 
genomically characterized HNSCC cell lines and PDX models for their responses to PI3K 
inhibitors. Importantly, we surveyed the efficacy of PI3K inhibition in PDX models on the 
basis of clinical trial response criteria, with the goal of making the findings more stringent 
and clinically-relevant. In doing so, we identified several potential biomarkers of response. 
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While PIK3CA hotspot mutations predicted sensitivity in vitro, alterations in other genes, 
including CSMD1 deletions, were associated with better responses to PI3K inhibition in 
vivo. One of the other main findings in this chapter was that while PI3K inhibition was 
unable to induce clinically-meaningful responses as a single agent, it was broadly active 
across PDX models with different genomic features. These findings highlight the optimal 
clinical implementation of PI3K targeted agents—in the neoadjuvant setting. As PI3K 
targeted drugs are already in clinical use, our findings may be directly applicable. 
In the second data chapter (Chapter 3), I studied hotspot HRAS mutations as a 
biomarker of non-response to PI3K inhibition. In Chapter 2, we observed HRAS mutant 
PDX models to be among the least-responsive to PI3K inhibition. HRAS mutations that 
cause constitutive HRAS activity are present in a subset of HNSCCs and in vitro, we found 
HRAS G12V mutant cells to be resistant to PI3K inhibition. We proceeded to explore a 
mechanism for the innate resistance of HRAS mutant cells. We identified persistent 
mTORC1 activation in HRAS mutant cells, compared to wildtype cells. We then examined 
ERK-TSC2 signalling downstream of RAS as a mechanism for mTORC1 activity. We 
concluded that mTOR inhibition may be a key therapeutic susceptibility of HRAS mutant 
tumour cells. 
 To explore acquired resistance to PI3K inhibition in the context of HNSCC, 
Chapter 4 focused on generating HNSCC models resistant to PI3K inhibition and 
subsequently characterizing resistance mechanism(s). We were able to generate multiple 
PI3K inhibitor-resistant HNSCC cell lines and PDX models from genomically distinct 
‘parental’ sources. Using reverse phase protein arrays, I explored the proteomic landscape 
of parental and resistant models. TAM (TYRO3, AXL, MER-TK)-family RTKs were 
found to be elevated in total protein expression and cell surface localization in BYL719-
resistant models. Modulating the expression of TYRO3 and AXL resulted in altered 
sensitivity to PI3K inhibition in BYL719-resistant cells, suggesting the involvement of 
these receptors in mediating drug response. Intracellularly, we found that BYL719-
resistant cells showed elevated activation of the MAPK pathway, downstream of TAM 
RTKs. We concluded that pan-TAM inhibition may be a promising avenue for 
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combinatorial or second-line therapy when PI3K inhibitors are used for treatment of 
HNSCC. 
Finally, Chapter 5 focused on RICTOR/mTORC2—both as a novel oncogenic 
target in HNSCC, and as a potential co-target to improve the efficacy of PI3K inhibition 
and that of other agents (e.g. EGFR inhibition, cisplatin). The RICTOR subunit of 
mTORC2 is amplified and overexpressed in a subset of HNSCC tumours. Across HNSCC 
cell lines, I found RICTOR to be abundantly expressed. Further, cell lines that were less 
sensitive to PI3K inhibition generally exhibited higher levels of Akt S473 phosphorylation. 
Owing to the inherent feedback loop that exists between S6K and RICTOR, we 
hypothesized that a resurgence of Akt activation mediated by mTORC2 may limit the 
efficacy of PI3K inhibition. I used CRISPR/Cas9 technology to examine the effect of 
RICTOR/mTORC2 loss, as no specific inhibitors exist to date. Deletion of RICTOR 
impaired cell growth and colony-forming ability of cells and sensitized cells to PI3K 
inhibition, EGFR inhibition and cisplatin treatment, to varying extents. Collectively these 
data emphasize RICTOR/mTORC2 to be a relevant oncogenic complex for therapeutic 
inhibition in HNSCC. 
 
6.3 Inhibition of the PI3K Pathway 
 Several classes of PI3K inhibitors have been developed and are under investigation 
in ongoing clinical trials(4,9). As multiple PI3K isoforms are typically expressed in cancer 
cells and have redundant functions, pan-class I PI3K inhibitors that target all four class I 
PI3K isoforms were initially thought to be optimal(10,11). However, data has shown pan-
PI3K inhibitors to be too non-specific, frequently having off-target effects on related family 
members (e.g. mTOR, ATR) (10). Further, pan-PI3K inhibitors tend to be poorly-tolerated 
for extended time periods and the toxicities experienced are generally dose-limiting(10).  
 The alternative option for inhibiting PI3K is the use of compounds that inhibit only 
a single PI3K isoform(4). These agents have the potential to more completely block the 
most context-relevant isoform, while limiting the burden of toxicity seen with other, 
 
211 
 
broader-acting agents(10). Inhibitors of p110 are the most advanced, owing to the 
prevalence of PIK3CA mutations in human cancers, including HNSCC(1-3,10,12). One of 
the primary clinical questions surrounding the use of PI3K inhibitors for cancer treatment 
revolves around which is the best approach for selecting patients. Should these agents be 
restricted only to those who have an established PIK3CA mutation, or even more 
specifically, a known hotspot (activating) mutation (such as at the codons E542, E545 or 
H1047 in PIK3CA) (1)? Or, can patients who are PIK3CA wildtype but whose tumours 
likely depend on PI3K-related signalling be included(9,10)? These are difficult but 
essential questions to optimize the use of PI3K inhibitors for HNSCC treatment and several 
are the subject of the investigations presented in this thesis.  
 In Chapter 2 we found that, in a panel of 28 established HNSCC cell lines, the pan-
PI3K inhibitor GDC-0941 and the dual pan-PI3K/mTOR inhibitor BEZ235 were both 
potent and universally effective across all of the genomically-distinct cell lines tested. In 
contrast, we observed the p110 selective inhibitor BYL719 to show more variability, with 
PIK3CA mutant cell lines being particularly susceptible. Interestingly however, when we 
challenged these observations in vivo in the form of a PDX clinical trial, the same trend 
was not apparent with regard to PIK3CA(13,14). That is, PIK3CA mutant PDX models 
were not the most sensitive to BYL719. Instead, our study emphasized the near-universal 
efficacy of BYL719 in slowing or stabilizing tumour growth relative to a vehicle treatment, 
regardless of PIK3CA mutational status. Our findings therefore support the general 
inclusion of HNSCC patients for treatment with a p110-specific inhibitor such as 
BYL719. We envision this could take the form of a short-course treatment ahead of a 
standard therapy. Short courses of pre-operative treatment with a targeted drug (e.g. < 2 
weeks), have documented measurable efficacy in several contexts already and may 
minimize the extent of resection required, in the case of subsequent surgery(15,16). 
Further, a defined window of time may help limit the acquisition of drug resistance that 
can compound the challenge of treatment (as addressed in Chapter 4). 
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6.4 Biomarkers of Response 
 The advent of next generation sequencing (NGS) has revolutionized the global 
approach to cancer research and treatment. In HNSCC, the genomic characterization of 
hundreds of patient tumours has revealed key underlying differences between HPV-
positive and HPV-negative disease, highlighting both common and rare genomic 
aberrations(1-3). Using the mutational data garnered from these investigations, efforts to 
exploit genomic features for targeted therapy and identify biomarkers of response have 
expanded greatly(17,18).  
 Biomarkers in cancer can take on many forms, including altered gene or protein 
expression, or genetic/epigenetic DNA alterations(19). Cancer biomarkers typically have 
implications for therapeutic intervention: either diagnosis, prognosis or treatment 
surveillance. Throughout this thesis, we have focused on determining potential biomarkers 
of response for targeted inhibition of PI3K signalling in HNSCC. In line with others, we 
have found that the complexity of the PI3K pathway, its degree of interconnectivity with 
adjacent networks and the inherent feedback loops all greatly compound the difficulty of 
making clear predictions of drug response on the basis of patient or cell line genotypes(20).  
 In Chapter 3 we explored the impact of constitutively-activating HRAS mutations 
on response to PI3K inhibition. We found that tumour cells with endogenous 
constitutively-active mutant HRAS were non-responsive to PI3K inhibition. We 
exogenously expressed both HRAS and HRAS G12V to validate this observation in 
wildtype HRAS HNSCC cells. As a whole, our findings led us to consider whether 
constitutively-activating HRAS mutations could serve effectively as a biomarker for 
exclusion from PI3K inhibitor treatment. This was supported by our observations in 
Chapter 2, in which we noted that all the mutant HRAS PDX models were among the least-
sensitive to PI3K inhibition by BYL719. It is possible that excluding HNSCC patients 
with constitutively-activating HRAS mutations from treatment with BYL719 (or another 
PI3K inhibitor) may eliminate unnecessary toxicity for those patients. We acknowledge 
the challenge of being able to clinically identify mutations in patients in an efficient and 
timely manner such that a targeted therapy can be initiated and provide sufficient exposure 
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for the patient(21). As we observed numerous HNSCC patient genotypes to all derive some 
degree of benefit from PI3K inhibition (based on our cell line screen and PDX clinical trial) 
(Chapter 2), the feasibility of checking patients for multiple biomarkers of response (e.g. 
various PIK3CA hotspot mutations, AKT1 alterations, EGFR amplifications, etc.) is likely 
unreasonable. However, if detection of a single variant can be optimized such that its 
detection excludes a patient from unnecessary and likely ineffective treatment, this may be 
a more accessible and actionable step forward. 
 
6.5 Emerging Targets and Drug Combinations 
 Throughout this thesis we have proposed several oncogenic targets in HNSCC, 
either alone, or in combination with PI3K inhibition. These targets emerged on the basis 
of their apparent role in either innate or acquired resistance, or in the case of mTORC2 
(Chapter 5), owing to their connectivity to the PI3K pathway through feedback 
mechanisms(22). While developing combination drug therapies is costly in terms of 
resources and time, experience has shown that combination approaches are justified in most 
cases, even for therapies that show impressive initial response rates(10,23). 
In Chapter 5 we focused on mTORC2 as a mediator of adaptive resistance to PI3K 
inhibition in the short term. Throughout our various investigations of PI3K inhibition, 
induction of Akt Ser473 phosphorylation was noted following drug treatment. mTORC2 
phosphorylates Akt at Ser473; while this modification is tightly controlled by a negative 
feedback loop between S6K and RICTOR, inhibition of PI3K/mTORC1 signalling relieves 
this feedback, enabling mTORC2 activity. Further, we and others have found that the 
presence of Akt Ser473 stimulates the phosphorylation of Akt Thr308, another site 
critically involved with Akt activity. These observations, as well as our investigations 
surrounding the impact of mTORC2 loss—which revealed impaired growth and reduced 
clonogenic capabilities of cells—framed mTORC2 as an important therapeutic target in 
HNSCC. Our findings suggest that even as a single target, mTORC2 inhibition may hold 
equivalent promise as mTORC1 or PI3K/Akt inhibition, owing to its ability to diminish 
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activation of Akt phosphorylation at both Ser473 and Thr308. We also examined mTORC2 
loss in combination with PI3K inhibition, EGFR inhibition and cisplatin treatment, where 
it was generally complementary. The development of a small molecule inhibitor specific 
to mTORC2 would greatly aid in further research to validate these findings and would help 
determine whether mTORC2 as a therapeutic target is tolerable, particularly in animal 
models(24). Additional studies focused on advancing our collective understanding of 
mTORC2 activation, regulation and its role in cancer would similarly help build a 
foundation for mTORC2 as a cancer target. 
When we challenged various HNSCC cell lines and PDX models over time with 
continued exposure to the PI3K inhibitor BYL719, we found that in all cases, drug 
resistance was eventually acquired (Chapter 4). Resistant cells grew readily in the presence 
of BYL719, despite continued inhibition of PI3K (as measured by evaluating Akt Thr308 
levels). Interrogation of the expression of several hundred total and phospho-proteins 
revealed altered expression of the TAM family RTKs AXL and TYRO3. AXL has been, 
and continues to be, implicated as a central mediator of resistance to a wide variety of anti-
cancer therapies, including targeted agents, chemotherapies and even radiation therapy(25-
32). In contrast, our investigation is among the first examining TYRO3 and its role in 
modulating response to targeted therapy(33). To the best of our knowledge, our study is 
the first implicating TYRO3 alongside AXL as a mediator of acquired resistance to PI3K 
inhibition. While many mechanisms of resistance likely exist for any given drug, 
particularly when used to treat different cancer types, our findings using a series of distinct 
cell lines, PDX models and even a primary tumour-derived cell line, all point to 
upregulation of TAM RTK expression. Downstream of TYRO3 and AXL, we observed a 
strong induction of MAPK pathway activation. Given the role of the MAPK network in 
mediating innate resistance to PI3K inhibition downstream of HRAS (as described in 
Chapter 3), this was an interesting observation and pointed to a common theme in our 
studies, described below. To date, targeting MAPK pathway effectors has shown little 
efficacy, leading us to conclude in Chapter 4 that combined inhibition of AXL and TYRO3 
(or pan-TAM inhibition to include their third family member; MER-TK) may be a 
promising therapeutic approach to re-sensitize cells to PI3K inhibitor treatment. 
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6.6 MAPK Pathway Crosstalk 
 A recurring theme throughout this thesis (in particular in Chapters 3 and 4) is the 
high degree of interconnectivity between the major PI3K and MAPK (RAS-RAF-MEK-
ERK) cellular signalling pathways and the impact of MAPK signalling on the efficacy of 
PI3K inhibition(34,35). Independently, both the PI3K and MAPK signalling networks 
represent key opportunities for tumour cells to regulate survival, growth and 
proliferation(34). Both pathways are known to be activated and/or mutated in a variety of 
tumour types(1,36,37). In addition to their independent, albeit similar activities, these 
pathways also cross-talk extensively(34,35,38,39). Consequently, compensation of one 
pathway for another has proven to be a major pharmacological challenge.  
 The MAPK pathway cross-activates the PI3K pathway by regulating the PI3K 
pathway members PI3K, TSC2, mTORC1 and S6 directly(34,35,38,39). In Chapter 2 we 
examined ERK-mediated TSC2 inactivation, which promotes mTORC1 activity in the 
PI3K pathway(38). In the case of constitutively-active RAS signalling, we highlighted the 
link between ERK and TSC2 to be particularly relevant, providing continued mTORC1 
activation, despite upstream PI3K inhibition(40). This is just one such example of how 
inhibition of PI3K signalling can be overcome by the activities and interconnectivities with 
the MAPK network.  
 In Chapter 4, where we investigated the acquisition of resistance to targeted PI3K 
inhibition over time, we again observed involvement of the MAPK pathway. In all the 
PI3K-inhibitor resistant cell lines surveyed, we observed strong induction of MAPK 
signalling, as indicated by the relative phosphorylation states of numerous members of the 
pathway (including, MEK1, ERK1/2, P90RSK and S6). Active MAPK signalling was 
associated with reduced susceptibility of cells to PI3K inhibition. These observations 
collectively highlight the compensatory nature of the MAPK and PI3K signalling pathways 
in HNSCC. Future work may centre on further elucidating the relationships between these 
pathways, including the identification of optimal targets to reduce compensation between 
them when one pathway is blocked.  
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6.7 Concluding Remarks 
In this thesis I set out to explore mechanisms of innate and acquired resistance to 
targeted PI3K inhibition in HNSCC. The studies presented in these four chapters have 
surveyed these topics from numerous angles using a multifaceted approach. In Chapter 2 
we used HNSCC cell lines and PDX models to interrogate PI3K inhibitor response 
heterogeneity and identify potential biomarkers of sensitivity or resistance. We discovered 
PI3K inhibition to be broadly effective across most models, with potential as a 
neoadjuvant therapy. In Chapter 3, we studied constitutively-active mutant HRAS as a 
genomic feature associated with innate resistance to PI3K inhibition and proposed ERK-
TSC2-mTORC1 signalling to be a key mechanism supporting this phenomenon. Chapter 
4 focused on acquired resistance to PI3K inhibition following prolonged treatment. Here 
we identified TYRO3 and AXL, as well as downstream MAPK signalling to be mediators 
of acquired drug resistance to PI3Kα inhibition, and suggested pan-TAM RTK inhibition 
as a second-line therapeutic approach. Finally, in Chapter 5 we characterized the role of 
RICTOR/mTORC2 in HNSCC, identified reactivation of mTORC2 signalling to modulate 
the efficacy of PI3K inhibition and described mTORC2 to be a potential therapeutic target.  
I am excited by the discoveries made in these studies and am confident that this 
body of work has achieved its goal of advancing the current state of knowledge regarding 
how the PI3K pathway can be targeted to treat HNSCC more effectively. Moving forwards, 
this work will serve as a foundation for future studies that will continue to expand our 
understanding of HNSCC pathogenesis and PI3K signalling, and will play a key role in a 
much larger body of knowledge that continually aims to understand and better treat human 
cancers. 
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Appendices 
Appendix A: Permission for reproduction of KM Ruicci, et al., 2018 Oral Oncology 
publication. 
 
The data presented in Chapter 3 appear published in the manuscript “ERK-TSC2 signalling 
in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K 
inhibition”. KM Ruicci, N Pinto, MI Khan, J Yoo, K Fung, D MacNeil, JS Mymryk, JW 
Barrett, AC Nichols. Oral Oncology. 2018, 84: 95103.  
 
Referencing style and format have been modified from the original publication to 
correspond with the formatting of this thesis.  
 
Article is available through ScienceDirect at: 
https://authors.elsevier.com/c/1XSNm4tFDI29sz 
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